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Abstract
Human skin cells (FEK-4) have been shown to undergo an immediate and transient 
release of low molecular mass iron (LMrFe) when subjected to UVA (320-380nm) 
irradiation and this iron may act as a pro-oxidant and increase the expression of 
oxidant-stress modulated genes such as HO-1 and COX-1. To assess the role of 
LMrFe in UVA-mediated gene expression, cells were either loaded with iron, in the 
form of haemin or ferric citrate, or treated with the iron chelators desferrioxamine 
(DFO) and salicylaldehyde isonicotinoyl hydrazone (SIH). However, although it was 
possible to modulate the iron pool with these compounds, an increase in the DNA 
binding activity of the hypoxia inducible factor-1 (HIF-1) was observed when DFO 
and SIH were administered to normal growing FEK-4 cells. Furthermore a 
subsequent increase in the expression of COX-2 and GAPDH was observed in 
response to these iron chelators. Since the induction of HIF-1 has been associated 
with protection against certain forms of oxidative stress, it is not meaningful to use a 
conventional HIF-1-activating iron chelator, such as DFO, for studies that probe the 
mechanism of protection against iron-mediated oxidative stress. In this study the 
effect of iron chelation on gene expression was measured without the induction of 
hypoxia responsive genes, by treating cells with the novel iron chelator N-(2- 
hydroxybenzyl)-L-serine (HBSer). Using the aforementioned iron chelator our study 
demonstrated that the transient release of LMrFe observed after UVA irradiation of 
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The skin is regarded as a covering for the protection of the deeper tissues. It plays an 
important part in the regulation of the body temperature and is also an excretory and 
absorbing organ. It consists principally of a subcutaneous hypodermis, a layer of 
vascular tissue named the dermis, corium or cutis vera, and an external covering of 
epithelium termed the epidermis or cuticle.
1.1.1 Stratum corneum
The stratum corneum is located at the interface between body and environment and 
lies above the epidermis. It is comprised of a unique, highly lipophillic 2- 
compartment system of structural, enucleated cells (comeocytes) embedded in a lipid- 
enriched intercellular matrix, forming stacks of bilayers that are rich in ceramides 
cholesterol and free fatty acids. The stratum corneum lipid composition and structure 
plays a key role in determining barrier integrity which is essential for skin 
moisturisation, normal desquamation and healthy skin condition. Because the stratum 
corneum is the outer most interface of the body, it is constantly exposed to a pro- 
oxidative environment, including air pollutants, UV solar light, chemical oxidants and 
microorganisms [reviewed in Thiele and Eisner, 2001]. The stratum corneum has a 
uniform distribution of melanin granules that are discussed in section 1.1.3.
1.1.2 The epidermis
The epidermis is accurately moulded on the papillary layer of the dermis and forms a 
defensive layer to the surface of the true skin where it limits the evaporation of watery
1
vapour from its free surface. It is mainly comprised of keratinocytes, Langerhans 
cells and melanocytes. Langerhans cells are antigen-presenting cells. The abundant 
keratinocyte cells provide the skin with the protein keratin, which in turn provides the 
epidermis with strength and flexability. Melanocytes are dispersed among the cells of 
the basal layer of the epidermis. Their extending cytoplasmic arms give them a 
dendritic appearance. These melanocytes provide keratinocyte cells with melanins.
1.1.3 Melanins
Melanin pigments are widely distributed throughout the animal kingdom and are 
found in some fungi. They are formed by the oxidation and polymerisation of the 
aromatic amino acid tyrosine, a reaction catalysed by specific enzymes such as 
tyrosine hydroxylase and tyrosinase. The brown or black melanins (eumelanins) are 
found in the skin and help to protect it against UV-radiation. They also have 
properties that enable them to act as free radical scavengers (in particular O2*”) 
[Chedekel and Zeise, 1997]. Melanin polymers contain un-paired electrons, resulting 
from the polymerisation process and these help to absorb UV-radiation by facilitating 
the movement of unpaired electrons between different energy levels. The red-brown 
or yellow pigments found in the skin and hair of certain individuals is pheomelanin, 
which is less effective than eumelanins as a radical scavenger [reviewed in Halliwell 
and Gutteridge, 1999].
It may be assumed that melanins such as darkly pigmented brown-black eumelanin 
granules form a protective cap over the outer part of the keratinocyte nuclei in the 
inner layers of the epidermis. This is demonstrated in very black individuals who 
produce melanin constitutively and are estimated to be protected by a factor of 10-15
2
fold against erythrema and 500-1000 fold against skin cancer as compared to 
individuals with white skin [reviewed in Tyrrell, 1994]
1.1.4 The dermis
The dermis is tough, flexible and highly elastic in order to defend the tissues and 
organs beneath it from damage. The dermal layer contains an immense variety of 
nerve endings and receptors. The thin upper part of the dermis is known as the 
papillary dermis because of its small finger-like projections (papillae), which contain 
capillaries that nourish the epidermis (displayed in fig 1.1). The papillary dermis is 
composed of loosely interwoven collagen with many fine elastic fibres. Coarse and 
horizontally running bundles of collagen are found in the lower thicker part of the 
dermis, known as the reticular dermis (shown in figure 1.1). The collagenous and 
elastic fibres of the dermis make the skin both strong and stretchy, demonstrated by 
the fact that this is the part of an animals’ skin, which tanners use for shoes, jackets 
and belts. A semi-solid matrix of glycosaminoglycans (GAG) affords the dermis its 
viscosity and hydration that allows dermal structures limited movement. The dermis 
contains several different cell types of which fibroblast cells provide the tissue with 
collagen, elastin and GAG. Other cell types present in the dermis include adipose 
cells, immune cells such as dermal dendrocytes, mast cells, macrophages and 
lymphocytes. The hypodermis consists of mainly fibrous loose connective tissue, 
such as adipose. This layer has a dense vascular network, and is the origin of hair 
follicles and sweat glands.
3
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The sun, with its light and heat, has been recognised in most ancient cultures as 
essential for life on earth and as having beneficial properties. Nevertheless, the 
damaging effects of sunlight were also known thousands of years ago. Sunlight was 
defined by Isaac Newton in 1672 as a mixture of colours (wavelengths). Light is a 
form of electromagnetic radiation that is characterised by its wavelength, (X), or its 
frequency, (v), which are related by the equation A,v=c where c is the propagation
n 1
velocity or speed of light, (3X10 ms' in vacuo). The wave-like nature of light
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explains properties such as diffraction, interference, refraction and polarisation. 
However, electromagnetic radiations, including light, are not fully described by 
electromagnetic waves. In order to understand the interaction of light with matter it 
has been necessary to consider light as being composed of packets of energy called 
‘light quanta’ (derived from the latin quantus meaning ‘how much’) and as ‘photons’ 
(Lewis, 1926) behaving as particles. The energy per photon (E) is related to the 
wavelength and frequency by the following equation:
E = hv = hc/X
where h is planks constant (6.626 X 10'34 Js). Energy and wavelength have a 
reciprocal relationship, so as wavelength increases the energy associated with it 
decreases, and vice-versa.
At the beginning of the nineteenth century, Gothus and Draper formulated the first 
law of photochemistry, which stated that only the light absorbed by a molecule can 
produce photochemical change in the molecule. Stark and Einstein modified this law 
stating that i f  a species absorbs radiation then one particle is excited for each 
quantum o f radiation absorbed. The second law takes into account that a chemical 
reaction is only one of a number of competing routes available to an excited species. 
When solar (electromagnetic) radiation hits a biological molecule, its subsequent 
effect is dependent on the energy of the incident photons and on the wavelength of the 
electromagnetic radiation. The second law constitutes the absorption spectrum of the 
molecule and is determined by its molecular structure. The target biological molecule 
(species) may only exist in certain defined, discrete (separate) energy states. A 
transition between two such states of specific energy must have associated with it a 
definite energy. Thus, for each individual species only specific energies, and 
therefore frequencies, or radiation can be absorbed or emitted. In addition to its
5
translational energy, a species may also posses internal energies, each one of which 
can be quantized as rotational energy, vibrational energy (which arises from the 
periodical oscillation of atoms in a molecule) and electronic energy which depends on 
the distance of the electron from the nucleus and the type of orbital that it occupies. 
When a species absorbs a quantum of radiation it becomes excited. How the species 
assimilates that energy, in vibrational, rotational, or electronic modes depends on the 
wavelength of the incident radiation. This can give rise to excited states of atoms or 
molecules. Of most interest to photochemists are the electronically excited states in 
which the electrons become distributed to a higher energy arrangement. The species 
are thus said to be electronically excited. The excited state of a species can exhibit a 
dramatically altered reactivity from that seen in the ground state. Not only does the 
species posses more energy, but it is also able to participate in different reactions 
because of the new electronic arrangement.
1.2.1 Solar Radiation
It is primarily the sun's surface temperature that determines the spectrum of energy it 
radiates.
6
Figure 1.2. The amount of energy that the sun radiates at different wavelengths. The bell-shaped 
curve of this radiation spectrum is characteristic of electromagnetic radiation emission. 
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Approximately 40% of the energy radiated by the sun falls into the visible portion of 
the spectrum, and around half radiates in the infrared portion (see figure 1.2). The 
remaining 10% is in the UV region. The ozone (03) layer and molecular oxygen in 
the stratosphere absorb most of the harmful types of radiation (below 290nm). The 
shortest wavelengths reaching the earth’s surface are in the non-ionising ultraviolet 
range. Although the term ‘light’ refers to the visible part of the electromagnetic 
spectrum with wavelengths between 400 and 700nm, it is often extended to include 
ultraviolet regions of the spectrum 280-400nm that are not visible to the human eye.
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1.2.2 Spectrum of harmful types of UV radiation
Ultraviolet light includes wavelengths from 10 to 380nm. These are divided into five 
distinct bands dependent on their wavelength as shown in table 1.1.
Table 1.1. Ultraviolet wavelengths






Figure 13. Diagrammatic representation of the range of ultraviolet and visible radiation 
incident on the surface of the earth, (reproduced from (Tyrrell, 1994])
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The UV that typically reaches the Earth’s surface at noon is comprised o f 
approximately 10% UVB, and 90% UVA (figure 1.2). The effective absorbance of 
DNA in the UVC and UVB region is shown in figure 1.2. UV light is the most 
prominent and ubiquitous carcinogen in our natural environment. It is highly 
genotoxic, yet only a small portion o f the UVA that reaches the earths surface can 
penetrate the body any deeper than the skin. Fortunately, all UV vacuum and UVC is 
absorbed in the stratosphere. UVC from artificial (non-solar) sources is strongly 
absorbed by biological material and consequently penetrates a minimal distance into 
tissue. Thus, only low amounts reach critical target cells in the skin. However, the 
UVB that reaches the Earth’s surface may cause damage to the skin. UVB is also
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known as erythemal UV due to its ability to induce erythema (skin reddening). Solar 
UVB is the major cause of the vast majority of cutaneous malignancies diagnosed in 
the human population [reviewed by Tyrrell, 1994 and de Grujil, 2000], It is known to 
impair the immune response and contribute to photoaging. DNA is one of the most 
prominent cellular targets for the absorption of UVB (as well as proteins, discussed in 
section 1.2.4.2). Due to the aforementioned properties, UVB elicits a diverse range of 
biological responses such as cytotoxicity, mutagenicity, carcinogenicity and gene 
activation [Ley et al., 1991]. At longer wavelengths, UVB-radiation also exhibits 
oxidative damage to diverse cellular substrates. UVA constitutes more than 90% of 
the UV radiation reaching the Earth’s surface, and was historically considered 
harmless. However, the harmful effects of UVA have now been firmly established 
and such damage is largely due to the generation of reactive oxygen species [reviewed 
by Tyrrell, 1991] (see 1.2.3.).
1.2.2.1 Singlet oxygen
Two singlet states of oxygen exist and for both the spin restriction, that makes ground 
state oxygen sluggish in its reactions, is removed. These singlet oxygens are more 
oxidising than ground state O2 . The !Sg+ state rapidly decays to the !Ag state, and so 
only the latter is normally considered in biological systems. In this thesis, the term 
‘singlet oxygen’ (shown as ^ 2) refers to the2Ag state. *Ag O2 is not a free radical, but 
it may be formed in free radical reactions and lead to the production of others 
[reviewed in Halliwell and Gutteridge, 1999].
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1.2.2.2 Other reactive forms of oxygen generated in biological systems
The oxygen molecule (O2) has two unpaired electrons, which have parallel spins and 
so qualifies for being defined as a free radical. This is the most stable or ground state, 
of oxygen. When molecular oxygen attempts to oxidise another atom or molecule (by 
accepting a pair of electrons from it), the electrons would have opposite spins in 
accordance with Pauli’s principle, and would not fit in the 71* orbitals of O2 . This 
imposes a spin restriction on electron transfers, which makes O2 sluggish in reactions 
with non-radicals. To overcome this spin restriction, O2 likes to accept electrons (e) 
one at a time. The complete reduction of O2 to H2O involves the addition of 4 
electrons. When the first electron is added we form the superoxide anion ((V"), 
followed by, hydrogen peroxide (H2 O2), the hydroxyl radical (*OH), and finally water
Figure 1.4. Shows the 4-electron reduction of molecular oxygen to water.
O 2  +  e >  02#-
0 2“  +  e +  2H+---------- ►H20 2
H20 2 + e + I T  ►H20  +  ‘OH
*OH + e + H+ ► H 20
UVA-irradiation of hydrogen peroxide can form *OH radicals by homolysis of the
peroxide bond:
UVA
H20 2 ^  2 #OH
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1.2.3 Beneficial effects of UV radiation on humans
Vitamin D is essential for maintaining blood calcium levels within a normal range and 
therefore for growth and maintenance of a healthy skeleton throughout life. Vitamin 
D is obtained either from the diet or by UV irradiation of a sterol precursor present in 
the skin [reviewed by Tyrrell, 1994]. In experiments with mice, it was recently 
shown that physiological doses of UVA abrogated the immunosuppressive effects of 
UVB and UVC [Reeve and Tyrrell, 1999] and could therefore be beneficial to the 
host.
1.2.4 Ultraviolet A (UVA) radiation as an oxidative stress.
UVA is the most prevalent form of UV radiation at the Earth’s surface. UVA is a 
component of sunlight and artificial sun bed radiation that acts as an oxidising 
carcinogen. Around 35-50% of UVA radiation may reach the dermis of Caucasian 
skin [Bruls et al., 1984]. A small amount of UVA radiation can even reach below the 
surface of the skin and penetrate blood vessels [Tyrrell, 1994]. Many biological 
macromolecules absorb UVA and in this process generate reactive oxygen 
intermediates. For example, the photochemical oxidation of tryptophan yields 
hydrogen peroxide and N-formyl kynurenin [McCormick, 1976]. Photooxidation 
products can also act as photosensitisers and further generate hydrogen peroxide and 
superoxide. Certain iron complexes (see 1.4.3) can react with hydrogen peroxide to 
generate the hydroxyl radical (the relevance of which is discussed in 1.4.3). 
Hydrogen peroxide and superoxide are also generated by UVA irradiation of NADH 
and NADPH. In addition to the normal metabolic generation of superoxide and
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hydrogen peroxide, animal and plant cells may contain chromophores such as 
riboflavin, chlorophylls, bilirubin, retinal and various porphyrins, that may generate 
singlet oxygen via type II photodynamic processes [Tyrrell, 1991]. Photosensitisation 
reactions occur when certain molecules are illuminated with light (including UV) of 
the correct wavelength. They absorb the light and raise the energy of the molecule to 
an excited state. During type II reactions, this excitation energy can be transferred to 
a nearby oxygen molecule converting the oxygen to the singlet state, whilst the 
photosensitiser returns to its ground state. The term type I and II refers to how a 
photodynamic sensitiser, such as UVA interacts in a biological system. For example, 
in type I the excited photosensitiser, may cause damage to itself whereas, as 
previously described, the competitive type II reaction energy is transferred to 
molecular oxygen to produce singlet oxygen (102) (See 1.2.3.1). In addition, several 
photosensitisers such as porphyrins have been reported to produce the hydroxyl 
radical (#OH) and superoxide (O2*') in addition to singlet oxygen [reviewed by 
Halliwell and Gutteridge 1999].
1.2.4.1 Damage to DNA by UVA
The genotoxicity of UVA has been firmly established using in vitro experiments. The 
low absorption of UVA by DNA means that any damage to DNA when irradiated 
between 320 and 380nm is often due to indirect effects mediated by reactive oxygen 
intermediates. Various types of DNA damage occur as a result of UVA irradiation, 
including the formation of cyclobutane type pyrimidine dimers, strand breaks and 
DNA-protein crosslinks. Cyclobutane-type dimers were the first type of UV-induced 
base damage identified in skin cells [Freeman et al., 1986 and 1989]. Cyclobutane-
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type dimers are mainly induced by UVB or UVC and arise from the production of 
excited states (normally the long lived triplet state). However, when DNA is 
irradiated with UVA only a limited amount of pyrimidine dimer formation occurs. 
For this to occur at 365nm, six orders of magnitude more energy is required than at a 
wavelength of 254nm. Cyclobutane-type dimer formation at 365nm is unaffected by 
markedly decreasing the oxygen concentration, suggesting that reactive oxygen 
species are not greatly involved [reviewed by Tyrrell, 1994]. In contrast, the fluence- 
dependent induction of DNA strand breaks in E.coli, by irradiation at 365nm, is 
completely prevented under anaerobic conditions. In fact, the induction of strand 
breaks is strongly dependent on the oxygen concentration throughout the UVB and 
UVA ranges and the damage at the longest wavelengths may involve direct 
generation of singlet oxygen [reviewed by Tyrrell, 1991]. The formation of DNA- 
protein cross links is also an oxygen-dependent process, since such damage is 
decreased by irradiating under hypoxic conditions and enhanced in the presence of 
deuterium oxide (known to increase the life of singlet oxygen) [Tyrrell, 1994].
1.2.4.2 Damage to proteins by UVA
Certain proteins are particularly susceptible to damage by UVA irradiation either 
directly or indirectly due to their interaction with UVA-generated ROS and end 
products of lipid peroxidation such as malondialdehyde (MDA) and 4-hydroxy-2- 
trans-nonenal (HNE). For example, the enzymes catalase and peroxidase contain 
photosensitive haem groups, which make them UVA chromophores. Several 
enzymes, such as amylase, catalase, pepsin, and the amino acid tyrosine are 
inactivated by UVA in an oxygen-dependent way suggesting an involvement of ROS
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in the damage. There is also evidence to suggest that DNA-repair enzymes are also 
damaged by UVA in an oxygen-dependent manner. This is of particular importance 
since UVA also causes DNA damage, as discussed in the preceding section [reviewed 
by Tyrrell, 1994].
1.2.4.3 Damage to lipids by UVA
Polyunsaturated fatty acids (PUFAs) are defined as those that contain two or more 
carbon-carbon double bonds. The major constituents of biological membranes are 
lipid and protein, with the lipid component containing large amounts of PUFA side 
chains. The presence of an increasing number of double bonds in a fatty acid makes it 
more susceptible to oxidative damage by free radicals and molecular oxygen; a 
process known as lipid peroxidation. Peroxidation of PUFA (L) is initiated when a 
free radical is able to abstract a hydrogen atom from a methylene carbon leaving a 
carbon-centred radical behind (L*). This radical is able to react rapidly with O2 (no 
spin restriction) to form a peroxyl radical (LO2*). The peroxyl radical abstracts a 
hydrogen atom from the PUFA converting itself to a lipid hydroperoxide (LOOH) and 
leaving a carbon-centred radical on the PUFA (L*). The process continues as a 
radical chain reaction, until radicals ‘cancel’ each other out, the substrate becomes 
exhausted, or a chain breaking antioxidant is added.
L + #OH ______ ► L* + H20
[ i]
15
L* + 0 2 ► lo2-
[2]
L + L02* *  LOOH + L*
[3]
Equations 1,2 and 3 represent the major free radical reactions of lipid peroxidation. 
The lipid peroxides (LOOH) can undergo fragmentation, particularly if suitable iron 
complexes are present to form aldehyde molecules such as malondialdehyde and 2- 
hydroxynonenal (HNE). UVA has been shown to cause a dose dependent increase in 
lipid peroxidation when liposomal membranes are used as a substrate and in the 
absence of a photosensitiser [Bose et al., 1989]. Lipid soluble antioxidants and 
singlet oxygen scavengers have been shown to inhibit this peroxidation [Girotti, 
1990], suggesting that both singlet oxygen and free radicals are probably involved in 
the process. UVA irradiation also causes changes to membrane fluidity [Gaboriau et 
al., 1993]. This is not surprising since membrane fluidity is due to the presence of 
unsaturated and PUFA side chains and any damage to these is likely to decrease 
membrane fluidity [reviewed in Tyrrell, 1994].
1.2.5 Damage elicited by UVA
The preceding sections have described some of the harmful, damaging effects that 
UVA radiation can exert on cellular molecules. The following section gives a brief
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description of some of the effects UVA radiation can have on cells, tissues and 
organisms.
1.2.5.1 Pathological consequences of UVA
Experiments using hairless mice show that UVA radiation promotes tumorigenesis 
[Strenborg, and Van der Leun, 1990]. The chronic response to UVA involves delayed 
effects such as cataract and photoageing that results from general alterations of the 
epidermal and dermal components of the skin [Tyrrell, 1994]. Irradiation of human 
skin with UVA resulted in decreased levels of elastic tissue [Lowe et al., 1995], most 
likely due to the induction, by UVA, of matrix degrading metalloprotease-1 (MMP-1) 
also known as collagenase [Brenneisen et al., 1998].
1.2.5.2 Cellular oxidative stress
The dermis is a primary target for oxidative stress generated not only by solar 
radiation, but also by other physical and chemical agents. In contrast to dermal cells, 
epidermal keratinocyte cells possess high basal activity of the enzyme 
haemoxygenase (HO), because the constitutively expressed isoform (HO-2) is present 
at high levels in these cells. The high and constitutive expression of HO-2 and GSH 
in these cells has been proposed as a defence against oxidative stress [Tyrrell and 
Pidoux, 1988] [Keyse and Tyrrell, 1990]. However, dermal fibroblast cells receive 
comparatively less UV radiation due to the shielding effect of the overlying 
epidermis, with a larger portion of this UV light being UVA. UVA radiation causes
17
significantly less damage to the membranes of keratinocytes compared to fibroblast 
cells [Applegate et al., 1994]. Fibroblast cells appear to elicit an adaptive response to 
UVA in contrast to keratinocytes which posses a high level of constitutive protection. 
For example, the constitutive level of HO-2 is very low in fibroblast cells, but 
haemoxygenase-1 (HO-1) (the inducible isoform) may be very strongly induced by 
UVA [Keyse and Tyrrell, 1989]. Indeed Kasid and co-workers described primary 
human epidermal keratinocyte cells as radiation resistant when compared with human 
fibroblasts [Kasid et al., 1987].
Using human dermal fibroblast cells as a model to study changes resulting from UVA 
irradiation, distinct early and late events were seen to occur. Immediately after UVA 
irradiation, there is an early dose-dependent increase in lipid peroxidation [Vile and 
Tyrrell, 1995] and a depletion of GSH [Lautier et al., 1992]. Cellular events are also 
initiated that lead to changes in iron homeostasis. There is an immediate increase in 
chelatable forms of ‘free’ iron within cells, which appears to result from the 
proteolysis of ferritin [Pourzand et al., 1999]. Haem also accumulates within cells 
following its release from microsomal haem proteins. The level of this haem release, 
following UVA irradiation, determines the degree to which HO-1 is transcribed 
[Kvam et al., 1997; Kvam et al., 2000], Previous data from this laboratory shows that 
UVA also causes lysosomal damage [Pourzand et al., 1999]. Apparently, it is this 
early lysosomal damage that leads to leakage of proteases, such as chymotrypsin, that 
cause the degradation of ferritin.
The delayed, or late events, take place several hours after the cell has been insulted by 
UVA. Of particular importance here is the observation that the 32kDa stress protein 
haemoxygenase-1 (HO-1) is up-regulated consistently and at high levels by UVA
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irradiation with a peak of activity between 14 and 48 hours post irradiation. HO-1 is 
discussed in detail in section 1.3.2.1. Immediately after UVA irradiation of cells, 
microsomal haem content is decreased to 60% of control levels but recovers within 22 
hours to 90% of the (non-irradiated) control value [Kvam et al., 1999; Kvam et al., 
2000]. Degradation of ferritin by decompartmentalised lysosomal proteases and the 
degradation of microsomal haem by HO-1 cause an immediate and transient cellular 
increase in ‘free’ iron. This ‘free’ iron modulates the expression of the iron 
regulatory proteins that in turn act to increase levels of the intracellular iron storage 
protein ferritin (see section 1.4.4.1). This change occurs around 22 to 46 hours post 
UVA irradiation. Interestingly, if a HO-1 inhibitor is administered to cells prior to 
UVA irradiation, the increase in ferritin is abolished [Kvam et al., 2000], this 
observation suggests that the degradation of haem is a major contributor to the 
increase in ferritin.
1.2.6 Antioxidant defence against UVA
An antioxidant is been defined as any substance that, when presented at low 
concentrations compared to those of an oxidisable substrate, significantly delays or 
prevents oxidation of that substrate (Halliwell and Gutteridge). UVA is a form of 
oxidative stress against which organisms have evolved efficient and effective 
protection. The cellular response to oxidative stress is known to be complex and 
involves an array of mechanisms that include antioxidant enzymes, antioxidant 
molecules (often low Mr), metal sequestering proteins and inducible responses such 
as HO-1.
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1.2.6.1 Antioxidant enzymes of the cell
Cells contain several enzymes that destroy reactive oxygen intermediates. These are 
normally constitutively present. Glutathione peroxidase (GPX) is a selenium- 
dependent enzyme that catalyses the oxidation of reduced glutathione (GSH) to 
oxidised glutathione (GSSG) utilising H2O2 and lipid hydroperoxides, to form water 
and an alcohol respectively. At least 4 different types of GPX are known to exist 
(reviewed in Halliwell and Gutteridge, 1999). Catalase is a haem-containing 
peroxidase enzyme that removes H2O2 , but unlike some of the peroxidases, catalase 
catalyses the decomposition of H2O2 with the formation of only ground state oxygen 
and water. As discussed previously in 1.2.4.2, catalase activity is decreased after the 
cell is irradiated by UVA. Thioredoxin reductase is a small protein that, in its reduced 
form, has protein disulphide reductase activity as a result of its two reactive thiol 
groups. Thioredoxin reductase has been implicated in the defence of skin against 
oxidative stress, as in vivo experiments have indicated that the protein may react with 
free radicals in human keratinocytes [Schallreuter and Wood, 1986]. Superoxide 
dismutases (SODs), are enzymes that catalyse the dismutation of superoxide anions to 
H2 O2 . SOD is present in the skin in two distinct forms, namely the copper-zinc SOD 
(Cu-Zn-SOD) and the manganese SOD (Mn-SOD). SOD activity is also decreased by 
UVA irradiation of the cell, however this is thought to result from damage by reactive 
oxygen species (ROS) and not from the direct absorption of UVA. However, 
repetitive exposure to UVA irradiation leads to an adaptive antioxidant response as a 
result of the induction of MnSOD [Poswig et al., 1999] The glutathione-s-transferase 
(GST) enzymes play an important role in cellular defence against xenobiotics by 
conjugating them to GSH, whereas some of the GSTs show a glutathione peroxidase­
like activity towards organic hydroperoxides. These enzymes are both cytosolic and
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membrane bound. The aforementioned enzymes are examples of constitutive cellular 
antioxidants. Specific enzymic and non-enzymic antioxidants also exist in 
extracellular fluids such as plasma. These appear to be mainly concerned with 
controlling the toxicity of iron-containing molecules and have therefore been 
described in section 1.4.3.3.
1.2.6.2 Antioxidant molecules of the cell
The most abundant thiol found in cells is glutathione (GSH). GSH is an important co­
factor for several enzymes involved in metabolic pathways, in addition to its role in 
the function of the GPX enzymes (as described previously). It can rapidly react with 
both radical species such as *OH and RO2*, as well as non-radical species such as 
hypochlorous acid (HOC1) and 1C>2 . Oxidised glutathione (GSSG) is reduced back to 
GSH by an enzyme glutathione reductase, using NADPH as a hydrogen donor. GSH 
plays a major role in the protection of cultured human skin cells from UVA radiation, 
providing additional evidence that ROS are involved in the toxicity of UVA [Tyrrell 
andPidoux, 1989].
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Figure 1.5. The structure of reduced (GSH) and oxidised (GSSG) glutathione. Image 
reproduced from Halliwell and Gutteridge, 1999.
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The terms a-tocopherol and vitamin E are often used interchangeably. This is strictly 
incorrect as many different tocopherols have vitamin E activity. Therefore, for the 
purposes of the thesis, both terms are used to mean the natural vitamin E isomer 
RRR-a-tocopherol. a-tocopherol is a lipid soluble molecule obtained from the diet. 
Its absorption depends upon the presence of other lipid molecules in the diet, a- 
tocopherol is found both within cells and in the extracellular space, where it is 
associated with lipo-protein particles. Intracellular a-tocopherol is mainly present 
inside membrane structures where it performs an important function as a chain- 
breaking antioxidant by scavenging lipid peroxyl radicals (1.2.4.3). There is also 
evidence, using skin cells, to suggest that a-tocopherol can act as a physical quencher 
and chemical scavenger of singlet oxygen [Thiele, 1997]. It is also important to 
remember that the tocopherols have reducing properties and can reduce Fe111 to Fe11 
and Cu11 to Cu1 and thus they can exert pro oxidant effects in some in vitro systems
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(see 1.4.2.4.) In addition, the transfer of an electron to a-tocopherol can create a 
radical that is slightly reactive with lipids.
Ascorbate (vitamin C) is a water-soluble vitamin obtained from the diet. Deficiency 
of vitamin C in the diet causes scurvy. Cells accumulate ascorbate from the tissue 
fluids against a concentration gradient coupled to uptake of Na+. Ascorbate has been 
shown to have many antioxidant properties in vitro, protecting biological molecules 
against damage by ROS and RNS. Ascorbate can quench or scavenge a variety of 
ROS and RNS such as *02, *OH, RO2*, O2*', ONOO' and HOC1. It can also restore 
the antioxidant properties of oxidised a-tocopherol in membranes by regenerating a- 
tocopherol from tocopheryl radicals. The topical application of vitamin C has been 
shown to protect porcine skin from ultraviolet radiation-induced damage [Darr et al., 
1992] and Tebbe and co-workers showed that vitamin C could inhibit UVA-induced 
lipid peroxidation in cultured human keratinocytes by regenerating a-tocopherol from 
tocopheryl radicals [Tebbe et al., 1997]. However, the experimental use of ascorbate 
at high concentrations (>lmM) can stimulate iron-dependent peroxidation of 
membrane lipids in cultured skin fibroblasts [Basu-Modak et al., 1993] by its ability 
to facilitate the reduction of Fe111 to Fe11.
p-carotene is a precursor molecule for the formation of vitamin A and is a member of 
the carotenoid family. Carotenoids are a class of linear polyenes that are widespread 
in plant tissues, algae and in some bacteria and fungi, p-carotenes act as key 
antioxidants by helping to prevent the formation of, and quenching ROS (especially 
singlet oxygen). Indeed, p-carotene administration is protective against light-induced 
skin damage in patients with porphyria [Mathews-Roth, 1982] and inhibited UV- 
induced epidermal damage as well as tumor formation in murine models [Mathews-
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Roth and Krinsky, 1987]. In a series of studies, P-carotene supplementation was 
shown to protect against sunlight-induced erythema and photoimmunosuppression in 
human skin [Gollnick et al., 1996]; [Fuller et al., 1992]. Numerous in vitro studies 
have been employed to unravel the mechanism by which p-carotene quenches singlet 
oxygen. Two major mechanisms have been proposed which consist of physical or 
chemical quenching and it is likely that both contribute [Garavelli et al., 1998].
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1.3 Oxidative stress-induced expression of genes
The term oxidative stress refers to a situation of serious imbalance between the 
production of reactive oxygen species (ROS)/reactive nitrogen species (RNS) and 
antioxidant defence. In a healthy aerobic organism, the production of ROS and RNS 
is approximately balanced by antioxidant defence systems. The balance is not perfect 
however, so that some ROS/RNS-mediated damage occurs continuously and the 
damaged molecules have to be repaired. Oxidative stress can result form diminished 
antioxidant defence or elevated production of ROS/RNS in conditions where 
phagocytic cells are inappropriately activated, for example rheumatoid arthritis. A 
diminished antioxidant defence may arise through mutations of enzymes such as 
copper-zinc superoxide dismutase (CuZnSOD), manganese superoxide dismutase 
MnSOD, or glutathione peroxidase as is observed in children with the protein 
deficiency disease Kwashiorkor. Inadequate intake of dietary antioxidants may also 
cause long-term oxidative stress, leading to life-threatening diseases such as cancer 
and heart disease [Gey et al., 1991; Ames, 1983]. There are several situations in the 
body that can lead to the increased production of oxidants. Such situations include 
exposure to elevated O2 levels, the presence of toxins that yield ROS/RNS during 
metabolism, or the excessive activation of endogenous ROS/RNS producing systems 
characteristic of phagocytic cells during chronic inflammatory responses such as 
rheumatoid arthritis and ulcerative colitis. A situation of oxidative stress within cells 
leads to the activation of protective pathways. Once the response is initiated, 
protective proteins in the form of antioxidant enzymes are induced. Transcriptional 
control of this response often occurs and involves antioxidant-response elements, 
present in the genes encoding several antioxidant enzymes. These DNA sequences 
are known to contain (among others) an activator protein-1 (AP-1) binding site. This
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response is accompanied by an adaptation to the oxidative insult. In extreme 
situations the cell may signal its own death by apoptosis or even necrosis [reviewed in 
Halliwell and Gutteridge 1999].
1.3.1 Up-regulation of specific genes by UVA radiation.
UVA radiation penetrates deep into the dermis. The response of cells, especially skin 
fibroblasts, is discussed in detail in following sections. The eukaryotic genes 
modulated by UVA radiation are, for the most part, distinct from those induced by 
shorter wavelengths. This appears to be due to the fact that UVA radiation acts 
indirectly by generating reactive oxygen intermediates (see 1.2.4), rather than being 
directly absorbed by biological molecules. There are several examples where UVA 
radiation has been shown to activate or modify gene expression and thereby lead to 
the synthesis of stress proteins. Such genes include catabolic enzymes, matrix 
components and proteins involved in signalling cascades. The UVA-modulated 
activation of genes in the skin has been implicated in the acute inflammatory 
response, erythema and immune suppression and the chronic responses of 
photoageing and skin cancer. Indeed the generation of the hydroxyl radical from 
hydrogen peroxide in the presence of UVA has been strongly implicated in the 
activation of the haemoxygenase gene in cultured human skin fibroblast cells [Keyse 
and Tyrrell, 1990]. The increased expression of haemoxygenase-1 [Keyse and 
Tyrrell, 1989] and cyclooxygenase-2 by UVA are of particular relevance to this thesis 
and are described in sections 1.3.2.1 and 1.3.2.2. Other genes are discussed below. 
Matrix metalloproteinase (mentioned previously in section 1.2.5.1), is also known as 
interstitial collagenase and is a neutral metalloproteinase that degrades extracellular 
matrix proteins including type I, type III and type IV collagen. In the skin, this
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enzyme is synthesised by fibroblasts and keratinocytes and plays a key role in the 
turnover of dermal collagen. The gene is transcriptionally activated when skin 
fibroblasts are irradiated with UVA. The induction of the cytokines interleukin-1 (IL- 
1) and interleukin-6 (IL-6) is greatly enhanced by singlet oxygen. Both IL-1 and IL-6 
are pivotal in the induction of collagenase by UVA. Expression of type VII collagen, 
a matrix protein, a major component of anchoring fibrils, is modulated in cultured 
skin fibroblasts irradiated with UVA. The protein usually described as p53 is the 
product of a tumour suppressor gene, which shows loss of function (by mutation or 
allelic loss) in many human malignancies. The UV induction and accumulation of 
p53 in human skin cells is not restricted to UVC and UVB radiation, since UVA, 
which reaches the deeper layers of the skin, also acts as an inducer [reviewed by 
Tyrrell, 1999]. Another gene that is strongly up-regulated by UVA is a dual 
specificity (thr, tyr) protein phosphatase (CL100) [Keyse and Emslie, 1992]. 
Interestingly, the only known target proteins for the phosphatase activity are the 42 
and 44 kDa (ERK2 and ERK1) MAP kinases (although other stress activated protein 
kinases are potentially substrates). An implication of this observation is that this 
enzyme may be involved in down-regulating pathways that are activated by stress and 
mitogens.
The UVA irradiation of human skin fibroblasts induces a pattern of mitogen-activated 
protein kinase (MAPK) activation consisting of rapid and transient induction of p38 
and c-Jun-N-terminal kinase (JNK) activity, but not extracellular signal-regulated 
kinases (ERK). UVA activation of p38 can be inhibited by intracellular singlet 
oxygen scavengers and the same effect has been shown for JNK [Koltz et al., 1999]. 
Several transcription factors are consequently modulated by UVA such as c-fos, an 
oncogene that has several properties related to the regulation of cell proliferation,
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differentiation and death [Bose et al., 1999]. c-fos may also dimerise with the c-jun 
protein to form the AP-1 (activator protein-1) transcription factor that modulates the 
expression of a whole series of genes [Bose et al., 1999]. AP-2 is also modulated by 
UVA, via a signal transduction cascade, and has the ability to modulate genes such as 
intercellular cellular adhesion molecule (ICAM-1) and possibly cyclooxygenase-2 
(COX-2) [Getherbeck et al, 1996; Getherbeck et al, 1997] and see 1.3.2.2.2 for further 
discussion. NF-kB (nuclear factor -kB) is a transcription factor that is a target of 
protein kinase C signalling and is involved in a variety of aspects of the immune 
response. UVA radiation at sub-lethal doses does activate the binding of NF-kB to 
well-characterised DNA recognition sequences [Vile et al., 1995], and this pathway is 
inhibitable by antioxidants and iron chelation [Reelfs, 2000]. NF-kB has the ability to 
affect many genes (containing kB recognition sites) associated with oxidative stress.
1.3.1.1 The haemoxygenases
Haemoxygenase was first described by Tenhunen and co-workers in 1968 [Tenhunen 
et al., 1968] where it was thought to be a species of P450. Subsequent work revealed 
the enzyme to be distinct from the P450 family, capable of catalysing the degradation 
of haem to biliverdin, LMrFe and carbon monoxide (CO) in equimolar amounts 
[Tenhunen et al., 1969]. To date three iso-forms of haemoxygenase (HO) have been 
identified. The expression of the inducible form, haemoxygenase-1 (HO-1), may 
increase in many tissues in response to the administration of haem, certain metal ions, 
hypoxia, cytokines, oxidised LDL, nitric oxide, and oxidative stress including UVA 
[Elbirt et al., 1999]. Several of these inducers act through antioxidant response 
elements. Stimulation of the HO-1 gene, by most stimuli, is primarily controlled at 
the transcriptional level, which is governed by recognition elements localised in the
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promoter 5’-flanking region of the HO-1 gene. HO-1 expression is suppressed by 
considerably fewer stimuli; these include angiotensin II and interferon-y [reviewed in 
Immenschuh 2000]. Haemoxygenase-2 (HO-2) is a 36kDa protein expressed 
constitutively in many tissues and located in the endoplasmic reticulum. Recently, a 
third protein species referred to as haemoxygenase-3 (HO-3) has been described in 
endoplasmic reticulum obtained from rat brain. HO-3 has a considerable sequence 
homology with HO-2 but is not as efficient at cataboiising heam to biliverdin. The 
protein has been shown to contain two haem regulatory motifs that are involved in 
haem binding, but its precise biological function(s) remains unknown [McCoubrey et 
al., 1997].
Haemoxygenases catalyse the first and rate-limiting step in the oxidative degradation 
of haem (iron protoporphyrin IX) to biliverdin, LMrFe and CO, as shown below in 
figure 1.6.
Figure 1.6. Haem degradation by haemoxygenase.
NADPH, 0 2 CO, Fe, NADP
Haem -----------   ► Biliverdin
Haemoxygenase
In mammals, biliverdin is reduced to bilirubin by biliverdin reductase (Tenhunen, 
1969) and following conjugation of this hydrophobic molecule with glucuronic acid it 
can be excreted. The active site of HO does not recognise the metal moiety of 
metalloporphyrins, rather having specificity towards the side chain of the porphyrin
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ring. Hence, zinc protoporphyrin (ZnPP) and copper protoporphyrin (CoPP) inhibit 
enzyme activity by competing against FePP. Such inhibitors are not isoform specific. 
The mechanism of the reaction between HO and its substrate has been characterised 
by Yoshida and colleagues [Yoshida et al., 1980; Yoshida et al., 1982]. HO binds 
haem to form an enzyme-haem complex. NADPH-cytochrome P450 reductase serves 
as an electron donor, transferring an electron from NADPH to haem and reducing it to 
the ferrous (Fe11) state. Haem uniquely acts as both the prosthetic group and as 
substrate. Molecular oxygen then binds rapidly to form an oxy-complex, which 
activates the cleavage of the haem molecule at the a-meso bridge (position 5) of the 
tetrapyrrole [Yoshida 1980]. The resulting complex is reduced to a ferric iron- 
biliverdin complex via intermediates. The carbon bridge is converted into CO and 
pyrole ring carbons in position 4 of ring A and position 6 of ring B are oxidised 
[Yoshida et al., 1982]. Finally, the ferric iron-biliverdin complex is reduced with the 
release of biliverdin and LMrFe11 [Yoshida and Kikuchi, 1978]. In total, 3 moles of 
oxygen and NADPH are consumed, with the production of 3 moles of water.
HO appears to be the only endogenous source of CO in the body. CO can act as a 
haem ligand, and it is postulated to be a physiological messenger molecule with 
signalling functions very similar to nitric oxide (NO) [Otterbein et al., 1999].
1.3.1.1.1 Pro-oxidant and antioxidant properties of haemoxygenase
Since HO-1 induction occurs in response to a variety of stimuli that cause direct or 
indirect oxidative stress in the host, its induction is often regarded as a stress-response 
that functions to protect organisms against oxidative stress. The precise 
mechanism(s) by which it protects has yet to be identified, although several proposals 
have been proffered (see figure 1.2). These include the removal of pro-oxidant haem
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[Stocker, 1990], (see section 1.4.3.1), the formation of the antioxidant bilirubin 
[Stocker et al., 1987] and the induction of de novo ferritin synthesis, (which can store 
LMrFe) [Vile and Tyrrell, 1993]. Bilirubin can act as a chain-breaking antioxidant by 
scavenging peroxyl and hydroxyl radicals, and reacting with singlet oxygen [Stocker 
and Ames, 1987]. Free and albumin-bound bilirubin have been reported to have an 
antioxidant activity in vitro and to be more effective than a-tocopherol [Stocker and 
Ames, 1987; Neuzil and Stocker, 1994]. The results from animal studies have lent 
support to this proposal (figure 1.3) [Yamaguchi, 1997] and data from HO-2 knockout 
mice strengthens the argument, showing that bilirubin was neuroprotective at a 
nanomolar range in cultured cells [Dore et al., 1999].
Recently, it was suggested that CO might also act as a protective agent by conferring 
increased tolerance to hyperoxia in rats [Otterbein et al., 1999].
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Table 1.2. The location and function of different iso-forms of HO (adapted from Elbirt and
Bonkovsky, 1999).
Iso-form Expression Mr Main Location Function
HO-1 Inducible 32kDa Spleen and liver 
cells
Stress protein, protects 
against oxidative stress. 
(Reviewed in Elbirt and 
Bonkovsky, 1999)
HO-2 Constitutive 36kDa Brain and testes Signal transduction in 
neural tissues and 
constitutive protection 
against oxidative stress. 
(Reviewed in Elbirt and 
Bonkovsky, 1999)
HO-3 Constitutive 33kDa Spleen, liver, 
thymus, prostate, 
heart, kidney, liver, 
brain, testes.
Unknown, it contains 
haem regulatory motifs 
and may be a haem 
sensing/binding protein. 
(Reviewed in 
McCoubrey et al., 1997)
Table 1.3. The effect of HO knockouts in animal models.
Gene knockout Effects in animal Ref.
HO-1 No increase in HO activity after hyperoxic Dennery et al.,
exposure.
Low serum iron, chronic inflammation in
1998
kidneys and liver. Poss and
Decreased stress response. Tonegawa,
1997.
HO-2 2 fold increase in lung glutathione (GSH). Dennery et al.,
Accumulation of redox active LMrFe and 
decreased tolerance to hyperoxic exposure. 
Over expression of HO-1 in the lungs of mice.
1998a
The pro-oxidant property of haemoxygenase, acting on haem, has received 
considerably less attention than its antioxidant properties. Using a microsomal 
system in which HO-1 was producing equimolar amounts of antioxidant (bilirubin) 
and pro-oxidant (LMrFe), Lamb and colleagues found that the pro-oxidant effects of 
the Fe11 outweighed the antioxidant properties of bilirubin [Lamb et al., 1999]. 
Furthermore, in an HO-2 gene-deletion mouse model, HO-1 induction increased 
oxidative injury and mortality during hyperoxia by mechanisms that appeared to 
involve the accumulation of redox active LMrFe [Dennery et al., 1998]. More 
recently, hamster fibroblasts transfected with HO-1 cDNA had moderate levels of 
HO-1 induction, which protected against hyperoxia. At higher levels of HO-1 
induction, however, LMrFe accumulation increased levels of oxidative stress during
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hyperoxia. These cytotoxic effects were limited by iron chelators and inhibitors of 
HO-1 [Suttner, 1999]. It is proposed that the levels of HO-1 expressed and the 
duration of the response determine whether it is protective or cytotoxic [Ryter et al., 
1998a]
1.3.1.2 The cyclooxygenases
Cyclooxygenase metabolites have a wide range of physiological and 
pathophysiological effects and are involved in a number of homeostatic processes. 
However, it is the role of these metabolites in cardiovascular homeostasis, 
inflammatory oedema, and pain that has made cyclooxygenase a therapeutic target of 
current interest since the majority of individuals, at some time in their lives, will be 
affected with at least one of these complications.
Polyunsaturated fatty acids (PUFAs) are used as substrates by the body to produce a 
large family of biologically active lipids called prostaglandins, leukotrienes and 
thromboxanes. These compounds are made when molecular oxygen is inserted into 
the lipid molecule by using stereospecific free radical mechanisms at the active site of 
enzymes. Such compounds are synthesised from 20 carbon-containing PUFA’s, and 
accordingly are often referred to as eicosaniods (because eikos is Greek for 20). The 
most important PUFA for their synthesis is arachidonic acid (20:4, i.e. 20 carbon 
atoms with 4 double bonds). The prostaglandins and thromboxanes act as local 
hormones and play key roles in inflammatory responses. Prostaglandins are not stored 
in tissues, but are synthesised as a result of membrane perturbations that release free 
fatty acids. The first requirement for prostaglandin synthesis is the provision of a 
fatty acid substrate, which is achieved by the release of arachidonic acid from a 
phospholipid, by activation of phospholipase A2 . Hence, substances that increase
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intracellular free calcium (a phospholipase activator) promote eicosanoid production. 
As expected, control over this process can be exerted by binding calcium. The body 
produces calcium-binding antiphospholipase proteins called lipocortins. Cell injury 
can cause intracellular free calcium to increase the levels of arachidonic acid, leading 
to increased ecosanoid production. Once arachidonic acid is available, the enzyme 
cyclooxygenase-1 (COX-1), (sometimes referred to as prostaglandin G/H synthase-1), 
acts upon the substrate to produce two endoperoxides designated PGG2 and PGH2 
(Figure 1.7).
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Figure 1.7. Structure of thromboxanes and prostaglandins derived from arachidonic acid. 
Enzymes involved: 1, cyclooxygenase, 2. glutathione S-transferase, 3. prostaglandin endoperoxide 
E isomerase, 4. prostaglandin endoperoxide reductase, 5. prostacyclin synthase, 6 and 7. 
prostaglandin endoperoxide: thromboxane A isomerase. Reactions 2 and 3 require glutathione. 
Figure reproduced from [Halliwell and Gutteridge 1999].
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13.1.2.1 COX-1
COX-1 is constitutively present in almost all mammalian tissues. It is a haem- 
containing protein, which uses molecular oxygen during the enzymatic conversion of 
arachidonic acid. Endothelial cells, platelets and kidney tubule cells are notable in 
that they express particularly large amounts of COX-1. COX-1 was initially 
identified and purified in the 1970s, using classical biochemical techniques, from 
bovine and sheep vesicular glands, and found to be a membrane bound homo-dimer 
of 70kDa. The protein contained both cyclooxygenase and peroxidase activities 
required to form respectively, PGG2 and PGH2 . Either free or protein-bound haem 
was required for activity. The primary structure of COX-1 was later determined from 
the complementary DNA sequence of 2.7 kilobases [DeWitt and Smith, 1988]. 
Cyclooxygenase activity can be inhibited by aspirin, which acetylates a serine residue 
at the active site and inactivates the enzyme.
13.1.2.2 COX-2
Cyclooxygenase metabolites are released in high amounts locally at the site of 
inflammation, or systemically after infection. It is now known that this increased 
COX activity is due to a second cyclooxygenase (COX-2). COX-2 occurs in many 
cells when the gene encoding it has been induced, although some brain and kidney 
cells may produce it constitutively. The gene encoding COX-2 is on chromosome 1, 
whereas that for COX-1 is on chromosome 9. The first observation of the 2 different 
isoforms was made when Rosen and colleges found that COX-1 cDNA probes not 
only hybridised to the 2.8 kilobase COX-1 mRNA but also to a 4.0 kilobase product 
[Rosen et al., 1989]. Analysis of the 5’-flanking untranslated region of COX-1 and 
COX-2 show that the COX-1 gene exhibits the features of a housekeeping gene,
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whereas the gene for COX-2 appears to be a primary response gene. The COX-2 
gene also contains a number of putative regulatory sites, including cyclic AMP 
response element, IL-6, AP-2, NF-kB, Sp-1, PEA-3, GATA-1 and the glucocorticoid 
response element. Interestingly, the COX-1 gene also has some putative regulatory 
sites, including Sp-1, PEA-3, AP-2, NF-IL-6, GATA-1 and a shear stress response 
element [Wu, 1995]. Although the genes for COX-1 and COX-2 are different, the 
proteins share approximately 60% homology at the amino acid level, with major 
differences resulting in a larger and more flexible substrate channel for arachidonic 
acid in COX-2 than in COX-1. Once arachidonic acid has been supplied, both 
isoforms of COX form PGG2 and PGH2 via identical enzymatic processes. In vivo, 
local increases in COX-2 have been associated with inflammatory responses, 
rheumatoid arthritis, seizures, ischaemia and cancer progression. COX-2 expression 
in the spinal cord is also elevated following peripheral inflammation. The 
intracellular pathways regulating these events appear to be numerous and 
complicated, varying between cell types and cellular stimuli. Among these pathways 
are those activated by reactive oxygen species [reviewed in Mitchell, 1999]. UVA 
irradiation of both human and murine skin fibroblast stimulates arachidonic acid 
release and cyclooxygenase activity in mammalian cells in culture [Hanson and de 
Leo, 1989]. In vivo analysis has shown an increase in the release of arachidonic acid 
and eicosanoids in iron-overloaded cardiomyocytes coupled with increased COX-2 
activity [Mattera et al., 2001] implicating iron in the modulation of COX-2.
Gene knockout mice have been produced lacking either COX-2 or COX-1. COX-1 
knockout mice seem healthy, but show decreased platelet aggregation, decreased 
inflammatory response to arachidonic acid and less iodomethacin-induced stomach 
ulceration, with the females producing fewer live offspring. COX-2 knockout mice,
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however, show more obvious pathological changes; such as, renal nephropathy, 
cardiac fibrosis and increased susceptibility to peritonitis [Halliwell and Gutteridge, 
1999].
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1.4 Iron release during cellular stress by UVA
Exposure of human skin to UV light induces significant dermal changes, which 
greatly alter the biochemistry and physiology of the skin. One such change was 
demonstrated by Bissett and co-workers, who showed that when the skin of albino 
hairless mice was exposed to UVB radiation, the level of non-haem iron increased. 
This increase in iron was associated with the UVB-induced increase in vascular 
permeability [Bissett et al., 1991].
When skin cells, growing in culture, are irradiated with a physiologically relevant 
dose (i.e. normal sun exposure of the skin) of UVA, the total amount of iron within 
the cell remains relatively unchanged, however, there is a substantial increase in 
chelatable iron. Mammalian cells control the availability of endogenous iron, by a 
post-transcriptional mechanism involving the iron-regulatory protein-1. This control 
prevents unnecessary accumulation of iron that could act as a catalyst for the 
generation of reactive oxygen species. When cultured primary skin fibroblast cells 
(FEK-4), are exposed to UVA irradiation there is an immediate release of ‘free* 
(chelatable) iron within the cell. This immediate and transient increase is a direct 
result of the proteolytic degradation of ferritin. Ferritin is the major intracellular iron 
storage protein (see 1.5.1.2) and proteolysis of ferritin is attributed to the leakage of 
lysosomal components, such as the ferritin protease: lysosomal chymotrypsin. 
Lysosomal components are released as a direct result of UVA-mediated damage to 
the lysosomal membrane [Pourzand et al., 1999]. Furthermore, the strong activation 
of haemoxygenase-1 by UVA, combined with the cyclooxygenase dependent release 
of haem from microsomal haemproteins [Kvam et al., 1999], results in the release of 
the iron from haem (see 1.3.2.1). This release of iron causes increased sensitivity of 
cells to oxidative stress [Kvam et al., 2000]. In order to better understand the
40
importance of this observation, a brief review of some of the biological roles of iron 
follows.
1.4.1. The importance of iron to aerobic life
ii.
Iron is the 4 most abundant element in the earth’s crust and metallic iron at the 
earth’s centre accounts for its magnetic field. Despite its widespread occurrence in 
rocks and mineral deposits, iron appears as only a trace constituent of natural rivers, 
lakes and seas. The reason for this apparent anomaly is the poor solubility of iron 
when present as a ferric hydroxide; the likely fate of iron at neutral pH values 
characteristic of large masses of water. Most aerobic life forms evolved to use the 
redox properties of iron to facilitate electron and oxygen transfers and to catalyse 
reactions within oxidases, oxygenases and antioxidants. The use of iron as a key 
element by complex life forms inevitably demanded the evolution of effective 
mechanisms for cells to capture and retain the iron in a safe and non-reactive state. 
Many microorganisms are able to synthesise siderophores when the availability of 
iron is scarce. These are iron-chelating chemicals that capture iron for the bacteria 
and can be internalised via specific receptors. The iron chelator, desferrioxamine 
mesylate, which will be discussed in 1.5, is an example of such a microbial 
siderophore.
1.4.1.1 Iron absorption
An average human adult contains about 4.5g of iron and if the individual is in iron- 
balance, will both absorb and excrete about lmg of iron each day. The main site of 
inorganic iron absorption is the duodenum, where iron is absorbed in the Fe11 state by 
transport proteins. Agents in the diet and the duodenal protein, duodenal cytochrome
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b (Dcytb) solubilise and reduce Fe111 to Fe11 in order to facilitate iron absorption. 
Examples of iron carrier proteins include; DMT-1 (divalent metal transport 1, (also 
known as Nramp2 (natural resistance-associated macrophage protein2)), and an iron 
export protein named IREG-1 (ferroportin-1). DMT-1 exists in both non-iron 
responsive element (IRE) and IRE containing forms that are abundant at brush 
borders of the intestine [reviewed by Lieu et al., 2001]. Once Fe11 has crossed the 
brush border into the intestinal epithelium beneath is either stored in ferritin or 
exported out of the intestinal epithelium by the aforementioned protein: IREG-1, 
where it is believed that the iron is then coupled to a ferrioxidase protein ‘hephaestin’ 
to facilitate the sequestration of LMrFe by transferrin. An antimicrobial peptide 
named hepcidin, which is present in the serum and urine, is predicted to be involved 
in the intestinal regulation of iron homeostasis because of its ability to repress 
intestinal iron absorption [Anderson, 2002]. In contrast, dietary haem iron is 
absorbed by a different pathway, whereby mucosal cells take-up the haem iron and 
enzymatically remove iron from it. The enzyme involved is probably haemoxygenase 
[Maines, 1988].
Since there are no specific mechanisms for the excretion of iron, efficient mechanisms 
exist to regulate the body’s iron content. Slight disturbances in this balance can push 
the body into states of iron-deficiency or into states of iron-overload. Both of these 
conditions significantly affect large populations worldwide.
42
Figure 1.8. Daily turnover of iron (mg) in normal adults. (Adapted from Bothwell, et al, 1979. 
Iron metabolism in man. Blackwell Oxford, and reproduced from Symons and Gutteridge, 1998. 
Free radicals and iron: chemistry, biology and medicine, Oxford).
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Absorbed iron enters the circulation bound to transferrin, although some iron remains 
within ferritin in the gut mucosal cells. The latter is lost in the faeces when these cells 
are shed.
1.4.2 Cellular and extracellular forms of iron
The 4.5g of iron present in the normal healthy adult is distributed within many 
structurally and functionally different forms. For simplicity these can be considered 




The haem molecule is a chelate of iron within four pyrole units forming a porphyrin 
ring. This haem unit can combine with amino acid residues (histidine) of the protein 
globin to form myoglobin, a protein used for storage of oxygen within muscle tissue. 
When four haem-globin units are complexed together, the haemoglobin (Hb) 
molecule is formed. Iron within haemoglobin and myoglobin is in the reduced 
ferrous (Fe11) state and binds oxygen reversibly in this form, which is the key to their 
function as oxygen transport or storage proteins. It has been estimated that around 
3% per 24 hours of oxyhaemoglobin undergoes an oxidation during its normal 
functioning to form the ferric form methaemoglobin. During this oxidation an 
electron is transferred to molecular oxygen to form superoxide (O2*"):-
HbFeII-0 2 ------------ ► HbFe111 + 0 2*'
Oxyhaemoglobin Oxidation Methaemoglobin
The HbFe111 form is unable to bind oxygen and so an enzyme methaemoglobin 
reductase exists to reduce the Fe111 back to the reactive HbFe11 form. Around two 
thirds of the body’s iron is associated with haem protens; the major contributor being 
haemoglobin.
1.4.2.2 Non-haem iron
These proteins contain iron, in transport or storage forms, but unlike haem do not 
have a porphyrin structure within the molecule. The major iron-containing proteins 
within this classification are the ferritins (discussed in 1.5), and transferrins (also 
discussed in 1.5). The ferritins are responsible for the safe storage of iron within 
cells, whereas transferrin and lactoferrin are iron transport proteins. The non-haem 
iron proteins can be made to release their iron at low pH values, whereas haem iron is
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not liable to release iron in response to pH alterations. This property is exploited in 
methods that specifically measure non-haem iron. Several non-haem iron-containing 
enzymes such as lipoxygenases, ribonucleotide reductase and aromatic hydoxylases 
also fall within this classification.
1.4.2.3 Iron-sulphur proteins
These proteins contain an iron-sulphur cluster and are essentially one-electron transfer 
centres. They are able to capture and donate electrons at very high rates and function 
within the mitochondrial electron transport chain. The citric acid cycle enzyme 
aconitase is an iron-sulphur protein and its relationship to the iron regulatory protein 1 
(IRP-1) is discussed in 1.4.4.1.
1.4.2.4 Low molecular mass iron (LMrFe)
Within cells, there normally exists a pool of low molecular mass iron that is essential 
for the synthesis of iron-containing proteins, DNA and gene signalling purposes. The 
structure and amount of this iron within cells has not been elucidated until recently. 
Development of the Calcein assay by Cabantchik and colleagues [Cabantchik et al., 
1996] has allowed direct measurement of chelatable iron within cells. Chelatable iron 
is presumed to be bound to low affinity ligands, highly available and likely to be 
redox active. The amount of iron within this pool is dependent on the type of cell, 
with values ranging from 0.2 to 1.5pM [Epsztejn et al., 1997]. The normal reducing 
environment within cells, leads to the conclusion that intracellular LMrFe is most 
likely present in the ferrous state. Even so, it does not pose a serious pro-oxidant 
threat [Halliwell and Gutteridge, 1986] since cells contain significant amounts of 
superoxide dismutase, glutathione peroxidase and catalase (see section 1.2.4.1) which
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speedily remove any (V~ and hydrogen peroxide (H2O2) likely to react with the iron. 
It is iron in this form that is a target for administered iron chelators. The extracellular 
compartments of the body, in contrast, do not normally contain LMrFe, although there 
are certain exceptions [reviewed in Symons and Gutteridge, 1998]. The bleomycin 
assay was developed specifically for the determination of chelatable iron in 
extracellular fluids obtained from normal subjects and disease states [Gutteridge et al., 
1981]. As expected, the assay revealed that human plasma from normal healthy 
individuals did not contain chelatable iron [Gutteridge et al., 1981], Human plasma 
from normal subjects contains around 3g per litre of transferrin and this is only 
around 25-30% saturated with iron, leaving a considerable iron-binding capacity. The 
ability of normal human plasma to remove ferric and ferrous ions gives it a potent 
antioxidant activity towards iron-driven free radical reactions (see 1.4.3.3), as well as 
antimicrobial properties since iron is a virulence factor for microbial growth. When 
iron is safely sequestered within extracellular components it enables the transiently 
stable reactive oxygen species (ROS) such as (V", H2 O2 and organic peroxides 
(ROOH) to perform useful functions as signal, trigger and messenger molecules 
[Gutteridge, 1995].
Low molecular mass iron, when present in extracellular compartments, has been 
found to be associated with ligands such as citrate, acetate and phosphate, and in the 
cellular environment with ATP, GTP, pyrophosphates and amino acids [reviewed in 
Symons and Gutteridge, 1998]. In addition, labile iron that enters iron pools may also 
be associated with proteins and DNA.
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1.4.3 Pro-oxidant forms of iron
The ability of ferrous ions to transfer electrons to molecular oxygen and form reactive 
oxygen species (ROS) necessitates the evolution of a variety of protective 
mechanisms to control the formation of damaging oxygen species.
1.4.3.1 Low molecular mass iron as a pro-oxidant
Ferrous iron in solution at a physiological pH value of 7.4 will rapidly autoxidise with 
the transfer of an electron to molecular oxygen
Fe11 + 0 2 *— ~ (Fe11—0 2 +— ~ Fem- O n * — ~ Fe111 + 0 2"
(pH 7.4) [4]
reducing it to superoxide (equation [4]). This O2*‘ can dismutate to form H2O2 
(equation [5]), which in turn
2 02* + 2YC----------► H2O2 + O2 [5]
can react with some of the ferrous ions to yield hydroxyl radicals (*0H) by the Fenton 
reaction (equation [6 ]). It is often proposed that a ferryl species (Fe™) such as Fe02+ 
is formed during Fenton chemistry and contributes to the oxidative damage observed. 
However, there is no clear evidence for their existence in Fenton systems.
Fen + H20 2 ----------► *OH + OH-  + Fem
[6]
At a low pH, the autoxidation of Fe is prevented. Ferric salts in the presence of a 
suitable reductant, such as ascorbate, will yield *0H radicals by reaction sequences
47
shown in equations 4, 5 and 6 . Addition of a ferric salt to H2O2 will also yield *OH 
radicals albeit at a considerably slower rate and yield compared to the addition of a 
ferrous salt [Walling et al., 1970]. The above examples of iron participating in the 
formation of ROS are inorganic reactions. Iron also reacts with organic peroxides 
such as lipid hydroperoxides (LOOH) to form organic ROS such as alkoxyl (LO*) and 
peroxyl (LOO*) radicals (equation [7],[8 ])
Fe11 + LOOH---------- ► Fe111 + LO* + OH~
[7]
Fe111 + LOOH---------- ► Fe" + LOO* + H+
[S]
1.4.3.2 Haem iron as a pro-oxidant
Ferrous ions chelated in the porphyrin ring of haem do not readily transfer electrons 
to molecular oxygen to form superoxide, in the same way that free ferrous ions do 
(equation [4]), (although, as mentioned in section 1.4.2.1 around 3% per 24 hours of 
the body’s oxygen bound haemoglobin (oxyhaemoglobin) undergoes a further 
oxidation with the transfer of an electron to molecular oxygen). Haem iron, however 
appears to act as a prooxidant by decomposing existing lipid hydroperoxides and in 
the process forming LO* and LOO* radicals that are able to abstract a hydrogen atom 
from a polyunsaturated fatty acid (PUFA) and stimulate a lipid free radical chain 
reaction (section 1.2.4.3). Another way in which haem iron can act as a prooxidant 
after reacting with H2O2 or LOOH, is to undergo a fragmentation with the release of 
LMrFe from the porphyrin ring [Gutteridge, 1986]. The LMrFe is chelatable and able 
to participate in the reactions described in section 1.4.3.1.
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Haem iron at the active centre of enzymes such as peroxidases is known to form ferryl 
species as intermediates. These, however, are not released into free solution.
1.4.3.3 Antioxidant protection against iron
As previously mentioned, the body does not have a specific mechanism for the 
excretion of iron and absorption is closely matched to an iron loss of around lmg per 
day when in normal iron balance. The body, therefore, is dependent on retaining and 
recycling its existing iron stores. When transporting and storing iron in biological 
systems, reactivity of the iron with oxygen must be kept to a minimum. 
Consequently, transport and storage proteins such as transferrin, lactoferrin and 
ferritin sequester iron in forms that do not participate in the reactions described in
1.4.3.1. Transferrin and lactoferrin are normally only partly loaded with iron and 
retain a considerable iron-binding capacity. This gives these proteins the potential to 
act as powerful antioxidants when LMrFe is the pro-oxidant [Gutteridge et al., 1981]. 
Studies with ferritin have yielded conflicting data concerning its ability to stimulate 
free radical reactions [Gutteridge et al., 1983]. However, it appears that around 10% 
of iron associated with ferritin is not loaded into the central core and can be released 
to participate in free radical reactions [Bolann and Ulvik, 1990]. The energy- 
dependent storage of iron within the central core of ferritin can therefore be regarded 
as a safe form of iron within biological systems. The major copper-containing protein 
of mammalian plasma is caeruloplasmin (Cp), an acute phase protein that responds to 
tissue damage. Caeruloplasmin has a ferroxidase activity, i.e. it is able to catalyse the 
rapid oxidation of ferrous ions to the ferric state (equation [9]), which can then bind to 
transferrin.
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4Cp-Cun + 4Fen + 0 2 + 4H+ *• 4Cp-Cu’ + 4Fem + 2H20  
[9]
When iron is the pro-oxidant, two proteins, namely transferrin and caeruloplasmin 
(representing no more than 4% of the total plasma proteins), are responsible for over 
90% of antioxidant protection shown by plasma [Gutteridge and Quinlan, 1992]. 
Plasma also contains proteins that bind haemoglobin and haem, ensuring that iron is 
conserved and recycled. Haptoglobins form stable complexes with haemoglobin 
ensuring that pro-oxidant haem is removed from plasma [Gutteridge, 1987] and iron 
is reused. Similarly, haemopexin binds haem with a high affinity for transport and 
release in the liver, ensuring that iron is conserved and pro-oxidant haem is safely 
removed [Gutteridge and Smith, 1988].
Other proteins within cells may sequester and transport pro-oxidant forms of iron. 
The recently discovered mitochondrial protein frataxin is such an example. Frataxin 
binds Fe11 and decreases its rate of oxidation to Fem. There is also evidence that 
frataxin may export iron into the cytoplasm [Adamec, 2001].
As previously mentioned in 1.4.2.4, protection against the reactivity of iron within the 
extracellular environment is achieved by sequestering iron in non, or poorly reactive 
forms [Halliwell and Gutteridge, 1986]. Within cells, however, iron is allowed to 
safely exist in a low molecular mass state, because ROS are effectively removed 
[Gutteridge, 1995]. This latter observation is of key importance to the work presented 
in this thesis, which describes attempts to manipulate the basal levels of cellular iron 
using chelators and to observe alterations in gene expression that occur as a 
consequence.
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1.4.4 Iron as a biological signalling molecule
Low molecular mass forms of iron are present inside cells (see section 1.4.2.4) and 
cells have evolved to adapt to the presence of such iron by carefully controlling levels 
of reactive oxygen species (section 1.4.3.3) and ensuring they do not interact with the 
iron. LMrFe is used by the cell for the synthesis of iron-containing proteins and as a 
signal carrier to regulate its own cellular uptake and turnover through the iron 
regulatory proteins (IRPs).
1.4.4.1 The iron-regulatory proteins
The expression of cellular ferritin and of the transferrin receptor (TfR) on the surface 
of cells is regulated post-transcriptionally by the IRPs. Two IRPs have been 
identified, namely IRP-1 and IRP-2. They are monomeric proteins, with a mass of 
90-95kDa and 105kDa, respectively, that are present in the cell cytosol. When the 
IRPs are activated they bind to iron responsive elements (IREs) in untranslated areas 
of the TfR and ferritin mRNAs [Klausner et al., 1993]. The IREs are stem-loop 
structures located in the untranslated 5’ region of ferritin mRNA and the 3’ region of 
untranslated TfR mRNA [Theil, 1994]. The binding of IRPs to IREs on ferritin 
mRNA is triggered by low levels of cellular iron and results in an inhibition of ferritin 
synthesis. In this process, the mRNA is prevented from associating with the 
ribosome. When IRPs bind to the IRE of TfR mRNA it prevents proteolytic 
degradation by targeted endonucleases, so stabilising the mRNA and resulting in 
increased synthesis of the TfR.
When cellular levels of iron are high, the IRPs are inactivated and ferritin synthesis is 
increased whilst TfR synthesis is inhibited. In this way, iron signals its own uptake
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and storage within cells. Activation of the IRPs involves an iron-sulphur cluster 
which, depending on its iron content, acts either as an RNA-binding protein or as a 
cytoplasmic aconitase i.e.
(3Fe-4S)+ + Fe11 ----------- ► (4Fe-4S)2+
[10]
IRP-2 does not show aconitase activity, nor does it possess an iron-sulphur cluster. It 
appears to be regulated by the proteosome-mediated degradation. Haem also appears 
to be capable of mediating IRP-2 degradation [Goessling et al., 1998].
Although iron is the major regulator of IRP activity, agents other than iron appear to 
be able to directly or indirectly activate the IRPs. Such agents include oxidants, 
inflammatory mediators and hypoxia. Often the responses elicited for IRP-1 and IRP- 
2 by these mediators are opposite [Recalcati et al., 1998; Hanson et al., 1999]. The 
IRPs show a highly conserved sequence identity in advanced life forms, suggesting 
that they are of vital importance for iron homeostasis.
1.4.4.2 IRP independent iron signalling
Several genes, which do not contain IREs, appear to be modulated directly or 
indirectly by iron. Many studies have focused on the ability of iron to generate ROS 
which act as secondary messengers, capable of altering gene expression via 
transcription factors such as NF-kB (nuclear factor -kB) and AP-1 (activator protein- 
l)[Hancock and Neill, 1999]. For example, in the presence of iron, lipid peroxidation 
can lead to the formation of various reactive aldehydes such as 4-hydroxy-2-nonenal.
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This n- 6  fatty acid peroxidation product exhibits many profound biological effects, 
and has recently been shown to inhibit NF-kB activation by preventing IkB 
phosphorylation [reviewed in Quinlan et al., 2001]. ROS may modulate P53 activity, 
(a tumour suppressor gene, responsible for cell cycle control) [Meplan et al., 2000]. 
Furthermore, there is strong evidence to suggest that several cellular signalling 
pathways are altered by ROS. ROS are known to associate with some well-known 
regulatory molecules such as: protein tyrosine kinase (PTK), protein kinase C (PKC), 
mitogen activated protein kinase (MAPK), NF-kB, AP-1 and Ca2+, cGMP [Qiu and 
Zeng 2001].
Iron has been known to have a direct effect on the expression of certain genes. This is 
illustrated in the microorganism Saccharomyces cervisiae, which contains a RAP-1 
binding site that confers iron-repressive transcriptional activity on heterologous 
downstream promoter elements [Dancis et al., 1992]. In the liver of rats, the 
accumulation of iron causes an increase in the antioxidant proteins Mn-dependent 
SOD and y-glutamyl transpeptidase (a key enzyme in the synthesis of glutathione).
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1.5 Iron-binding mechanisms
1.5.1 Sequestration of iron by biological proteins
Iron is carefully retained and recycled by the body for reasons discussed in section
1.4.1. In addition, the ligands evolved to carry out these functions do so in a way that 
keeps iron as poorly reactive in electron transfers to molecular oxygen as possible 
(1.4.3).
1.5.1.1 Transferrin and lactoferrin
Human plasma transferrin has a Mr of around 79,000 and binds 2 moles of 
mononuclear ferric ions per mole of protein. In order for iron to bind to transferrin an 
anion, usually bicarbonate (HCO3") is required to be present. Transferrin has an
affinity for ferric ions of around 1 0 22 and in normal healthy individuals is around one 
third loaded with iron. Its available iron-binding capacity, and therefore its ability to 
sequester LMrFe, gives transferrin antimicrobial properties, because of its ability to 
deprive bacteria of iron essential for their growth, and (as previously discussed in 
1.4.3.3) antioxidant properties as well. The release of iron from transferrin is 
triggered by a fall in pH in which the bicarbonate ligand plays a key role in being 
converted to CO2 .
Most of the plasma transferrin is synthesised in the liver and secreted as the 
apoprotein. Iron loaded transferrin enters cells via transferrin receptors (TfR) on the 
surface of cells. Expression of these TfR’s is determined by the cells requirement for 
iron and is post-transcriptionally regulated by the iron regulatory proteins which 
increase the stability TfR mRNA when bound to corresponding elements present in 
the mRNA (see 1.4.4.1). In addition to this major receptor-mediated transfer of iron
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into cells, there is a minor transferrin-independent membrane-bound pathway, which 
involves a ferrireductase enzyme and a Fe11 transmembrane transport system [Eide, 
1992]. Once iron-loaded transferrin is inside the cell, iron is released from the 
complex by an acidification process involving a protein-pumping ATPase, within an 
endosome. The released iron is used for synthesis of iron-containing proteins, 
whereas the remaining apotransferrin is returned to the circulation to continue its 
cycle.
Lactoferrin is present in milk and other body secretions and is released from activated 
neutrophils at sites of inflammation. It has a Mr of around 82,000. Like transferrin, it 
binds 2  moles of ferric iron per mole of protein, but holds onto this iron more tightly 
at low pH values [Johansson, I960]. Its exact biological roles are not yet clear, with 
proposals made that it binds to DNA and may influence gene transcription [reviewed 
in Halliwell and Gutteridge, 1999], effects cells of the immune system [reviewed in 
Halliwell and Gutteridge, 1999] and may be an important antimicrobial agent in milk 
[Ellison et al., 1988].
1.5.1.2 Ferritins and haemosiderin
Once inside the cell, iron is stored within two major proteins, namely ferritin and 
haemosiderin. Large amounts of ferritin are present in liver parenchymal cells, 
although there is probably some ferritin in all human cells. Ferritin is a water-soluble 
molecule with a Mr of around 480kDa, composed of a hollow protein shell of 24 
subunits, which can contain up to 4,500 atoms of iron. Iron enters the protein as Fe11 
but is stored as Fem in an iron-core, sequestered within a protein shell. In order for 
iron to exit the core and return to the cellular iron pool, it must be converted back to 
Fe11. This reductive conversion may involve an electron transfer mechanism [Kadir
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1991], or perhaps entry of a reductant to within the core. Human ferritins are 
composed of two subunit types known as H- and L- chains. The H-chain has a metal 
binding site involved in its ability to catalyse the oxidation of Fe11 to Fe111 (ferrioxidase 
site). Tissue ferritins widely vary in their H/L ratios, ranging from H2 4L0  to H0L24 and 
these ratios can further change in a variety of disease states [reviewed in Crichton, 
1991].
Haemosiderin, unlike ferritin, is not water soluble and is excessively deposited in 
tissue lysosomes when iron overload occurs. During iron-overload diseases, such as 
idiopathic haemochromatosis, iron rich ferritin molecules accumulate in the cell 
cytosol when they form clusters that are taken up by lysosomes. Clusters undergo 
proteolytic degradation, which decreases the protein content and leaves an iron-rich 
core known as haemosiderin. Similar iron cores can be produced in vitro by 
subjecting ferritin to free radical damage [O’Connell and Peters, 1986].
As previously mentioned in section 1.4.2.4, ferritin can release a small amount of 
LMrFe when under oxidative stress. The iron released appears to be that associated 
with a ‘pool’ at the surface of the core and not that loaded into the core. 
Haemosiderin is less prone than ferritin to release iron under oxidative stress 
[O’Connell and Peters, 1986]; hence the conversion of ferritin to haemosiderin could 
be viewed as a protective stratagem during situations of iron overload [O’Connell 
1987].
1.5.1.3 Haptoglobins and haemopexin
The haptoglobins are plasma glycoproteins with molecular masses of around 86,000. 
They bind haemoglobin in a 1:1 ratio to form stable complexes with an extremely 
tight bonding between the proteins. There is sufficient haptoglobin in the total plasma
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volume to bind and conserve around 3g of haemoglobin. Iron conservation and 
recycling is their main function, but as previously noted, they also decrease any pro­
oxidant potential free haemoglobin may have in the circulation [Gutteridge, 1987]. 
The haptoglobins do not bind haem iron and there exists in the plasma a specialised 
haem-binding protein known as haemopexin, with a Mr of around 60,000. The 
haemopexin-haem complex is transported into the liver and enters cells by a receptor- 
mediated process. Inside the cell, haem is released and the apo-protein returned to the 
circulation as an intact protein [Gutteridge and Smith, 1988]. Haemopexin is not the 
only haem-binding protein in the plasma, since albumin tightly binds haem to form a 
complex known as methaemalbumin. As discussed for other iron complexes, the 
binding of haem to haemopexin greatly decreases the pro-oxidant properties of haem.
1.5.2 Iron chelators
The word ‘chelate’ was coined by Morgan and Drew in 1920 to describe bidentate 
ligands in which each ligand has two binding sites. A monodentate ligand (L“ )
complexes with a metal ion (M+) in the following way, whereby the ligand is free to
leave the complex (M-L) on dissociation:
M-L M+ + L ~
[11]
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7  L —  L ~
[12]
One of the L units is free close to M and reassociation is unimolecular. If it returns
before the other M-L bond breaks, then complete dissociation will not occur.
The widely used iron chelator, ethylene-diaminetetraacetic acid (EDTA), can 
coordinate metal ions via its nitrogen and oxygen, making it potentially hexadentate.
EDTA (figure 1.9) forms extremely stable complexes with ferric ions, with a stability 
constant of around 25. Other types of chemical chelators such as the bidentate 
ferroin-type compounds form stable complexes with ferrous ions and in the process 
produce intense chromophores. Examples of these are, 2,2-dipyridyl, ferrozine and 
bathophenanthroline, widely used for measuring non-haem iron in plasma and other 
fluids.
Figure 1.9. The structure of the chelator EDTA at pH 7.4.
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In addition to the chemically synthesised iron chelators described above, there are a 
group of naturally occurring iron chelators that have been isolated from 
microorganisms, and are known as siderophores. Iron is essential for the growth of 
most aerobic microorganisms and when deprived of it they synthesise siderophores to 
capture iron from their environment. These siderophores have high affinity and 
specificity for iron and allow the microorganism to acquire iron [reviewed in 
Neilands, 1995]. Many of these microbial siderophores have been isolated in recent 
years and chemically modified in attempts to produce chelators for clinical use in 
conditions such as idiopathic haemochromatosis and p-thalassaemia [reviewed in 
Bergeron and Brittenham, 1994].
1.5.2.1 Clinical use of iron chelators for iron-overload
Iron-overload is a chronic condition that occurs over a period of time resulting in high 
body iron stores, particularly in the liver. Examples of diseases that cause this to 
occur are primary iron-overload seen in idiopathic haemochromotosis [reviewed by 
Halliday and Powell, 1992] and secondary iron overload conditions such as p- 
thalassaemia [reviewed by Hershko and Rachmilevitz, 1975]. To treat these diseases, 
by lowering body iron stores, chelation therapy was introduced [reviewed in Bergeron 
and Brittenham, 1993]. This involves introducing a powerful iron chelator capable of 
removing iron from tissue iron stores. The chelator currently in widespread use, 
which has a product licence for this purpose, is the microbial siderophore 
desferrioxamine mesylate. The advantages of this type of therapy are apparent with a 
substantial decrease in iron stores, and an ability to maintain a low level that 
decreases associated iron toxicity. Indeed, a subcutaneous infusion of DFO, usually 
overnight, is enough to completely diminish existing liver iron stores and in the
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longer term increase the life expectancy of liver fibrosis patients. However, patients 
with iron overload who receive iron chelation therapy often undergo a lengthy and 
traumatic intravenous transfusion five days per week and for patients receiving 
intensive therapy, there is an associated neurotoxicity and visual impairment. Patients 
receiving continuous 24-hour infusions of DFO to treat established organ damage 
may also suffer from hearing loss [Bergeron and Brittenham, 1993].
1.5.2.2 Desferrioxamine mesylate
Desferrioxamine mesylate (DFO) is a siderophore produced by Streptomyces pilosis. 
It is a hexadentate iron-chelator with a powerful affinity for ferric ions (binding 
constant for ferric ions of 1030 M’1)
F ig u re  1 .1 0 . T h e  str u c tu r e  o f  th e  iro n  c h e la to r  D e s fe r r io x a m in e  B . Iro n  c o m p le x e s  w ith  six  
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Desferrioxamine binds ferric ions in a 1:1 ratio forming a bright red complex known 
as Ferrioxamine. The complex o f iron and DFO prevents iron participating in free 
radical reactions such as lipid peroxidation and Fenton chemistry [Gutteridge et al.,
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1979]. In addition, the ferrioxamine complex is poorly reduced, if at all, by 0 2 *" or 
by cellular electron transport systems [reviewed by Halliwell, 1989].
DFO is widely reported in the literature as being unable to enter cells. However, 
Lloyd et al., showed in 1991 that DFO does not enter cells by passive diffusion, but it 
can enter cells by pinocytosis and once internalised, it will remain in the lysosomes 
[Lloyd et al., 1991].
1.5.2.3 Salicylaldehyde isonicotinyl hydrazone
Salicylaldehyde isonicotinyl hydrazone (SIH) was developed as a lipophilic analogue 
of the parent compound pyridoxyl isonicotinyl hydrazone (PIH). PIH was developed 
in response to the problematic use of DFO therapy in certain patients. PIH and its 
anologues have been studied for more than 1 0  years as promising new candidates for 
iron chelation therapy in iron-overload diseases. Sub-millimolar levels of SEH can 
inhibit the Fem-EDTA/ascorbate-mediated formation of *OH radicals or hydroxyl-like 
oxidants, tested by the release of ethylene from 2-keto-4-methylthiobutyric acid 
(KBM assay) and the formation of malondialdehyde from 2-deoxyribose. SIH also 
decreases the rate of Fem-EDTA mediated oxidation and blocks the peroxidation of 
rat brain liposomal phospholipids, induced by ferrous iron-EDTA [Schulman et al., 
1995]. SIH also protects plasmid pUC-18 DNA against *OH-mediated strand breaks. 
Iron efflux from cells is very rapid when complexed to SIH, as there is an active 
removal of iron-chelator complex from the cell [Hermes-Lima et al., 1998].
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Figure 1.11. The structure of SIH, reproduced from Schulman et al., 1995.
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A series of tyrosinate protein compounds have been synthesised which possess ‘mild’ 
iron chelating properties. The ligands that bind iron are derived from the 
condensation of salicylaldehyde and L-amino acids. The iron-chelating properties of 
such molecules arise from ligand residues that are potential electron donor groups of 
Fem in the proteins, e.g. the imidazole and carboxylate groups of the amino acid 
residues [Casella et al., 1987]. Kitazawa and Iwasaki recently focused their research 
on these tyrosinate compounds, as they believed that such compounds showed great 
similarity to the iron-binding site of iron-binding proteins. Moreover, these synthetic 
complexes were analogous to iron with respect to the occupation of the iron-binding 
site and the catalytic states of iron. It was therefore, expected that the mimetic 
compounds would only chelate iron released from safe sequestration within the cell 
and prevent this chelated iron from catalysing free radical reactions [Kitazawa and 
Iwasaki, 1996].
In 1999, Kitazawa and Iwasaki tested two such novel compounds, namely 
hydroxybenzyl serine (HBSer) and hydroxybenzyl glycine (HBGly), in a cell model 
involving the UVB irradiation of murine dermal fibroblasts.
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Figure 1.12. Synthesis of HBSer and HBGly. Compounds are synthesised by the condensation of 
the corresponding amino acid with salicylaldehyde in an alkaline solution to form the N- 
salicylidene amino acids and their direct catalytic reduction. Figure has been reproduced from
Kitazawa and Iwasaki, 1999.
R
6nh-(COOH  .OHr
H B G ly : R =H  
H B Ser : R = C H 2OH
In Vitro studies showed that HBSer and HBGly formed 2:1 complexes with ferric iron 
with an affinity of log Ka = 21-22 and effectively inhibited iron-induced hydroxyl 
radical formation. They also suppressed UV-induced cytotoxicity in a cell model 
using murine dermal fibroblasts, (measured by the MTT cytotoxicity assay). In the 
same study, Iwasaki and Kitazawa showed that the iron chelator DFO was ineffective 
in protecting against UV-induced cytotoxicity [Kitazawa and Iwasaki, 1999].
More recently, the compound HBGly has been shown to effectively suppress UVB- 
induced inflammatory responses mediated by IL-la and NF-kB in keratinocyte cells 
[Iwasaki et al., 2001].
1.5.3 Gene induction by the removal of basal iron from cells
The design of clinically useful iron chelators has concentrated on their ability to bind 
iron (III) with high affinity, enabling them to be used for the treatment of body iron 
overload diseases [reviewed by Hershko and Rachmilevitz, 1975]. This is very useful 





fibrosis and organ failure. When, however, such compounds are used in clinical 
conditions where there is a disturbance in iron homeostasis but no evidence of body 
iron overload, their high affinity for ferric iron can have serious consequences. The 
use of DFO in patients with rheumatoid arthritis for example caused depletion of 
brain iron and induced coma [Blake et al., 1985].
Iron chelators can modulate gene expression by manipulating intracellular iron 
levels, specifically at the post-transcriptional level through the IRPs (see 1.4.4), but, 
also in an IRE independent manner. This section shall focus on genes that are 
modulated by iron removal, but do not involve the IRPs.
Iron chelators have been known to act as effective antiproliferative agents. Some 
chelators can inhibit the activity of ribonucleotide reductase, an enzyme critical for 
the conversion of ribonucleotides to deoxyribonucleotides. A decrease in 
deoxyribonucleotide concentration is thought to prevent DNA synthesis, which then 
results in Gi/S arrest. This observation was studied further by Darnell and 
Richardson, who were able to show that the chelators DFO and pyridoxal isonicotinyl 
hydrozone (PIH), affected several p53-transactivated genes. These genes are crucial 
for cell cycle control and DNA repair and include wild-type p53 activating fragment 
(WAF-1), growth arrest and DNA damage gene (GADD-45) and the murine double 
minute gene (mdm-2) [Darnell and Richardson, 1999].
Iron chelation, using DFO, was shown to have a beneficial effect when administered 
to patients infected with the HIV-1 virus. It was found to decrease the bioavalibility 
of tumour necrosis factor alpha (TNF-a), preventing the replication of HIV-1 in 
mononuclear cells. The study also showed that DFO decreased the activity of the 
transcription factor NF-kB. The authors hypothesised that it was the decrease in NF- 
kB activity that resulted in decreased TNF-a biological availability [Bellocq et al.,
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1998]. TNF-a has been shown to increase the expression of COX-2, as well as 
overall cyclooxygenase activity. However, the administration of DFO to an intact cell 
system increased eicosanoid production in a cyclooxygenase-dependent manner 
[Laughton et al., 1989]. More recently, Tanji and collegues demonstrated an increase 
in COX-2 expression and activity in response to DFO [Tanji et al., 2001]. When 
cardiac myocyte cells were treated with DFO, there was a subsequent decrease in an 
extracellular factor that modulates matrix assembly. This factor is called 
transforming growth-factor-1 (TGF-1). There was also a parallel decrease in the 
mRNA expression of the matrix component collagen type I and the proteoglycan 
biglycan. In this study DFO was used at a high concentration (ImM) for 48 hours 
[Parkes et al., 2000].
A more detailed study was performed by Ye and Connor in which brain glial tumour 
cells (astrocytoma cells) were screened for the induction or suppression of genes 
following iron chelation with DFO. The authors’ primary interest was to see whether 
iron chelators could restrict tumour progression [Ye and Connor, 1999]. Ye and 
Connor performed a comprehensive study of the modulation of genes by DFO. They 
treated cells with 50pM DFO for 48 hours and performed two-dimensional 
suppression subtraction hybridisation using the mRNA from DFO treated cells. 
Reverse Northern blots were used to screen the cDNAs generated by PCR and 
Northern blot analysis was used to confirm the modulation of a gene by DFO. 
Figures 1.13 and 1.14 show the modulation of known and novel genes by DFO.
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Confirm ed by 
N orthern  
blot
Hum an glyceraldehyde-3-phosphate dehydrogenase  
(GAPDH) m RNA
Y es
Hum an grow th factor-inducible 2A9 gene Y es
Human lam in in  receptor hom olog Y es
Hum an SnR N P core protein  Sm  D2 mRNA Y es
Homo sap ien s M eta llop an stim u lin  m RNA Y es
Homo sap iens cG M P-PDE gene N o
Hum an clone 23722 m RNA N o
Hum an cytochrom e c ox idase su b u n it I N o
H um an ficolin m RNA N o
Hum an mRNA for TI227H N o
Novel gene: ASM  1 (G enBank #: AF 169959) No
Novel gene: ASM  2 (G enBank #: AF 169958) No
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Figure 1.14. Reproduced from Ye and Connor, 1999 and displays the 29 mRNA species
inhibited by DFO
Deferoxamine Inhibited mRNA Species
G ene N am e
Confirm ed by 
N orthern  
blot
N ovel gene: DEFIG  (D ef inh ib ited  gene) 1 Yes
G en B a n k fA F l 69482
N ovel gene: DEFIG  (D ef inh ib ited  gene) 2 Yes
G enB ank# AF 189956
N ovel gene: D EFIG  (D ef inh ib ited  gene)3 Y es
G enB ank# A F 169957
Hom o sa p ien s dbpB -like protein  m RNA Yes
H om o sa p ien s m itochondrial c o x ll m RN A for Yes
cytochrom e C ox id ase  II su b u n it
H om o sa p ien s cytochrom e C oxidase su b u n it III Yes
m RNA
H omo sa p ien s cox V llb  m RN A for cytochrom e C Yes
oxidase su b u n it V llb
H um an N A D H :ubiquinone oxidoreductase MLRQ Yes
su b u n it m RNA
H um an M itochondrial A T P ase coupling factor 6 Yes
m RNA
H um an m R N A  for proteasom e su b u n it z Yes
H um an m R N A  for proteasom e su bu n it hsC  10-11 Y es
H um an C a2-activated  n eu tra l protease  large Y es
su b u n it (CANP)mRNA
Hom o sa p ien s proteasom e su b u n it XAPC7 m RN A Y es
H um an m R N A  of branchio-oto-renal syndrom e Y es
candidate gene
Hom o sa p ien s nucleophosm in m RNA Y es
H um an m R N A  for orn ith ine  decarboxylase Yes
a ntizym e
H um an G protein  G am m a-11 su b u n it m R N A Yes
H om o sa p ien s  clone 24408 2-oxoglutarate carrier Y es
protein  m RNA
H um an cortex m RN A conta in ing  an  A lu rep etition Y es
elem en t
H om o sa p ien s androgen receptor asso c ia ted  protein Y es
24 m RN A
H um an m RNA for TI227H Y es
H um an prothym osin  a lph a  m RNA Y es
H um an ribosom al protein L28 m RNA Yes
N ovel gene: ASM  1 (Gene bank num ber: AF No
169959)
H om o sa p ien s SR protein  fam ily, pre-m R NA No
sp lic in g  factor(SR p20)m RN A
H om o sa p ien s  m RNA from H IV -associated  non- No
H odgkin’s  lym phom a
H um an D N A -dependent protein  k in a se  cata ly tic No
su b u n it m RNA
H um an acid ic ribosom al phosphoprotein  PO  m RNA No
Hom o sa p ien s  m RNA from  ribosom al protein  L31 No
Ye and Connor showed an increase in the expression of 12 mRNA species and a 
decrease in 29 different mRNA species, some of which were novel cDNAs [Ye and 
Connor, 1999].
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1.5.3.1 Induction of HIF-1
The optimal delivery of oxygen to cells and tissues is essential to ensure adequate 
energy provision and to avoid the toxic effects of higher oxygen concentrations. For 
this to occur, organisms must be able to sense oxygen and respond to changes in 
oxygen tension by altering gene expression [Gleade and Ratcliffe, 1998]. Cells have 
evolved to utilise a transcription factor called hypoxia inducible factor-1 (HIF-1) to 
facilitate such changes in the expression of physiologically relevant genes. The 
transcription factor HIF-1 is a heterodimer composed of the helix-loop-helix / Per- 
Amt-Sim protein HIF-1 a  and the aryl hydrocarbon nuclear translocator (ARNT) also 
known as HIF-1 p. In 1993, Wang and Semenza discovered that DFO induced HIF-1 
DNA binding. Since this key observation was made, several other ‘high’ affinity iron 
chelators, such as mimosine, SIH and deferiprone [Wanner et al., 2000] [Dalle et al., 
2000] have been shown to elicit the same response. Iron chelators, especially DFO, 
have been used as standard models for hypoxic signal transduction.
In order to elicit this change, an active HIF-1 complex must accumulate in the nucleus 
and bind to a specific DNA sequence, that is, the HIF-1 binding site within the 
hypoxia responsive element (HRE), (an 8  base pair sequence 5’-TACGTGCT’ in the 
erythropoetin enhancer element). Such binding enhances the expression of genes 
containing HREs.
Although much research has focused on the mechanism by which various stimuli 
cause HIF-1 to accumulate in cells, the exact reason for the increased HIF-1 activity 
elicited by iron chelation remained, until recently, unclear. In 1988, Goldberg et al., 
provided evidence to show that the oxygen sensor regulating HIF-1 was a haem 
protein. This finding helped explain how metals, (such as cobalt), which activate 
HIF-1 activity, could substitute for the central iron atom in the haem moiety, allowing
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it to remain active [Goldberg et al., 1988]. Further investigation showed that the 
haem ligand carbon monoxide (CO) could suppresses the hypoxic activation of HIF-1 
[Zhu and Bunn, 1999] further supporting the findings of Goldberg et al. The proposal 
was also made that iron chelators could access the iron in or around the oxygen 
sensing haem protein, without abstracting it, causing the oxygen sensing haem protein 
to remain in its active conformation [Gleade and Ratcliffe, 1998].
Accumulation of HIF-1 has also been attributed to the generation of reactive oxygen 
species such as superoxide (O2*") and hydrogen peroxide (H2O2), but in the absence 
of oxygen these species cannot be produced. When oxygen levels are restored, such 
species may rapidly degrade the HIF-1 a  subunit. It is proposed that chelators may 
prevent metal ions, particularly iron, from catalysing the production of such ROS, and 
thereby lead to the increased prevalence of HIF-la [Fandrey et al., 1997].
Very recent research into the mechanistic activation of HIF-1 has been based on the 
evidence that HIF-1 activity is determined by the presence/absence of the HIF-la 
subunit. In several types of cells the expression of the HIF-la subunit is controlled 
by extracellular stimuli such as hypoxia, cobalt chloride and iron chelators. These 
extracellular stimuli elicit the activation of signalling cascades such as the mitogen 
activated protein (MAP) kinase signalling cascade, which ultimately serves to 
regulate transcriptional events within the nucleus. However, it was discovered that 
certain cell lines constitutively expressed both HIF-la and HIF-1 p at the mRNA 
level, whereas, at the protein level, HIF-la is degraded under normoxic conditions in 
complete contrast to the constitutively expressed HIF-1 p protein. This finding has led 
to a widely accepted and ultimate mechanism of HEF-1 modulation. Studies in Von- 
Hippel-Lindau-defective renal carcinoma cells indicated that the Von-Hippel-Lindau 
prolyl hydroxylase enzyme fulfils a critical function in HIF-la degradation, thus
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accounting for the extremely short protein half-life [Zhu and Bunn, 2001] [Sandau et 
al., 2001]. The mechanism for the rapid degradation of HIF-la appears to be a 
ubiquitin-proteosome pathway. HIF-la binds to the von Hippel-Lindau tumor 
suppressor protein (pVHL), which forms the recognition component of an E3 
ubiquitin ligase complex leading to ubiquitylation of HIF-la and subsequent 
proteasomal destruction (figure 1.15) [Epstein et al., 2001].
Figure 1.15. A simplified diagrammatic representation showing the mechanism for the 
degradation of the H IF-la protein under conditions of normoxia. pVHL represents the prolyl 
hydroxylase enzyme. The figure has been adapted from a presentation by P. J. Ratcliffe.
Further research lead to the classification of the HIF-1-regulating prolyl hydroxylase 
(pVHL) as belonging to the extended super family of 2-oxoglutarate-dependent- 
oxygenases [Epstein et al., 2001]. These enzymes have an absolute requirement for 
dioxygen as cosubstrate and are modulated by iron chelation and cobaltous ions. This 
dioxygenase enzyme was identified in C. elegans as a prolyl hydroxylase that 
modulated HIF-1 [Epstein et al., 2001]. Recent reports in the literature suggest that 
different stimuli activate HIF-1 by using contrasting pathways. This was 




pathways by DFO, nitric oxide and tumour necrosis factor-a (all stimuli of HIF-1) 
[Sandau et al., 2001] [Daghman et al., 1999].
Once the active HIF-1 protein has bound to the HRE of genes, transcription may be 
altered. Several of the genes containing HREs, not only have an influential effect on 
oxygen homeostasis, but also iron homeostasis. HIF-1 target genes may be divided in 
to three classes; 1 ) genes which represent an adaptation of the whole organism to 
hypoxia such as erythropoetin (EPO), 2) those which are local acting factors such as 
vascular endothelial growth factor (VGEF) and 3) genes which have intracellular 
functions such as glycolytic enzymes [Thornton et al., 2000] & [Wenger et al., 1995]. 
Genes, modulated by HIF-1, include, the gene for inducible nitric oxide synthases 
(iNOS), a enzyme producing vasodilator nitric oxide (NO) [Gleade and Ratcliffe, 
1998]. The gene for the transferrin receptor also contains an HRE, which is 
modulated by HIF-1 (see 1.5.1.1) [Bianchi et al., 1999], as does caeruloplasmin. 
Caeruloplasmin is an acute-phase reactive protein that can catalyse the oxidation of 
ferrous ions to the ferric state (ferroxidase activity), apart from this function its 
biological importance it not fully known [Mukhopadhyay et al., 2000]. The enzyme 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is involved in the production 
of ATP from glucose in the absence of oxygen (anaerobic glycolysis). GAPDH is 
often used as a non-inducible internal control in molecular biology experiments. 
However the promoter of GAPDH contains several HREs and this results in its up- 
regulation during hypoxia and hence during iron chelation [Escoubert et al., 1999]. 
Another enzyme that contains HREs is haemoxygenase-1. As discussed in section
1.3.2.1, HO-1 is highly induced during hypoxia [Lee et al., 1997]. However, 
experiments have indicated that there is a strong dependence on the presence of 
LMrFe in order for this induction to occur. When cells were pre-treated with the iron
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chelator DFO, the induction of HO-1 in response to hypoxia was abrogated [Visner et 
al., 1999].
When strong iron chelators are used in cell experiments, it is important to consider 
that they increase HIF-1 activity and that the induced HIF-1 DNA binding and 
activity can protect cells against certain forms of oxidative-stress [Siren et al., 2001], 
[Digicaylioglu and Lipton, 2001], [Zaman et al., 1999]. One of the first examples was 
the observation made by Zaman and colleagues who reported on neuronal epithelial 
cells subjected to increased oxidative stress by depleting them of glutathione. The 
cells, however, could be protected by the administration of cobalt, a known stimulus 
of HIF-1 [Zaman et al., 1999]. More recently, Siren and collegues have shown that 
HIF-1-dependent induction of erythropoetin could also prevent neuronal apoptosis 
triggered by cerebral ischemia and metabolic stress [Siren et al., 2001]. 
Consequently, any protection against oxidative stress that is observed following the 
addition of a strong iron chelator has the possibility of being due to either the 
induction of HIF-1 responsive genes or to the chelation of iron.
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1.6 Implications for iron chelation during protection against UVA skin damage
Sunlight is the most prominent and ubiquitous carcinogen in our natural environment. 
Ultraviolet A radiation is a component of sunlight that exerts its carcinogenicity by 
acting as an oxidant. We have discussed in 1.4 how UVA irradiation of cells causes 
an immediate and transient release of low molecular mass iron (LMrFe) by the UVA- 
dependent degradation of lysosomal membranes. This increase in iron is 
accompanied by a cyclooxygenase-dependent release of haem from microsomal haem 
proteins. The simultaneous induction of haemoxygenase-1 by UVA results in the 
release of free iron from haem, adding to the accumulation of LMrFe within cells 
discussed in 1.4.
The role of UVA-generated singlet oxygen in the activation of signalling pathways 
and subsequent gene activation is well defined (see 1.3.2). Somewhat less well 
defined, is the role of iron in the inactivation or activation of signalling pathways and 
the expression of genes that are modulated by UVA. MMP-1 may be one such gene, 
since Brenneisen and co-workers showed that the iron-driven generation of lipid 
peroxides and hydroxyl radicals were early events in the downstream signalling 
pathway of the UVB response. The addition of iron dextran and iron citrate to human 
dermal fibroblasts resulted in a 15-fold increase in JNK2 activity, a 3.5-fold increase 
in c-jun mRNA and a 6-fold increase in MMP-1 mRNA levels compared to non-iron 
loaded cells irradiated with 150kJ/m2 of UVA. [Brenneisen et al., 1997]. Skin 
fibroblast cells may be sensitised by the addition of iron. For example when human 
skin cells were pre-treated with non-toxic concentrations of nitrilotriacetate and 
irradiated with low to moderate (150kJ/m2 and 450kJ/m2) doses of UVA, the rate of 
lipid peroxidation doubles without affecting the viability of iron-loaded cells. This
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response was abrogated by the addition of vitamin E or desferrioxamine which inhibit 
or prevent iron driven lipid peroxidation [Morliere et al., 1997].
UVA-mediated cytotoxicity in primary human fibroblasts can be significantly 
decreased by pre-treating cells with iron chelators such as DFO [Keyse and Tyrrell, 
1989]. Similarly, UVA-mediated protein oxidation, (measured by sulphydryl loss) is 
strongly decreased by pre-treating cells with iron chelators [Vile and Tyrrell 1995] 
and increased in the presence of ferrous iron [Hu et al., 1992]. In addition to this 
evidence, UVA-induced lipid peroxidation in the membranes of cultured human 
primary fibroblasts was shown to occur via pathways involving iron and singlet 
oxygen [Vile and Tyrrell 1995]. Indeed, topical application of an iron chelator can 
decrease the UV-mediated generation of alcoxyl radicals (LCV) in murine and human 
skin [Jurkiewwicz and Buettener, 1996].
In view of the fact that various studies have shown an increase in signalling, damage 
and the sensitisation of skin cells by iron, we hypothesised that a degree of protection 
may be afforded against such changes by the addition of a compound that could safely 
sequester LMrFe in a non-reactive form. In order to achieve our aims we needed to 
be able to chelate the intracellular LMrFe without inducing a hypoxic response such 
as would be expected from the addition of a conventional strong iron chelator 
(discussed in 1.5.3.1). Most conventional iron chelators are designed to have a high 
affinity for Fem since they are for use in situations where patients suffer from body 
iron overload. We sought an iron chelator that could mimic an iron-binding protein in 
its ability to safely sequester LMrFe in a non-reactive form yet, was unable to disturb 
iron homeostasis substantially enough that it would initiate a hypoxic response. By 
adding to our cells, an iron chelator that does not modulate genes associated with the 
hypoxic response, we might expect to observe a difference in the UVA-mediated
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expression of several genes such as HO-1 and COX-2 associated with exposure to 
UVA radiation.
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1.7 Aim of the study
The aim of this study was to elucidate the role of LMrFe in UVA-mediated gene 
expression. Human skin cells (FEK-4) have been shown to undergo an immediate 
and transient release of low molecular mass iron (LMrFe) when subjected to UVA 
(320-380nm) irradiation [Pourzand et al., 1999] and such iron may act as a pro­
oxidant as well as increasing the expression of certain genes such as HO-1 and COX- 
2 that are associated with oxidative stress. To assess the extent to which the 
immediate and transient release of LMrFe is responsible for the UVA-mediated 
expression of HO-1 and COX-2 it was necessary to modulate the intracellular level of 
iron in growing skin fibroblast cells. To achieve this cells were exposed to two 
different forms of iron in order to assess whether increased intracellular iron levels 
could increase the expression of HO-1 and COX-2, as was observed after the UVA 
irradiation of cells. Furthermore, it was equally important to assess whether the 
removal of LMrFe could prevent the UVA-mediated increase in HO-1 and COX-2 
expression. In order to decrease intracellular LMrFe, cells were treated with 
established iron chelators, namely, desferrioxamine mesylate (DFO) and 
salicylaldehyde isonicotinoyl hydrazone (SIH), of which DFO is used clinically in 
conditions of iron overload. However, because the removal of iron from normal 
growing cells causes problems of toxicity [Li et al., 2001] we also employed a weaker 
iron chelator designed to sequester LMrFe in conditions where there are mild or 
transient increases in body iron [Kitizawa and Iwasaki 1999]. After pre-treatment of 
the cells with the aforementioned iron chelators the cells were subjected to UVA 
radiation. Changes in mRNA expression of the oxidative stress-induced enzymes 
HO-1 and COX-2 were then measured in order to elucidate the role that low 
molecular mass iron plays in the UVA-modulated expression of HO-1 and COX-2.
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2. Materials and Methods
2.1 Cells and Conditions of culture
Skin fibroblast cells used for all experiments were either of the cell line FEK-4, 
derived from an infant foreskin explant (see figure 2.1) or 1BR-3 derived from an 
adult arm punch biopsy.
F ig u r e  2 .1 . x 4 0  m a g n if ica t io n  o f  F E K -4  h u m a n  sk in  f ib r o b la s t  c e lls  u s in g  a lig h t m icr o sc o p e .
Cells were cultured in Earle’s Minimal Essential Medium (EMEM) (Life 
Technologies, Paisley, Scotland) supplemented with 15% v/v foetal calf serum (PAA 
laboratories, UK) (inactivated at 56°C for 45 minutes), glutamine (Life Technologies) 
(2mM), sodium bicarbonate (Life Technologies) (0.2% w/v), penicillin and 
streptomycin (Life Technologies) (50 IU/ml each). Cells were grown in T 125 flasks 
(MBI Fermentas, USA) and were passaged by trypsinisation once a week performed 
by removal of the medium, a single wash with PBS and gentle detachment by 
incubation for 5-10 minutes at 37°C in 0.25% w/v trypsin (Life Technologies). FEK-
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4 cells were seeded at 2.5 x 105 on a 10cm dish to reach a plate confluence of 50 - 
60% on the day of treatment. 1BR-3 cells were seeded at 3.0 x 105 and grown in 
10cm plastic plates to reach 60% confluency after 4 days. Plates were incubated at 
37°C in an atmosphere of 5% v/v CO2 . Cells were only used for experiments between 
passages 10 to 15.
To determine the number of cells for the purpose of plating and normalising data, 
trypan blue was used. The procedure was carried out by adding 30pl of cell 
suspension to 30pl of 0.1% w/v trypan blue in PBS. Samples were loaded into a 
standard haemocytometer, and all viable (clear) and non-viable (blue) cells were 
counted using the calculation:
Number of cells 
___________________  x Dilution factor x 104
4
2.2 Chemicals
All chemicals used were supplied by BDH (Poole, Dorset, UK) unless otherwise 
stated. Stock solutions were prepared under sterile conditions in water unless 
otherwise stated. Salicylaldehyde isonicotinoyl hydrazone (SIH -  kindly provided by 
Dr. P.Ponka), and hemin, were dissolved in dimethyl sulphoxide (DMSO), where the 
ultimate concentration of DMSO used to treat cells did not exceed 0.1% v/v. 
MilliQ® water was used to prepare phosphate buffered saline (PBS) (Oxoid, 
Basingstoke, UK) and all solutions that required the addition of water (MilliQ 
cartridge: Millipore, Bedford, MA). The use of MilliQ water minimized the presence 
of trace elements such as transition metals.
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2.3 Chemical treatments
The ‘conditioned’ medium on the plate was removed and a portion (8ml) was treated 
with the desired reagent (listed below) and incubated at a temperature of 37°C in an 
atmosphere of 5% v/v CO2 for the specified period;
2.3.1 Haemin treatment
Stock haemin solution: 20mM in dimethyl sulfoxide (DMSO)
Cells were treated with 10pM haemin (final concentration in conditioned medium) for 
various time intervals.
2.3.2 Ferric citrate treatment
Stock ferric citrate solution: lOOmM in water
Iron citrate (FeCb) was freshly made by mixing a 1:1 ratio of (200mM) iron(III) 
chloride-6-hydrate with (200mM) tri-sodium citrate in water. Cells were treated with 
50pM or lOOpM of the resultant iron citrate (final concentration in conditioned 
medium) for various time intervals indicated in each experiment.
2.3.3 DFO treatment
Stock desferrioxamine solution: 200mM in water
Desferrioxamine mesylate (DFO) (Ciba-Geigy, Basel, Switzerland) treatments were 
usually performed with a range of concentrations (0.5-500pM) (final concentration in 
conditioned medium) for a predetermined length of time to suit the individual 
experiments. Ferrioxamine was prepared by the addition of 3.6ml of 200mM 
desferrioxamine to a slight excess of 200mM ferric chloride, the excess iron was
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recovered by dialysing the complex for 2 hours against 20ml human apotransferrin 
(5g/l) solution containing 0.5g sodium hydrogen carbonate.
2.3.4 SIH treatment
Stock SIH solution: lOOmM in DMSO
Salicylaldehyde isonicotinyl hydrazone (SIH) treatments varied in the reaction 
concentration of SIH used and in the duration of incubation of the iron chelator with 
the cells.
2.3.5 HBSer Treatment
Stock HBSer solution: 167mM HBSer was dissolved in NaOH and then neutralised 
with equimolar HC1
Hydroxybenzyl serine HBSer (>99% pure) was kindly provided by Dr. Manabu 
Kitizawa and Dr. Keiji Iwasaki (Ajinomoto Co., Inc., Japan). HBSer was used over a 
wide range of concentrations, with an incubation period that varied depending on the 
experiment. HBSer was often incubated with cells at millimolar concentrations. This 
is due to its poor penetration into cells.
2.3.6 Cobalt chloride treatment
Stock cobalt chloride solution: 200mM in water
Cobalt chloride (C0 CI2) was used in a range where the reaction concentration ranged 
from 50 to 500pM. The length of incubation was dependent on the type of assay 
conducted.
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2.3.7 Sodium arsenite treatment
Stock sodium arsenite solution: 40mM in water
Sodium arsenite (NaAsC^) was used at a final reaction concentration of 50pM. 
Sodium arsenite was added to serum free media (serum free media is made in exactly 
the same way as the 15% v/v FCS EMEM (see 2.1), except that water was substituted 
for FCS). The cells were then incubated for 30 minutes before the removal of the 
media, followed by replacement with the conditioned media and incubation for a 
further 2.5 hours.
2.3.8 TNF-a and IL-1 treatment
Stock solutions: lOOpg/ml and lOpg/ml respectively of the above cytokines were 
prepared in water.
Tumor necrosis factor-a (TNF-a) and interleukin-1 (IL-1) were used in combination 
at a final concentration of 50ng/ml and 0.5ng/ml, respectively. The incubation period 
was between 18 and 48 hours depending on the assay conducted.
2.3.9 IL-6 treatment
Stock IL-6 solution: lOOpg/ml in water
Interleukin-6 (IL-6) was used at a reaction concentration of 20ng/ml, and incubated 
with the cells for 18 hours.
2.3.10 NMMA and 1400W treatment
Stock NMMA and 1400W solutions: lOOmM and 200mM, respectively 
N°-Methyl-L -arginine (NMMA) and N-(3-(aminomethyl)benzyl) acetamide (1400W) 
were used at a reaction concentration of 500 and lOOpM, respectively. Both
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compounds were added to cells 30min prior to the addition of DFO for a total period 
of 18.5 hours.
2.3.11 Stock solutions and buffers
Stock solutions and buffers used exclusively for an assay are displayed as an attached 
table to the corresponding section. Here, the concentrations of stock solutions are 
represented as a magnitude greater than their final concentration required in the assay 
and this is denoted by (x). For example, the stock solution 20x SSPE is twenty times 
more concentrated than the final concentration required in the assay.
2.4 Irradiation conditions
FEK-4 and 1BR-3 fibroblast monolayers were irradiated with different doses (250 and 
500 kJ/m ) of UVA, using a broad spectrum (350-400nm and slight near-visible 
emission in the range >400nm) (shown in figure 2.2) Sellas 4kW UVA lamp with an 
incident dose rate of 500W/m2 (Sellas, Germany). The UVA fluency was measured 
using an IL 1700 radiometer (International light, Newbury, MA).
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Prior to irradiation, the ‘conditioned’ medium on the plate was retained and cells were 
rinsed with Ca2+/Mg2+ (0.01% w/v of each) containing PBS (Oxoid, Basingstoke, 
UK). Cells were covered with 5ml of the aforementioned Ca2+/Mg2+ containing PBS. 
Irradiations were performed at a controlled ambient temperature of 25°C. After 
irradiation, the ‘conditioned’ medium was replaced and cells were incubated at 37°C 
in a 5% v/v CO2 atmosphere for either 3 or 4 hours prior to analysis. Control (sham) 
fibroblasts were exposed to exactly the same conditions as the irradiated cells, except 
they were not irradiated.
2.5 Cell extracts
For the various methods employed in this thesis, several different procedures were 
used to obtain the required cellular fractions for analysis;
2.5.1 Cytosolic extracts, as described by Mullner et al (1989).
Immediately after carrying out the desired treatments, cells were washed with 10ml of 
cold PBS and collected by detachment from the plates using a rubber scraper. Cells 
were suspended in cold PBS and centrifuged at 1500 rpm for 5 min at 4°C in a Jouan 
CR412 centrifuge. The supernatant was then removed and cells were re-suspended in 
1 ml of freshly prepared, ice-cold PBS. Cells were then counted (see 2.1) and 
centrifuged as above. The remaining supernatant was aspirated and the cells were re­
suspended in ice-cold (IX) lysis buffer (see 2.5.1.1). Cells were lysed on ice for 10 
min (30pl of IX lysis buffer/lxlO6 cells). Cell lysates were centrifuged at 2500 rpm 
for 7 min at 4°C in a Jouan CR412 centrifuge. The resultant cell extract (supernatant) 
was removed and placed in an microfuge tube and flash frozen in a mixture of dry ice
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and 99.7-100% v/v ethanol. Extracts were then stored at -70°C for no more than one 
week prior to use.
2.5.1.1 Buffers for cytosolic extracts, as described by Mullner et al (1989). 
lx  Lysis buffer
lOmM Hepes pH 7.5, 3mM MgCb,
40mM KC1, 5% v/v glycerol and freshly 
added chymostatin (50pg/ml), leupeptin 
(20pg/ml), and 0.3% w/v NP-40 (Merck,
UK)
2.5.2 Cytosolic and nuclear extracts, as described by Schreiber et al (1989).
Cells were washed on the plate with 10ml of cold PBS. This PBS was removed and 
replaced with 3ml of freshly prepared, cold PBS. Cells were gently scraped from the 
plates using a rubber scraper and placed in a corresponding microfuge tube. Cells 
were spun at 13,000rpm for 1 min in a Sanyo MSB010 microcentrifuge. The 
supernatant was completely removed and discarded. 3x the packed cell volume was 
calculated and a corresponding amount of buffer A (see 2.5.2.1) with freshly added 
DTT and protease inhibitors was used to resuspend the packed cell pellet. The 
resuspended cell pellet was incubated on ice for 15 min. Nonident P40 (NP40) was 
then added to the suspension to give a final concentration of 0.5% v/v. The 
suspension was quickly vortexed for 10 sec. The suspension was centrifuged at 
13,000rpm for 1 min in a Sanyo MSB010 microcentrifuge as previously described. 
The resultant supernatant comprised the cytosolic compartment of the cell. This was
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removed and placed in a labelled microfuge tube. The extract was flash frozen in a 
mixture of dry ice and 99.7-100% v/v ethanol. Extracts were stored at -70°C for no 
more than a week.
The remaining cell debris in the initial tube was re-spun at 13,000rpm for 1 min (as 
previously described) and any remaining supernatant was discarded. The resultant 
pellet was re-suspended in (2x packed cell volume) of buffer C (see section 2.5.2.1) 
and shaken vigerously at 4 °C for 30 min in an microfuge shaker. The suspension was 
then spun at 13,000rpm for 10 min at 4 °C in a Sanyo MSB010 microcentrifuge. The 
supernatant, which contained the nuclear compartment of the cells, was collected and 
flash frozen, as previously described.
2.5.2.1 Buffers for cytosolic and nuclear extracts, as described by Schreiber et al
(1989).
Buffer A Buffer C
HEPES (pH 7.9) lOmM, Potassium HEPES (pH 7.9) 20mM, sodium chloride
chloride lOmM, EDTA O.lmM, EGTA 400mM, EDTA lmM, EGTA lmM,
O.lmM, Magnesium chloride 1.5mM, freshly added; DTT lmM, protease
freshly added; DTT lmM, protease inhibitors (leupeptin and chemostatin)
inhibitors (leupeptin and chemostatin) 100pg/ml, sodium fluoride lmM
lOOpg/ml, sodium fluoride lmM
2.6 Protein measurement
Cell extracts (containing specific proteins for analysis) varied in their protein content 
according to the original number of cells and the efficiency of preparation. In order
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that samples may be analysed on the basis that each contained the same amount of 
protein, total protein content was calculated.
Quantification o f cytosolic and nuclear proteins; The extracts obtained from the 
various methods were thawed or used freshly prepared. Protein concentration was 
determined using the Bradford assay with a BioRad reagent kit, UK [Bradford, 1976]. 
In order to provide a standard calibration curve, a series of concentrations of bovine 
serum albumin (BSA) (lOOmg/ml stock, Roche, UK) were prepared, ranging from 0 
to 25pg/ml. Absorbance measurements of the samples were obtained using a 96-well 
microplate reader (Dynatech MR5000) at an absorbance of 595 nm. Measurements 
were all performed in duplicate and the mean values were calculated if the means 
were in close agreement. The protein concentrations of the various extracts were 
calculated from the standard curve prepared using known dilutions of BSA.
2.7 IRP/IRE bandshift assay
A bandshift assay provides a fast and sensitive method for detecting sequence specific 
proteins. Using a radiolabelled RNA or DNA oligonucleotide as a probe, proteins 
that specifically bind to these sequences retard the mobility of the fragment during 
nondenaturing polyacrylamide gel electrophoresis (PAGE). This results in discrete 
band shifts corresponding to the individual protein (DNA/RNA) complexes.
Cellular cytoplasmic extracts were prepared according to the method described by 
Schreiber et al. [Schreiber, et al., 1989] or Monroe (see section 2.5). Cytoplasmic 
protein content was calculated using the Bradford assay [Bradford, 1976] (see section 
2.6). Plasmid pGem-3Zf(+), contains the wild type IRE (clone 42, Henderson et al, 
1996 [Henderson et al., 1996]) from the 5’ untranslated region of the human ferritin 
heavy chain mRNA, as described in [Henderson et al., 1996].
«
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2.7.1 Restriction o f the IRE sequence; A total of 20pg of plasmid pGem-3Zf(+) was 
linearised by the addition of a restriction enzyme (6pl of 10u/A, Bam HI) with 8pi of 
(lOx) buffer B (provided by the manufacturer; Promega, UK) in a total volume of 
80pl (adjusted using water). Digestion of the plasmid was carried out at 37°C for 2h, 
followed by 15 min at 65°C.
2.7.2 Gel electrophoresis,; A simple and widely used method to investigate the 
presence of specific sized DNA fragments is gel electrophoresis, whereby fragments 
of DNA migrate, according to their charge and mass, towards a cathode within an 
agarose gel.
To ensure the digestion had occurred correctly, 2pi of the resultant digest was added 
to 3.3pl (6x) DNA loading buffer (see 2.7.1), and made up to 20pl with water. 2pg of 
a 1 kilo base ladder (Promega, UK) and the crude (undigested) plasmid (pGem- 
3Zf(+)) were also mixed with the DNA loading buffer and water to give a volume of 
20pl. Samples were heated at 65°C for 10 min, cooled on ice and run at 80 volts for 
lh in a 1% w/v agarose gel containing lx TBE and 6pl of 10,000x ethidium bromide 
(Appligene, Oncor). The gel was visualised and photographed under a UV-light 
(figure 2.1).
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lkb  ladder; The lkb DNA ladder shown in figure 2.1 was purchased from Life 
Technologies. The ladder is suitable for sizing linear double-stranded DNA 
fragments from 500bp to 1 2 kb.
F ig u re  2 .2 . I llu s tr a tio n  o f  th e  s ize  and  p o s it io n  o f  D N A  fr a g m e n ts  o f  th e  lk b  D N A  la d d er .  
P ic tu re  ta k en  fr o m  P ro m e g a , L ife  T e c h n o lo g ie s  2001 ca ta lo g u e .
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0.5 ng/lane; 1.0% agarose gel stained with ethidium bromide. W/'nf I 
fragments of the vector
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2.7.3 Preparation o f the probe; The 32P-labelled RNA probe was transcribed in vitro 
from lpg of linearised (.Bam Hl-cleaved) plasmid, (prepared as described previously). 
2pg of DNA template was transcribed using T7 RNA polymerase (Promega, UK.) in 
the presence of 2.5mM each GTP, ATP, and UTP (Pharmacia, Uppsala, Sweden) and 
60pCi of [a-32P]CTP (Amersham, Buckinghamshire, UK, 800 Ci/mmol) in the 
presence of 45 units of an RNAse inhibitor; Rnasin® (Promega, UK.). The mixture 
also contained a final concentration of lx TSC buffer (see 2.7.1). The solution was 
incubated for 2h at 40°C.
2.7.4 Checking the integrity o f the probe’, The resultant RNA probe was precipitated 
overnight from solution by the addition of two and a half times the total volume of 
99.7-100% v/v ethanol. The RNA was centrifuged at 13,000rpm for 20 min in a 
Sanyo MSB010 microcentrifiige. An RNA pellet formed on the side of the microfuge 
tube. The supernatant was removed and the air-dried RNA pellet was dissolved in 
30(4.1 of RNAse free water, prepared by autoclaving MilliQ water for 40 min. The 
RNA probe was run in a 40% w/v polyacrylamide gel containing 15% w/v urea and 
an ultimate dilution of lx TBE. The probe (30 j l x 1) was added to 270pl of 5x 
formamide loading buffer (see 2.7.1), and heated at 80°C for 10 min before being 
cooled on ice. The probe was run at a continuous 35mAmps for 1 hour, dried and 
exposed to a phosphorimager cassette for 5 minutes (Molecular Dynamics, 
Sunnyvale, CA.). Visualisation was carried out using a phosphorimager (Molecular 
Dynamics, Sunnyvale, CA.) and use of the software Image Quant 3.3 (figure 2.2).
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pairs)
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2.7.5 RNA-protein interaction; RNA-protein complexes were formed by the addition 
of 2pg of the cytosolic (protein) extract to 5xl05cpm of the IRE (RNA) probe with an 
ultimate concentration of 1 x lysis buffer (Monroe or buffer A), in a total volume of 
18pl. Binding was allowed to occur for lOmin before the addition of 2pl (50mg/ml) 
heparin solution (Sigma) (to prevent non-specific binding). After a further 10 min, 
4pl of 5x IRP/IRE loading buffer (see 2.7.1) was added.
2.7.6 Gel electrophoresis; The resultant complex was resolved at 4°C in a 6% w/v 
acrylamide gel containing 0.3x TBE, 720pl ammonium persulphate (see 2.7.1) and 
18pl TEMED (Sigma) for 1.5h, at a constant 200V in a Danaphore type 107 gel 
electrophoresis tank. The gel was removed from the electrophoresis apparatus and
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immersed in a ‘fixing’ solution (see 2.7.1) for 15 min which allowed the RNA-protein 
bands to become permanent. The gel was then dried under vacuum and exposed to a 
a-32P sensitive phosphorimager screen.
2.7.7 Visualisation o f the complexes:; Bands were visualised and quantified using a 
phosphorimager (Molecular Dynamics, Sunnyvale, CA.) and software (Image Quant 
3.3). Any changes in ERP/IRE binding indicate that added iron or iron chelating 
agents interfere with the low molecular mass iron that normally reacts with the iron- 
sulphur cluster of the IRP-1 protein.
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2.7.8 Solutions and buffers for IRP/IRE bandshift analysis
lOx TBE buffer (Tris/borate/EDTA)
890mM Tris-HCl (pH 8), 890mM Boric 
acid, 20mM EDTA (pH 8)
5x DNA loading buffer
50mM EDTA (pH 8), 50mM Tris-HCl 
(pH 8), 50% v/v glycerol
5x IRP/IRE loading buffer
30mM Tris-HCl (pH 7.5), 40% w/v 
sucrose, 0.2% w/v bromophenol blue
5x TSC buffer
200mM Tris-HCl (pH 8), 30mM MgCl2, 
20mM NaCl, lOmM spermadine 
(Promega, UK.)
10% w/v Ammonium persulphate 
(AMPS)
AMPS was made freshly by the addition 
of lg of AMPS to 10ml of water. This 
was filtered under sterile conditions using 
a 0.4pm filter (Gibco BRL)
‘Fixing9 solution
10% v/v methanol, 10% v/v acetic acid in 
water
5x Formamide loading buffer
83% v/v formamide, lOmM EDTA, 
0.14% v/v-10% w/v bromophenol blue
2.8 HIF-1 Bandshift assay
Cellular nuclear extracts were prepared according to the method described in 
[Schreiber, et al., 1989] (see section 2.5.2). Nuclear protein content was calculated 
using the Bradford assay (Bradford, 1976) (see section 2.6). Electrophoretic mobility 
shift assays (EMSAs) were performed by incubating nuclear extracts with a double
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stranded DNA oligonucleotide probe. The wild type (W18) oligonucleotide probe 
contains a wild type (W18) HIF-1 binding site derived from the erythropoetin (EPO) 
gene, sense 5’GCCCTACGTGCTGTCTCA3’ and antisense 
5’TGAGACAGCACGTAGGGC3’ [Wang and Semenza 1995].
2.8.1 Preparation o f the probe; The oligonucleotides, synthesised by Promega, UK, 
were annealed at a concentration of 250mM in 250mM Tris (pH 7.8) at 95°C for 15 
min and then slowly cooled to room temperature and stored at -20°C. Radiolabelled 
probes were produced by ‘end labelling’ 5mM of the oligonucleotides using 1-0.74 
MBq of fresh [a-32P] dATP (Amersham) in the presence of lOmM each; dGTP, dCTP 
and dTTP (Pharmacia, Uppsala, Sweden) and Klenow polymerase, (with Klenow 
polymerase buffer) (Gibco BRL) in a total volume of 40pl. The oligonucleotide 
mixture was incubated at 30°C for 20 min to allow the labelling to occur. The end- 
labelled probe was purified from unincorporated [a- P] dATP using a Sephadex 
G50 column. A 1cm3 column was packed with 0.7cm3 of Sephadex G50, and washed 
with water to remove any TE buffer (see 2.8.1). This was performed by the addition 
of 0.3ml water to the top of the column, followed by centrifugation in a Jouan CR412 
centrifuge at 2500rpm for 3 min. The probe was added to the column followed by 
100pi of water. A final centrifugation (as described previously) eluted the purified 
probe from the column. The resultant probe was counted in a liquid scintillation 
counter (1209 Rackbeta, Wallac, Germany) and stored at -20°C until its use.
2.8.2 DNA-protein interaction; DNA-protein binding reactions were carried out at 
room temperature in a total volume of 20pl. The reaction contained lOpl of nuclear 
extract (lpg/pl of protein), lpl of (0.2ug/pl) ‘competitor’ DNA to inhibit non-specific 
binding, (sequence, sense 5’GCCCTAAAAGCTGTCTCA3’ and antisense
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5TGAGACAGCTTTTAGGGC3’), 2-3^1 purified probe (104 CPM) and 4pl of 5x 
BSRB (see 2.8.1).
2.8.3 Gel electrophoresis; The samples were loaded in a 4% w/v non-denaturing 
polyacrylamide gel containing 400pl ammonium persulphate (see 2.8.1) and 40pl 
TEMED (Sigma, UK). A (DNA loading buffer) control was placed in an empty lane 
of the gel to indicate the progress of the samples through the gel. Electrophoresis was 
performed at 300V using 0.5 X TBE buffer (see 2.8.1) at 4°C in a Danaphore-type 
107 gel electrophoresis tank. For ‘supershift’ analysis 0.6pg of HIF-1 a  antibody 
(Becton Dickinson, Mountain view, CA, USA) was added to the reaction mixture and 
incubated for 30min at 4°C. For competition experiments, a 100-fold excess of 
unlabelled annealed oligonucleotide was added to the reaction mixture with the 
labelled probe.
2.8.4 Visualisation o f  the gel; The gel was allowed to run for approximately lh 45 
min after which one of the glass gel plates were removed and the gel was immersed in 
a ‘fixing’ solution (see 2.8.1). The gel was removed and dried under vacuum. The 
dried gels were visualised and quantified using a phosphorimager (Molecular 
Dynamics, Sunnyvale, CA.)
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2.8.5 Solutions and buffers for HIF-1 bandshift analysis
lx  TE buffer (Tris/EDTA)
lOmM Tris-HCl (pH 8), lmM EDTA (pH 
8)
5x Bandshift running buffer (BSRB)
50mM Tris-HCl (pH 8), 250mM NaCl, 
5mM EDTA (pH 8), 20% v/v glycerol, 
50% v/v water. Freshly prepared DTT 
was added immediately before use at a 
final concentration of 2.5mM
lOx TBE buffer (Tris/borate/EDTA)
890mM Tris-HCl (pH 8), 890mM Boric 
acid, 20mM EDTA (pH 8)
Fixing solution
20% v/v methanol, 10% v/v acetic acid
10% Ammonium persulphate (AMPS)
AMPS was made freshly by the addition 
of lg of AMPS to 10ml of water. This 
was filtered under sterile conditions using 
a 0.4pm filter (Gibco BRL)
2.9 Transient transfection and reporter gene assay
The reporter gene assay allows the characterisation of a promoter. However, the 
product of a promoter’s natural gene may be difficult or impossible to assay. This can 
be overcome by a manipulation that allows the connection of a gene, whose product 
can easily be assayed, to such a promoter.
The hypoxia responsive luciferase gene construct pGLTfERH is one such construct. 
It contains a transferrin derived hypoxia-responsive-element (HRE)-enhancer 
upstream of a heterologous simian virus 40 (SV40) promoter (see figure 2.3). An
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almost identical plasmid, pGLTfHRE, contains a mutated HRE-enhancer and may be 
used as an internal control plasmid (see figure 2.4).
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Figure 2.5. Reporter plasmid map for pGLTfHREmm. Kindly provided by Roland Wenger
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pGLTfERH, and pGLTfHRE were kindly provided by Dr. Roland Wenger (Rolfs et 
al., 1997) as a small amount of plasmid DNA spotted on to a piece of 3MM Whatman 
paper. Because large amounts of plasmid DNA (2pg per sample) are required for an 
efficient transfection asssay, it was necessary to reproduce large amounts of the 
plasmids by using the DNA replication machinery of bacteria. This is a process 
known as transformation.
2.9.1 M aking competent E.coli bz-243\ A single colony of E.coli bz-243 was picked 
from a fresh agar plate and inoculated into 5ml of TY medium (see 2.9.1) and 
incubated on a shaking platform at 37°C overnight. The following morning, 1ml of 
the culture was diluted into 50ml of 2x TY medium containing 25pg/ml of 
tetracycline and grown until they reached an absorbance of approximately 0.45 at
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550nm. The cell suspension was then chilled on ice for 15 minutes before 
centrifugation at 4°C, in a sterile tube, for 7 min at 3000rpm in a Beckman Avanti J- 
25 centrifuge with a JA 20, 34, or SM 24 rotor. The supernatant was discarded and 
the cells were re-suspended in 15ml of TfBI solution (see 2.9.1) and chilled on ice for 
5 min. Cells were centrifuged at 3000rpm (Beckman Avanti J-25) for 7 min at 4°C 
and the supernatant was discarded. Cells were then re-suspended in 2ml of TfBII 
buffer (see 2.9.1) and chilled on ice for 3-4h. Cells were stored in aliquots of 200pl at 
-70°C until required.
2.9.2 Transformation o f competent E. coli bz-243 cells; Escherichia coli strain bz- 
243 was used for the propagation of both plasmids. A volume of 200pl of competent 
cell suspension was thawed at room temperature before being placed on ice for 10 
min. 10pl (approximately 0.1 pg) of the original plasmid DNA solution was gently 
mixed with lOOpl of the bacteria and placed on ice for 30 min. The cells were then 
shocked by incubation at 42°C for 2 minutes before being returned to a container of 
ice for 2 min. The cell suspension was then diluted to 800pl with LB broth (2.9.1) 
followed by incubation at 37°C for 1 hour. After this time, lOOpl of the suspension 
was plated on to a LB-agar (see 2.9.1) plate containing ampicillin at a concentration 
of lOOpg/ml. Plates were incubated overnight.
2.9.3 Colony selection and plasmid purification; A sterile wire loop was used to 
transfer single colony forming units from separate LB plates into 10ml of LB broth 
containing 100pg/ml ampicillin. The cultures were incubated overnight at 37°C on a 
shaking platform. The following day 5ml of the bacterial suspension was expanded in 
250ml of LB broth (containing ampicillin), by incubation overnight on a shaking 
incubator at 300rpm (New Brunswick Scientific, UK). The plasmid was recovered 
from the E.coli bz-243 using the Hybaid Recovery™ quick flow kit according to the
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manufacturers instructions. This kit employs a gravity flow anion exchange resin that 
yields ultra pure DNA.
2.9.4 Quantification o f plasmid DNA; A 4pl sample of the DNA solution was added 
to 796pl of water to form a 1:200 dilution. The absorbance of the solution was 
measured at 260nm and 280nm using a Kontron (Uvikon 720LC) spectrophotometer. 
The concentration of the DNA was calculated as follows:
Concentration of DNA (pg/ml) = dilution factor x 50* x A260  
*The value of 50 is based on the assumption that a solution of 50pg/ml double 
stranded DNA has an absorbance of 1 at 260nm.
The purity of the DNA was calculated as a ratio of DNA to protein (on the 
assumption that proteins strongly absorb light at 280nm). A ratio of between 1.6 and 
2 was considered acceptable.
2.9.5 Plasmid identification ; A total of 20pg of purified plasmid DNA was linearised 
by the addition of 40 units of the restriction endonucleases Xba I and Sal I and 
incubated for 2h at 37°C. The samples were loaded into a 1% w/v agarose gel (as 
described in detail in 2.7). A 1 kilobase ladder (Promega, UK), crude (undigested) 
plasmids and a control plasmid were also prepared for running in the gel. Samples 
were heated at 65°C for 10 min, cooled on ice and run at 80 volts for lh in a 1% w/v 
agarose gel containing lx TBE and 6pl of 10,000x ethidium bromide (Appligene, 
Oncor). The gel was visualised and photographed under a UV-light (figure 2.5).
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2.9.6 Transient Transfection o f  cells', Plasmid DNA (2pg of either pGLTfERH or 
pGLTfHRE in the presence or absence of 0.25pg of plasmid pCMVp) was diluted in 
lOOpl of Opti-MEM™ (serum free media) (Life Technologies). Separately, 5 pi of 
1 mg/ml Lipofectin™ (a 1:1 w/w mixture of the cationic lipid N-[l-(2,3- 
dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and the neutral 
lipid DOPE), was also diluted in lOOpl of Opti-MEM™ (Life Technologies). The two 
solutions were combined after a 30 min incubation and allowed to incubate for a 




with PBS. The PBS was removed and replaced with 800pl of Opti-MEM™, an 
additional 200 pi of the plasmid and Lipofectin™ mixture in Opti-MEM™ (produced 
as previously described) was added to the cells. The cells were incubated for 5h in 
the presence of the plasmid and Lipofectin™ solution. The solution was removed and 
replaced with normal serum containing media that also contained any of the required 
stimuli (for example DFO) and incubated for 41h.
Co-transfection with 0.25pg of a reference plasmid the p-galactosidase expression 
vector (pCMVpGal) was performed simultaneously to enable differences in 
transfection and growth to be corrected.
2.9.7 Preparation o f cell extracts for analysis; Luciferase levels within the cells were 
quantified using the Promega luciferase assay system (Promega) according to the 
manufacturers instructions. Cells were washed twice with ice cold PBS and treated 
with 125pl of ice-cold reporter lysis buffer (see 2.9.1) (Promega). The plates were 
rocked and allowed to stand at room temperature for 15 min. Cells were scraped from 
the plates using rubber cell scrapers and ‘flash’ frozen in Eppendorf tubes using a 
mixture of dry ice and 99.7-100% v/v ethanol. The following day, extracts were 
thawed for 30 min at room temperature and spun at 13,000rpm in a Sanyo MSB010 
microcentrifuge for 2 min, at a temperature of 4°C. The resulting supernatant was 
removed and analysed for luciferase activity, p-galactosidase activity, protein content, 
(as described in 2.6) or stored at -70°C for future use.
2.9.8 Quantification o f  luciferase activity; A volume of 20pl of cell extract, at room 
temperature, was placed in a disposable 50mm plastic test tube (Promega) and mixed 
with lOOpl of luciferase assay reagent (Promega) (luciferase assay substrate + 
luciferase assay buffer). The test tube was quickly vortexed then immediately placed
102
in a TD-20/20 luminometer (Turner designs, Sunnyvale, CA) and luciferase activity 
was measured using the settings:
Delay: 10 sec 
Integration time: 10 sec 
Number of repeats: 3
2.9.9 Quantification o f P-galactosidase; p-galactosidase activity was determined by 
incubating 50pl cell extract with 150pl of reagent containing 2.5mM CPRG 
(Boehringer Mannheim, Mannheim, Germany) and 1.25mM MgCb. The activity of 
P-galactosidase was calculated from the absorbance at 550nm obtained in the final 
reaction using a 96-well microplate reader (Dynatech MR5000).
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2.9.10 Solutions and buffers for the transformation of bacteria and for HIF-1
reporter gene analysis
TY Medium
16g tryptone, lOg yeast extract, 5g 
sodium chloride, to 1000ml with water
LB Medium
lOg tryptone, 5g yeast extract, 5g sodium 
chloride, 1ml sodium hydroxide 10M, to 
1000ml with water
LB Agar
lOg bacto-tryptone, 5g bacto-yeast 
extract, lOg sodium chloride, 12g agar 
technical, to 1000ml with water
Tfbl Buffer
30mM potassium chloride, lOOmM 
rubidium chloride, lOmM calcium 
chloride, 50mM manganese chloride, 
15% v/v glycerol
Tfbll Buffer
lOmM MOPS, 75mM calcium chloride, 
lOmM rubidium chloride, 15% v/v 
glycerol
Reporter Lysis Buffer
5x reporter lysis buffer (Promega) was 
diluted to lx in water
P-galactosidase Reagent
1M magnesium chloride, lOOmM 
clorophenolred-p-galactopyranoside
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2.10 Northern blot analysis
Northern blot analysis is based on the isolation of mRNA from cells, its separation 
according to charge and mass on a gel, followed by the transfer of this RNA from the 
gel to a membrane. The final step is the detection of mRNA of interest by a labelled 
probe.
2.10.1 Isolation and analysis o f  RNA\ Cells (2xl06/10cm plate) were stimulated and 
incubated at 37°C in EMEM (as described in 2.3). Total cellular RNA was isolated 
using the acid guanidinium thiocyanate-phenol-extraction method. Cells on 10cm 
plates were washed twice with PBS. A total volume of 2ml of solution D (see 2.10.1) 
was added to the cells and incubated at room temperature for 10 min. The resultant 
cell lysate was transferred to a plastic falcon tube (Becton Dickinson, UK). To 
separate the RNA from the protein 0.2ml of 2M sodium acetate was vigorously mixed 
with the lysate, followed by 2.5ml of aqua phenol (pH 7) (Appligene, Oncor), which 
was gently mixed by a series of 50 inversions of the tubes. The mixture was chilled 
on ice for 15 min then centrifuged at 10,000rpm for 30 min at 4°C in a Beckman 
Avanti J-25 centrifuge, with a JA 20, 34, or SM 24 rotor. The biphasic solution 
obtained from the centrifugation was rapidly isolated by transferring the supernatant 
in to a fresh, labelled plastic falcon tube. Isopropyl alcohol (2ml) was added to the 
supernatant to precipitate the RNA from the solution overnight. The following day, 
the suspension was centrifuged at 10,000rpm as previously described. The liquid was 
aspirated off and the pellet (which was apparent on the side of the falcon tube) was re­
dissolved in 0.3ml of solution D and transferred to a fresh, labelled microfuge tube. 
A volume of 0.3ml of isopropanol was added to the solution prior to its storage at -  
20°C overnight to allow a second precipitation of the RNA. The following day the 
tube was centrifuged at 13,000rpm in a Sanyo MSB010 microcentrifuge for 15 min, at
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a temperature of 4°C, to form a small pellet. The pellet was washed with 1ml of 75% 
v/v ethanol and re-spun, in a microcentrifuge, as previously described. The ethanol 
was removed from the RNA pellet using a glass pipette and further removal, if 
required, was carried out by leaving the open microfuge tube at room temperature for 
2 to 5 min. The pellet was dissolved in 25pi of RNAse free water and quantified 
using 4pl of the solution in 796pl of water and measuring the resultant absorption at 
260nm using a Kontron (Uvikon 720LC) spectrophotometer:
Concentration of RNA (pg/ml) = dilution factor x 40* x A260  
*The value of 40 is based on the assumption that a solution of 40pg/ml RNA has an 
absorbance of 1 at 260nm.
The purity of the RNA was calculated as a ratio of RNA to protein (on the assumption 
that proteins strongly absorb light at 280nm). A ratio of between 1.6 and 2 was 
considered acceptable.
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2.10.2 Gel electrophoresis; A 25pg RNA solution was calculated and added to an 
equal volume of MOPS loading buffer (see 2.10.1) which was then heated at 65°C for 
15 min. The mixture was cooled on ice and loaded into a MOPS/formaldehyde-1.3% 
w/v agarose gel (see 2.10.1). The gel was prepared in a Danaphore type 105 gel tank, 
assembled as shown in fig 2.6 and immersed in 1.1L of lxMOPS buffer (see 2.10.1). 
The gel was run at a constant 70V until the bromophenol blue (in the MOPS loading 
buffer) was 6 to 8cm from the end of the gel.
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2.10.3 Transfer o f  RNA to a nylon membrane; for convenience the RNA was
transferred to a membrane in an empty, clean gel tank (Danaphore type 105). The 
pre-run gel was soaked in water for 15 min to remove any excess formaldehyde. 
During this period the transfer equipment was constructed, comprised of a 3MM 
Whatman paper bridge spanning the width and length of the gel tank. The ends of the 
tank were filled with lx  transfer buffer (see 2.10.1) to the point that the buffer did not 
reach the position of the gel. The gel was placed facedown above the paper bridge, 
and a stack was placed above the gel, comprised of a Zeta-Probe® Blotting (BioRad, 
Hercules, CA, USA) nylon membrane, 1 layer of (transfer buffer-soaked) 3MM
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Whatman paper, and a further 2 sheets of 3MM Whatman paper. A stack 
approximately 10cm deep of paper towels were then placed above this in order to 
draw the transfer buffer upwards by capillary blotting as shown in figure 2.7. The gel 
was allowed to transfer overnight.
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The following day, the membrane was removed from the stack and sandwiched 
between two pieces of 3MM Whatman paper. The membrane was then baked in an 
oven at 80°C for 2h.
2.10.4 Preparation o f  cDNA probes; cDNA probes were either restricted from pre­
formed DNA plasmid kits or provided as a PCR product. To prepare the probes for 
the RNA of GAPDH, HO-1 and COX-2, 20pg of the respective plasmid was 
linearised by the addition of the appropriate restriction enzyme and buffer (provided 
by the manufacturer; Promega, UK) in a total volume of 80pl (adjusted using water). 
Plasmid digestion was performed at 37°C for 2h, followed by 15 min at 65°C. The
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GAPDH cDNA probe was prepared as a 1400bp HindlW EcoKL fragment of the 
murine glyceraldehyde phosphate dehydrogenase gene. The HO-1 cDNA probe was 
a lOOObp EcoKL fragment of the human hemeoxygenase clone 2/10 (Keyse and 
Tyrrell, 1989) and the COX-2 probe was an 1800bp xho-l/Hindlll fragment of human 
cyclooxygenase cDNA (Invitrogen corporation). The p-actin cDNA probe was a 
PCR product of 545bp from human p-actin cDNA, which encompassed regions 267 
to 791 of the p-actin cDNA (kindly provided by Dr Quinlan (Royal Brompton 
Hospital, London)). PCR primers used were obtained from Life Technologies; 
homosapien p-actin primers:
5’ to 3’ CAG GAA GGA AGG TTG GAA GAG 
3’ to 5’ GGC ACC ACA CCT TCT ACA ATG.
2.10.5 Gel electrophoresis'.\ To ensure the digestion had occurred correctly 2pi of the 
resultant digests were added to 3.3pi (6x) DNA loading buffer (see 2.10.1), and made 
up to 20pl with water. In addition, 2pg of a 1 kilo base ladder (Promega, UK), (see 
figure 2.2) and the crude (undigested) plasmids were mixed with the DNA loading 
buffer and water to give a volume of 20pl. Samples were heated at 65°C for 10 min, 
cooled on ice and run at 80 volts for lh in a 1% w/v agarose gel containing lx TBE 
and 6pl of 10,000x ethidium bromide (Appligene, Oncor). The mini-gels were 
visualised and photographed under a UV-light (figures 2.8 and 2.9).
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The remaining plasmid digest was run on a large 1% w/v agarose gel made in exactly 
the same way as the aforementioned mini-gels. The cleaved DNA fragments were 
pre-treated in exactly the same manner as before and loaded into wells created in the 
large agarose gel. The gel was run as previously described with A lkb ladder. When 
run, the gel was very rapidly exposed to a ultraviolet transilluminator at a wavelength 
of 310nm, and the positions of the required fragments were marked. The marked 
fragments were excised from the gel using a scalpel blade. The gel was re-examined 
and photographed to ensure the correct fragment had been removed, figure 2.11.
F ig u re  2 .1 1 . A  p h o to g r a p h  o f  1%  w /v  a g a ro se  ge l sh o w in g  d a r k  r ec ta n g u la r  a rea s  w h e r e  cD N A  
(p r o b e ) fr a g m e n ts  h a v e  b een  r em o v ed . 1) xho-l/H indlll d ig e ste d  p la sm id  C O X -2  p la sm id , 2) 
lk b  D N A  la d d e r , 3 )  H indlU / EcoRl d ig e ste d  G A P D H  p la sm id , 4 ) EcoRl d ig e ste d  H O -1
1 2  3 4
The DNA was purified from the gel using the Qiaex II agarose gel extraction kit 
according to manufacturers instructions.
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2.10.6 Labelling o f  RNA using cDNA probes; the PCR product or restriction 
fragments (cDNA probes) were radiolabelled by random primed synthesis method 
using a high prime enzyme kit (Boehringer Mannheim) and P dCTP (Amersham) 
based on the method originally developed by Feinberg and Vogelstein, 1984. lOOng 
of the cDNA was made up to a volume of 11 pi with water and heated at 100°C for 10 
min. The mixture was immediately placed on ice and 4pl of high prime enzyme 
(Boehringer Mannheim) was added. A further 5 pi of P dCTP was added and the 
mixture was incubated at 37°C for 20 min. The labelled cDNA probe was then 
purified from free unbound 32P dCTP using Elutip-D columns (Schleider and Schuell, 
Dassel, Germany) according to manufacturers instructions.
A maximum of four membranes were placed in a single hybridisation cylinder, which 
in turn was placed inside a rotisserie oven set at 60rpm. The temperature of the 
hybridisation oven was dependent on the probe used; 68°C for HO-1 analysis, 63°C 
for COX-2 analysis, 65°C for GAPDH analysis and 60°C for p-actin analysis. 
Membranes were pre-hybridised for 1 hour in a hybridisation solution (see 2.10.1). 
After an hour, the solution was removed and replaced with fresh, pre-heated 
hybridisation solution. The 32P-labelled cDNA probe was added to the hybridisation 
solution at an equivalent of 3xl06 counts per membrane. After an overnight 
hybridisation, non-specifically bound probe was washed from the membrane using 
SDS (at a final concentration of 0.1% w/v) and 20X SSPE (see 2.10.1). Washings 
were performed twice with 6X SSPE for 5 min at 37°C, twice with IX SSPE for 15 
min at 37°C and twice with 2X SSPE for 15 min at the hybridisation temperature.
2.10.7 Visualisation o f  the RNA\ The membranes were sealed inside a plastic 
envelope and exposed to a phosphorimager screen for between 1 and 3 days. 
Following exposure the cDNA probe was stripped from the membrane by boiling in
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0.3% w/v SDS (twice for 30 min each time), if required the membranes were re­
probed with a different cDNA probe using the method previously described. RNA 
levels were quantified using a phosphorimager (Molecular Dynamics, Sunnyvale, 
CA.) and the software; Image Quant 3.3.
2.10.8 Solutions and buffers for RNA isolation and Northern blot analysis
20x MOPS buffer
0.4M 3-[N-morpholino]-propane- 
sulphonic acid (MOPS), 0.02M EDTA, 




1.73ml 36% w/v formaldehyde, 0.533ml 
87% v/v glycerol, 0.533ml saturated 
bromophenol blue solution, 0.533ml 
water, 1.07ml 20x MOPS buffer, 4.8ml 
deionised formamide
20% w/v SDS solution
20g of SDS diluted in 100ml water
20x SSC
3M sodium chloride, 0.3M trisodium 
citrate dihydrate.
Hybridisation solution
0.001M EDTA, 0.25M disodium- 
hydrogen-phosphate, 7% w/v SDS
20x SSPE
3M sodium chloride, 0.2M sodium- 
dihydrogen-phosphate, 0.02M EDTA, pH 
7.4 with sodium hydroxide.
0.5M disodium-hydrogen-phosphate
0.5M disodium-hydrogen-phosphate, pH 
7.2 with phosphoric acid
6x SSPE, 0.1% w/v SDS solution
60ml of 20x SSPE and 1ml of 20% w/v 
SDS adjusted to 200ml with water.
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2x SSPE, 0.1% w/v SDS solution
20ml of 20x SSPE and 1ml of 20% SDS 
adjusted to 200ml with water.
lx  SSPE, 0.1% w/v SDS solution
10ml of 20x SSPE and 1ml of 20% SDS 
adjusted to 200ml with water.




8.5M guanidine, 40mM sodium citrate, 
0.8% v/v sarcosine, For every 50ml used 
add 0.36ml of 2-mecaproethanol 
immediately prior to use.
2.11 Western blot analysis
Western blot analysis requires isolated cellular proteins to be separated according to 
size by gel electrophoresis, followed by transfer from a gel to a membrane. The 
membrane is incubated with an antibody directed against the protein of interest. The 
antibody bound to the filter can then be detected by reaction with various reagents.
2.11.1 Cell lysis and sample preparation; Monolayers of FEK-4 cells were washed 
with ice cold PBS prior to the addition of 50pl of ice-cold lysis buffer (see 2.11.1). 
Cells were detached using a rubber cell scraper. The resultant lysates were 
transferred to chilled microfuge tubes, and incubated at 4°C for 15 min, followed by 
centrifugation at 13,000 rpm for 2 min at 4°C in a Sanyo MSB010 microcentrifuge. 
Supernatants were transferred to labelled microfuge tubes and kept on ice. Total 
protein content was calculated by Bradford analysis as described in section 2.6.
2.11.2 Separation o f cellular proteins by electrophoresis; The cell lysate was diluted 
to a final concentration of lpg/pl protein. A 20pl solution containing the lysate was 
boiled for 5 min with 5x sample buffer (see 2.11.1). Proteins were separated by
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sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using the 
Bio-Rad Mini protean II equipment with a 5% w/v acrylamide stacking gel and a 
7.5% w/v acrylamide resolving gel (described in 2.11.2). The resolving gel was 
poured into the gel equipment and overlaid with water. Once (anaerobic) 
polymerisation had occurred the water was aspirated off and the stacking gel was 
poured. A 10-well comb was sequentially inserted in the top of the gel. The wells 
were then filled with lx SDS-PAGE running buffer (see 2.11.1) before 20pl of each 
sample was loaded into the wells in parallel with molecular mass markers. The gel 
was run in a lx SDS-PAGE running buffer at 80V through the stacking gel, followed 
by 150V through the resolving gel until the bromophenol blue in the loading buffer 
had reached the bottom of the gel.
2.11.3 Semi-dry transfer o f proteins to nitrocellulose; The gel was removed from the 
apparatus and soaked in semi-dry transfer buffer (see 2.11.1). The graphite electrodes 
of the semi-dry transfer apparatus (Pharmacia-Biotech Multiphor II) were dampened 
with semi-dry transfer buffer. Following this, a stack was made consisting of 4 pieces 
of 3MM Whatman paper (that matched the size of the gel), one piece of nitrocellulose 
membrane, the gel and another 4 pieces of 3MM Whatman paper, all of which were 
soaked in the transfer buffer. Air bubbles were expelled and the transfer was run for 
60 min at a constant 0.8mA/ cm2 of membrane. The membrane was then stained with 
Ponceau S (see 2.11.1) to check for transfer and even loading of the samples and to 
determine the location of the molecular mass markers. The stain was removed by 
washing the membrane in water for 2 min, followed by 10 min wash in Tris-buffered 
saline (TBS) (see 2.11.1).
2.11.4 Blocking and developing; The non-specific protein binding was blocked by 
overnight incubation of the membrane with a blocking agent containing 20% w/v
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powdered milk (Marvel, UK), lxTBS and 0.05% w/v sodium azide. After a 10 min 
wash in TBS, the membrane was incubated for 3h with a 1:500 dilution of the primary 
COX-1 or COX-2 antibody in fresh blocking solution (without sodium azide). The 
membrane was then washed once with TBS, three times with TBSN (see 2.11.1) and 
once again with TBS for 10 min each wash. The membrane was then incubated for 
lh with lpg/ml of the secondary antibody, diluted in TSBN. This was followed by 
extensive washings with TBS and TBSN as described previously. A further wash was 
performed in TBS for 10 min before the addition of enhanced chemiluminescent 
(ECL) reagent for 1 min. The membrane was exposed to X-ray film for 5min- 
ovemight using a RGII Fuji X-ray film developer.
116
2.11.5 Solutions and buffers for SDS-PAGE and Western blot analysis
Lysis buffer
50mM Tris-HCl, 150mM NaCl, 1% v/v 
Nonident P40,10% v/v glycerol, 5mM 
EDTA, ImM sodium ortho vanadate, 
ImM sodium molybdate, lOmM sodium 
fluoride, 40pg/ml phenylmethylsulfonly 
fluoride (PMSF), 1 pg/ml pepstatin A, 
lOpg/ml aprotinin, 10pg/ml leupeptin, 
lOpg/ml soyabean trypsin inhibitor
5x SDS-sample buffer
5% w/v SDS, 50% v/v glycerol, 200mM 
Tris-HCl (pH 6.8), bromophenol blue, 
5% v/v 2-mercaptoethanol (50jil/ml)
SDS-PAGE running buffer
25mM Trizma base, 192mM glycine, 
0.1% w/v SDS.
Tris-buffered saline (TBS)
20mM Tris-HCl (pH 7.5), 150mM NaCl, 
pH to 7.5
Tris-buffered saline (TBSN)
TBS+ 0.05% v/v NP40
Ponceau S
0.1% w/v Ponceau S, 5% v/v acetic acid
Semi-dry transfer buffer
39mM glycine, 48mM Trizma base, 
0.0375% w/v SDS, 20% v/v methanol
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2.11.6 Gels used for SDS-PAGE
Constituents of the gel* 5% w/v Acrylamide gel 
(Stacking gel) ml




1M Tris pH 8.8 5.6
1M Tris pH 6.8 1.25
10% w/v SDS 0.15 0.25
Total 9.07 15.2
*each gel had an addition of 50jli1 of 10% w/v ammonium persulphate and 20pl 
TEMED.
2.12 Spectrophotometric analysis of compounds
When assessing whether an iron chelator afforded protection against UVA mediated 
damage, we firstly needed to demonstrate that the compound itself did not absorb any 
radiation in the UVA region. This would show that the iron chelator could not act as a 
direct physical barrier against harmful UVA that would otherwise reach the cells. 
Spectrophotomrtric analysis was performed using a Kontron (Uvikon 720LC) 
spectrophotometer programmed to perform a wavelength scan from 190-425nm. 
Compounds were added at concentrations analogous to those used in most 
experiments and measured against a control blank that contained water.
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2.13 Fluorescence activated cell sorter (FACS) analysis
Growing FEK-4 fibroblast cells on 10cm plates were incubated overnight with the 
appropriate compound. The following day the media was removed and saved. The 
cells were washed twice with PBS and incubated for 5 min with 3ml of 0.25% w/v 
trypsin (Life Technologies). After detachment, 3ml of the saved media was reapplied 
to the cells and the cells were transferred to a flow cytometer tube (Becton Dickinson, 
UK). The cells were spun into a pellet by centrifugation at lOOOrpm for 5 min in a 
Jouan CR412 centrifuge. The supernatant was removed and replaced with 5ml of AV 
binding buffer (see 2.13.1) and a second centrifugation was performed as previously 
described. The resultant supernatant was removed by tipping the tube, and the 
remaining residual buffer and the pellet were mixed with a further 50pl of FACS 
buffer. 2pi of AV was added to this suspension and incubated in a dark area at room 
temperature for 15 min. After this period, 400pl AV binding buffer containing 
5pg/ml PI was mixed with the suspension. The resultant suspension was then 
analysed on a (FACS) Vantage SE (Becton Dickinson, UK) using an Argon ion laser 
at 488nm (lOOmW) for excitation and measured emission fluorescence at 515nm with 
a band pass filter (± 30nm) for AV florescence and a long pass >560nm filter for PI 
fluorescence. Acquisition and analysis was carried out using cellquest (version 3.9) 
software.
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2.13.5 Solutions and buffers for FACS analysis
AV binding buffer
140mM sodium chloride, lOmM 
Hepes/NaOH. Prior to use, add 5mM 
calcium chloride.
2.14 Ferritin analysis
Cell extracts were prepared for the analysis of intracellular ferritin content using a 
polyclonal enzyme -linked immunosorbent assay (ELISA) named the Enzymun- 
Test® Ferritin Kit (Roche, UK). Cytosolic extracts were prepared from FEK-4 cells 
on 10cm plates as described in 2.5.2. Total protein content was measured as 
described in 2.6. Ferritin was analysed in compliance with the manufacturers 
instructions. All components of the Enzymun-Test® Ferritin Kit were brought to 
room temperature before use. 20pl of cytosolic extracts and ferritin standards 
(provided in the ELISA kit) were added to separate streptavidin-coated tubes. 1ml of 
incubation buffer (containing the anti-ferritin antibodies) was added and the tubes 
were incubated for 30 min at room temperature. The contents of the tube were 
removed by aspiration and the tube was washed with 2ml of the washing solution. 
The washing solution was then aspirated from the tube and 1ml of a chromogen- 
substrate solution was added to each tube. The tubes were incubated at room 
temperature for 15 min producing a green substrate-chromagen solution. The 
absorbance was determined immediately at 420nm using a Kontron (Uvikon 720LC) 
spectrophotometer. The concentration of ferritin protein in each extract was 
determined against the ferretin standards. This value was then normalised using the
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total protein content obtained from Bradford analysis (section 2.6) and expressed as 
nanograms (ng) of ferritin per milligram of protein.
2.15 Bleomycin assay for redox active iron
The bleomycin assay was very kindly performed on samples of Eagles Earls Minimal 
Essential Medium (prepared as described in 2.1) by Dr. Gregory Quinlan of the Royal 
Brompton hospital. Bleomycin is an antitumor antibiotic that chelates iron and binds 
to DNA. When bound to DNA in the presence of iron and an iron-reducing agent, 
such as ascorbate, the Fe11 may undergo autoxidation to generate hydroxyl radicals. 
These radicals cleave DNA, (which is also added to the sample), at the deoxyribose 
sugar to release malondialdehyde (MDA), which can be measured by the 
thiobarbituric acid (TBA) reaction. This reaction forms the basis of an assay to 
measure chelatable redox active iron in extracellular fluids [Gutteridge and Hou, 
1986]. Most glassware, reagents and solutions used in the laboratory contain 
sufficient contaminating iron, in micromolar concentrations, to activate the bleomycin 
reaction and cleave DNA. Carefully controlled blanks and standards are therefore 
introduced [Gutteridge and Hou, 1986], so that chelatable iron found only in the 
sample under assay is ultimately measured.
2.16 Statistical analysis
Results were expressed as the mean ± one standard deviation. Significant differences 
(p<0.05) between sets of data containing three or more samples were determined 
using a paired t-test.
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T-tests were performed using Microcal™ Origin® version 6. software. 




3.1 Iron release following UVA irradiation of (FEK-4) human skin fibroblast 
cells
FEK-4 skin fibroblast cells were grown to a confluence of 80% on 10cm plates. Cells 
were subjected to a moderate dose of UVA (250kJ/m2) irradiation using a Sellas 4kW 
UVA lamp (as described in 2.4). Typically, a UVA dose of 250 kj/m2 is equivalent to 
the amount the surface of the skin would be exposed to over 70 min of sunlight on a 
summer day around noon at northern latitude of 30-35 [Frederik et al., 1989]. Prior 
to irradiation, the medium bathing the cells was removed and replaced with PBS to 
prevent any absorption, by the medium, of the UVA radiation destined for the cells 
beneath. The integrity of the cell membrane was maintained by 0.01% w/v Ca2+/Mg2+ 
present in the PBS. Immediately after the cells had been irradiated, the PBS was 
replaced with the ‘conditioned’ medium that had been removed from the plate. After 
the desired incubation period, following irradiation, the medium was removed and 
cells were lysed (section 2.7) for analysis. Changes in iron homeostasis resulting 
from the UVA irradiation of primary skin fibroblast cells (FEK-4) were examined 
using an RNA bandshift assay (EMSA). Interaction of a radiolabelled 
oligonucleotide, containing the human IRP-1 specific motif, with the IRP-1, present 
in cytosolic extracts of normal, growing FEK-4 cells, were used to estimate the level 
of intracellular low molecular mass iron within cells. A UVA radiation dose of 
250kJ/cm caused a detectable increase in low molecular mass iron, since 1 h after 
UVA irradiation IRP/IRE binding appears to decrease from the basal level 
represented by (‘control’). A partial increase (recovery) was observed after 6 h, and 
the basal level of IRP/IRE binding was restored 18 h after exposure to UVA. A
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representative gel of a single assay is shown in figure 3.1. The results shown were 
consistent with the findings of Pourzand et al., 1999 who observed a similar pattern of 
iron release after UVA irradiation of FEK-4 cells.
F ig u re  3.1. In cr e a sed  iro n  re lea se  fo llo w in g  a m o d e r a te  (2 5 0 k J /m 2) d o se  o f  U V A  r a d ia t io n . A
radiolabelled (RNA) iron regulatory element (IRE) was hybridised with the iron regulatory proteins 
(IRPs) present in the cytosolic extracts obtained from FEK-4 skin fibroblast cells. Cells were 
incubated for lh, 2h, 4h, 6h, and 18h time intervals after exposure to 250Kj/cm2 UVA radiation. The 
resultant complexes were visualised using a phosphorimager (Molecular Dynamics, Sunnyvale, CA.). 
The positions of the IRP/IRE complexes and the excess free probe are indicated on the figure.






3.2 Alterations in gene expression following UVA irradiation of (FEK-4 and 
1BR-3) human skin fibroblast cells.
Growing cells were subjected to a physiologically mild dose (250kJ/m ) of UVA 
radiation using a Sellas 4kW UVA lamp (as described in 2.4). The cells used for 
these experiments were 1BR3 skin fibroblast cells which contained 1.99pM ± 0.41 
intracellular low molecular mass iron, and FEK-4 ceils which contained 1.21pM ± 
0.45 (Zhong, 2001). These cells also differ in their origin (see 2.1). The cells were 
grown to a confluence of 80% in cell culture medium as described in section 2.1. The
94- 9 +medium was removed and replaced with Ca /Mg containing PBS prior to UVA 
irradiation. Cells were re-incubated with their original ‘conditioned’ medium for the 
specified period, after which RNA from the cells was isolated and separated by gel 
electrophoresis for Northern blot analysis. Northern blot analysis relies on the 
principal that a labelled complementary cDNA sequence will bind with a high affinity 
to its respective RNA sequence. If the excess probe is washed away, the remaining 
‘bound’ radiolabelled cDNA produces a signal that is assumed proportional to the 
amount of RNA (of a specific gene), which is present on the membrane. Such a 
signal was measured using a phosphorimager (Molecular Dynamics, Sunnyvale, CA.) 
as described in section 2.10. This signal can be ‘normalised’ according to the mRNA 
expression of a constitutively expressed gene, and glyceraldehyde phosphate 
dehydrogenase (GAPDH) was used in this instance. The resultant data are displayed 
as an increase over the basal level of gene expression; the basal level of expression 
was the value obtained form cells that were treated under exactly the same tissue 
culture conditions as the irradiated cells apart from the exposure to UVA radiation. 
This value was given an arbitrary value of 1. Using the conditions described, UVA 
radiation increased the mRNA expression of both the genes for HO-1 and COX-2 in a
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time-dependent manner, until a ‘peak’ of expression was reached and expression 
started to return towards its basal level. There is an apparent difference in the UVA- 
induced expression of COX-2 between the two different fibroblast cell lines (FEK-4 
and 1BR-3) as shown in figures 3.2A and D. FEK-4 fibroblast cells displayed a peak 
induction of COX-2 at 2 hours post irradiation with an increase of 2.5 fold over the 
basal level, whereas the peak of COX-2 expression in 1BR-3 cells was seen 4 hours 
post irradiation as a 23 fold increase of the basal level (figure 3.2D). The expression 
of HO-1 was similar in both FEK-4 and 1BR-3 cells. The peak in HO-1 mRNA 
expression occurs 5 hours after UVA irradiation in both FEK-4 and 1BR-3 cells 
displaying a 15 and 21 fold increase respectively. Throughout the ensuing 
experiments in this thesis that involve UVA irradiation, a time point of 4 hours after 
UVA irradiation was used for all RNA analysis. Figures 3.2 F and H display the 
increase in HO-1 mRNA expression. At this time point we observe an increase in 
HO-1 mRNA expression of 14-fold for FEK-4 and 18 fold for 1BR-3 at the 4 hour 
time point. Similarly, COX-2 mRNA expression was also measured at this time point 
(4 hours post UVA irradiation). In figures 3.2B and D, this represents a 2 and 23 fold 
increase in COX-2 mRNA expression in FEK-4 and 1BR-3 cells, respectively.
F ig u r e  3 .2 . In c r e a se d  C O X -2  a n d  H O - 1 m R N A  e x p r e s s io n  in  b o th  F E K -4  a n d  1 B R -3  sk in  
f ib r o b la s t  c e lls  su b je c te d  to  a m o d e r a te  d o s e  (2 5 0 k J /m 2) o f  U V A  r a d ia t io n . T h e R N A  from  c e lls  
irradiated 1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,1 8  and 2 4  hours prior to  a n a ly sis  w a s transferred to  a m em brane and  
ra d io lab elled  u s in g  a c D N A  probe. Su bseq uent e x c e ss  p rob e w a s rem o v ed  and the resultant a c tiv ity  
w a s qu antified . E ach  b lo t is  d isp la y ed  ab o v e  its resp ectiv e  G A P D H  m R N A  ex p ress io n  that w a s u sed  
to  n o rm alise  the data. A ll  data sh o w n  in  figu res B , D , F  and  H  are the m ea n  (± )  standard d ev ia tio n  for  
three ind ep en d en t experim en ts. S tatistica l a n a ly s is  w a s perform ed  u s in g  a pa ired  t-test. S ig n ifica n t  
d ifferen ces (a t the p <  0 .0 5  le v e l)  com p ared  to  the co n tro l (Oh) are in d ica ted  u s in g  (* ). N o te  the
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increase in basal gene expression (y-axis) is displayed using a different scale in each of figures B, D, F 
and H.
Figure A, displays a representative single blot that has been probed for COX-2 and then GAPDH 
mRNA obtained from FEK-4 cells. Note the presence of two bands in the COX-2 blot that depicts two 
splice variants. Throughout this thesis the mean of these two bands was calculated for the purpose of 
quantification. B, displays the mean of expression of 3 independent experiments. Using the same 
COX-2 cDNA probe.
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RNA isolated from 1BR-3 cells exposed to the same conditions was analysed as previously described. 
Figure C, displays a representative single blot that has been probed for COX-2 and GAPDH mRNA in 
1BR-3 cells that were irradiated 1,2,3,4,5,6,7,8 and 18 hours prior to the analysis of mRNA. D, 
displays the mean expression seen in 3 independent experiments.
c
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Figure E, displays a representative single blot of HO-1 mRNA and GAPDH mRNA in response to 
different time intervals after irradiation with UVA (250kJ/m2) (1,2,3,4,5,6,7,8,18 and 24 hours after 
UVA) in FEK-4 cells. F, displays the mean of expression of 3 independent experiments.
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G, displays a representative single blot that has been probed for HO-1 mRNA followed by GAPDH 
mRNA in 1BR-3 cells that have been irradiated 1,2,3,4,5,6,7,8 and 18 hours prior to the analysis of 
mRNA. H, displays the mean of expression of 3 independent experiments
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3.3 Chemically induced alterations in iron homeostasis
3.3.1 Measurement of iron levels within tissue culture medium
To new, clean plastic test tubes were added calf thymus DNA (1 mg/ml), bleomycin 
(1.5 units/ml), Tris buffer 1M pH 7.4 and the sample of tissue culture medium 
(prepared as described in section 2.1). Ascorbic acid (7.5mM freshly prepared) was 
added to start the reaction and the mixture is incubated at 37°C for 30 min. Iron 
chelated from the tissue culture media sample by bleomycin was reduced by the 
added ascorbate to a reactive iron-oxygen species that degrades DNA with the release 
of malondialdehyde (MDA). MDA was measured spectrophotometrically (A532nm) 
after reacting it with Thiobarbituric acid (TBA) and quantitatively relating it to pure 
iron standards treated under the same reaction conditions [Gutteridge and Hou, 1986]. 
The samples of 15% v/v FCS Eagles Earls Minimal Essential tissue culture medium 
were shown to contain no free redox active iron. In contrast, the assay revealed the 
capacity for the media to bind up to 42.09pM iron, most likely due to the presence of 
serum transferrin in the media.
3.3.2 Disruption of iron homeostasis by iron chelators
Two chemically different iron chelators were added to normal, growing and viable 
FEK-4 skin fibroblast cells as described in section 2.1. Approximately 6xl05 cells 
were present on each plate. The first chelator used was desferrioxamine mesylate 
(DFO) a hydrophilic hexadentate iron chelator with an affinity for iron of around Ka
3010 . The second was salicylaldehyde isonicotinoly hydrazone (SIH), a lipophilic 
tridentate iron chelator with an affinity for iron of around Ka 1029. DFO and SIH, 
dissolved in water and DMSO respectively, were separately added to growing
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fibroblasts at variable time points and concentrations. To investigate the effect of its 
incubation period DFO was added at a concentration of lOOpM for 1, 2, 4, 8, 12, 18, 
20 and 24 hours prior to analysis. Separately, the effect of varying DFO 
concentrations was investigated by adding DFO at a preset time point of 18 hours at 
final concentrations of 5, 50, 100 and 500pM. In contrast, SIH was only added at the 
commonly used concentrations of either 100 or 200pM for a predetermined 
incubation period of 18h. After the chelators had been incubated with the cells for the 
required time, the media was removed from the cells, which were lysed for RNA 
bandshift assay (EMSA) analysis (as described in section 2.7). Under the conditions 
described, normal viable fibroblasts, not treated with iron chelators, showed a light 
band indicating a lack of binding of the radiolabelled iron regulatory element (IRE) to 
the iron regulatory proteins (IRPs) present in the cytosolic extracts shown in figure 
3.3A and B (see section 2.5). This represented the control (basal) value for this 
experiment (see figure 3.3). Incubation of fibroblasts with both DFO and SIH 
decreased the basal level of intracellular low molecular mass iron. This was shown to 
have occurred since the binding of iron regulatory proteins (IRPs), (obtained from 
cytosolic extracts, of the fibroblasts), to the radiolabelled iron regulatory element 
(IRE) increased in a time and/or dose dependent manner which was dependent upon 
the level of chelatable low molecular mass iron within the fibroblasts. The addition of 
an iron chelator produced a much darker band, which for treatment with 500pM DFO 
for 18h represented a 3.5-fold increase in the binding of the IRPs to the radiolabelled 
IREs and a 3-fold increase when this was repeated using 200p.M SIH. When FEK-4 
skin fibroblast cells become more confluent, the level of intracellular iron is known to 
decrease which leads to an increase in IRP/IRE binding activity [Pourzand et al, 
1999]. To demonstrate that the observed alterations in IRP/IRE binding at time points
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of 24 hours were not solely a consequence of increased cell confluence an indication 
of iron homeostasis 24 hours after the analysis of the 0 hour control is displayed in 
figure 3.3A. This displays a slight increase in IRP/IRE binding compared with the 0 
hour control, indicating a depletion of intracellular iron, but is not equivalent to the 
increase in IRP/IRE binding that is observed 24 hours after the addition of DFO 
(figure 3.3). A time and dose dependent increase in the affinity of the IRPs is shown 
in figure 3.3 and represented in table 3.1 as a percentage increase of that seen in 
control cells. In order to establish that changes in iron homeostasis were dependent 
solely upon iron chelation, iron saturated forms of the two different iron chelators 
were prepared. These consisted of equimolar preparations of the chelator with ferric 
citrate freshly prepared and administered to the fibroblasts as described in section 
2.3.3. When saturated with iron prior to administration to the fibroblast cells, both 
ferrioxamine (FO) and iron saturated SIH (Fe-SIH) failed to significantly alter the 
binding of the IRPs to IREs yielding a basal activity characteristically seen in control 
cells not subjected to iron chelators, (figures 3.3B and 3.3C).
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F ig u re  3.3. T h e e ffe c t o f  in c u b a tio n  p er io d  or c o n c e n tr a tio n  o f  an iro n  c h e la to r  o n  iro n  
h o m e o sta s is . Cytosolic extracts were obtained from cells that had been pre-treated with either DFO or 
SIH at various concentrations and/or incubation periods with the iron chelators. IRPs present in the 
cytosolic extracts were hybridised with radiolabelled IREs and visualised on a polyacrylamide gel. 
Representative blots o f IRP/IRE binding after (A) 0-24 hour pre-incubation with lOOpM DFO or (B) 
an 18 h pre-treatment of normal skin fibroblast cells (FEK-4) with 5, 50, 100, 500pM DFO or 500pM 
FO, (C) An 18 hour incubation with either 100, 200pM SIH, 500pM DFO or 200pM Fe-SIH. The 
resultant complexes were visualised using a Phosphorimager (Molecular Dynamics, Sunnyvale, CA.), 
positions of the IRP/IRE complexes are indicated on the figure. Each figure is representative of n=3 
independent experiments.
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T a b le  3 .1 . T h e  e ffe c t  o f  c o n c e n tr a tio n  th e  o f  an  iro n  c h e la to r  on  iro n  h o m e o sta s is . Cytosolic 
extracts were obtained from cells as previously described. IRPs present in the cytosolic extracts were 
hybridised with radiolabelled IREs and visualised on a polyacrylamide gel. Three representative blots 
displaying IRP/IRE binding after an 18 h pre-treatment of normal skin fibroblast cells (FEK-4) with 5, 
50, 100, 500pM DFO or An 18 hour incubation with either 100, 200pM SIH were visualised using a 
Phosphorimager (Molecular Dynamics, Sunnyvale, CA.) and quantified using Imagequant software 
(Version 3 .3 ). The table displays the mean of n=3 independent experiments.









3.3.3 Measurement of intracellular ferritin levels in cells pre-treated with 
DFO and SIH
The iron chelators DFO and SIH both increase IRP/IRE binding activity (figure 3.3). 
Because several factors other than iron homeostasis such as hypoxia and 
inflammatory mediators can directly or indirectly modulate the IRPs of cells (section 
1.4.4.1), it is important to demonstrate that the iron chelators DFO and SIH can 
modulate an IRP target gene. In this study we have analysed the response of the 
intracellular iron storage protein ferritin. Growing FEK-4 skin fibroblast cells were 
pre-treated for 18 hours with either DFO or SIH. Cytosolic extracts were obtained as 
described in section 2.5.1. The ferritin content of the chelator-treated cells was 
analysed using the Enzymun-Test® Ferritin kit (Roche, UK) as described in section 
2.14. The binding of ferritin epitopes to anti-ferritin antibodies allowed a secondary 
bound chromagen (which absorbs light at 420nm) to be compared with a range of pre­
prepared standards of known ferritin concentration. The resultant value for ferritin 
protein was normalised according to the total protein content of each sample and 
expressed as ng of ferritin per pg of total protein. Figure 3.4 displays a 66% and 67% 
decrease in intracellular ferritin when cells are pre-treated with DFO and SIH, 
respectively.
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F ig u re  3 .4 . T h e  e ffe c t o f  D F O  and  S IH  o n  in tr a ce llu la r  fe rr it in  lev e ls . Growing FEK-4 cells were 
pre-treated for 18 hours with either lOOpM DFO or lOOpM SIH. Cytosolic extracts were analysed 
using a ferritin ELISA technique as described in section 2.14. The data shown are the mean of three 
independent experiments and display the (±) standard deviation. Statistical analysis was performed 
using a paired t-test. Significant differences (at the p< 0.05 level) compared to the untreated control 




3.3.4 Disruption of iron homeostasis by haemin and an iron salt
Two different forms of iron were used to increase the level of intracellular low 
molecular mass iron in normal viable FEK-4 skin fibroblast cells. The first form of 
iron used was haemin. Haemin is the chloride of haem in which the ferrous form of 
iron has become oxidised to the ferric state. The second form of iron was freshly 
prepared ferric citrate, which is as an aqueous, equimolar mixture of ferric chloride 
and sodium citrate prepared as described in section 2.3.2. Under such conditions, 
ferric citrate forms a polymer or relatively high molecular weight oligomer, as a 
consequence of this ferric citrate has been shown to be less effective at increasing the 
level of intracellular low molecular mass iron in skin fibroblast cells when compared 
to haemin [Zhong, 2001]. Haemin and ferric citrate were separately added to growing 
FEK-4 fibroblasts at a final concentration of lOpM and lOOpM, respectively. 
Haemin and ferric citrate were incubated with the cells for either 1, 2, 3, 4, 5, 6, 7, 8 
or 18 hours after which the media, containing the source of iron, was removed and the 
cells were lysed for analysis by an RNA bandshift assay (EMSA) (as described in 
section 2.7). Under the conditions described normal viable fibroblasts, not treated 
with haemin or ferric citrate, showed a dark band indicating a control (basal) level of 
binding of the radiolabelled iron regulatory element (IRE) to the iron regulatory 
proteins (IRPs) present in the cytosolic extracts (see section 2.5) and this represented 
the control value for this experiment (figure 3.5)
Incubation of fibroblasts with both haemin and ferric citrate increased the basal level 
of intracellular low molecular mass iron. This was shown to have occurred since the 
binding of iron regulatory proteins (IRPs), (obtained from cytosolic extracts of the 
fibroblasts), to a radiolabelled iron regulatory element (IRE) decreased in a time 
dependent manner which was dependent upon the level of chelatable low molecular
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mass iron within the fibroblasts. The addition of haemin or ferric citrate produced a 
light band representing a decrease in IRP/IRE binding, which for treatment with 
lOpM haemin for 5 hours and lOOpM ferric citrate for 5 hours produced the greatest 
decrease in IRP/IRE binding. A time-dependent decrease in the affinity of the IRPs is 
shown in figure 3.5. The values obtained are a mean of two independent experiments.
F ig u re  3 .5 . T h e  e ffe c t  o f  h a em in  a n d  fe rr ic  c itr a te  o n  iro n  h o m e o sta s is  in  F E K -4  sk in  fib r o b la st  
ce lls . Growing FEK-4 skin fibroblast cells were treated either with (A) lOpM haemin or (B) lOOpM 
iron citrate for either 1, 2, 3, 4, 5, 6, 7, 8 or 18 hours. After which, cells were lysed and IRPs present in 
the cytosolic extracts of cells were hybridised with a labelled IRE probe. The complex was resolved on 
a polyacrylamide gel using a Phosphorimager. IRP/IRE complexes are displayed and are 
representative of 2 independent experiments.
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3.4 The modulation of gene expression in FEK-4 cells by iron chelators
In order to assess any changes in the expression of oxidant-stress-modulated genes by 
pre-incubating cells with iron chelators, it was necessary to demonstrate the effect the 
iron chelator alone had on the expression of such genes.
3.4.1 The modulation of gene expression in FEK-4 cells by increasing 
concentrations of desferrioxamine
The aforementioned hydrophilic, hexadentate iron chelator, DFO, was added to 
normal, growing FEK-4 skin fibroblast cells at a range of final concentrations of 0.5, 
1, 1.5, 2, 2.5, 5, 100 and 500pM. Lower concentrations of DFO are not generally 
thought to be toxic to cells; hence, to avoid potential toxicity particular emphasis was 
put upon the lower concentrations of the chelator. The DFO was incubated with the 
cells for 18 hours prior to the removal of the medium and lysis of the cells for RNA 
analysis. Once the RNA from each different treatment had been transferred onto a 
nylon membrane it was probed for the mRNA of four different genes including those 
for HO-1, COX-2, GAPDH and p-actin. Initially GAPDH was used to normalise data 
as a ‘housekeeping’ gene as previously shown in section 3.2. However, we noted an 
apparent modulation of the mRNA for GAPDH by the iron chelator DFO. The 0 
hours pre-treatment with DFO represents the normal (basal) level of mRNA 
expression for cells that have not been exposed to any chelator compounds, and 
represents a value against which all treatments may be compared and represented as a 
fold increase. Figure 3.6B displays that under such conditions DFO did not 
significantly alter the expression of HO-1 mRNA. However, the data represented in 
figures 3.6D and 3.6F show that the mRNA expression of both COX-2 and GAPDH 
was significantly increased by incubating the cells for 18 hours with concentrations of
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DFO equal to, or greater than 5pM. A 5pM concentration of DFO significantly 
increased the expression of COX-2 and GAPDH mRNA by 2.2 and 1.9 fold 
respectively (figures 3.6D and 3.6F). Furthermore, the addition of lOOpM DFO to 
these cells, significantly (p<0.05) increased the expression of COX-2 mRNA by 7 
fold (figure 3.6D) and GAPDH mRNA by 2.8 fold (figure 3.6F). When the iron 
saturated form of DFO (FO) was added to these cells (figures 3.6 B, D and F) there 
was no significant change in the basal mRNA expression of HO-1, COX-2, GAPDH 
or P-actin. Furthermore, when sodium arsenite and tumour necrosis factor alpha 
(TNF-a) in combination with interleukin-1 (IL-1) were separately added to cells (as 
described in 2.3.7 and 2.3.8) they showed a highly significant increase in the level of 
HO-1 and COX-2 mRNA respectively. A 40 (±14) fold increase in HO-1 and a 19 
(±8) fold increase in COX-2 mRNA, demonstrated that the mRNA of these genes was 
readily inducible under the aforementioned conditions.
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F ig u re  3 .6 . T h e  e f fe c t  o f  d iffe re n t  c o n c e n tr a tio n s  o f  D F O  o n  th e  e x p r ess io n  o f  H O -1 , C O X -2  and  
G A P D H  m R N A  in  F E K -4  sk in  f ib r o b la st  ce lls . FEK-4 skin fibroblast cells were subjected to an 18 
hour pre-incubation with 0.5, 1, 1.5, 2, 2.5, 5, 100 and 500pM DFO. The RNA obtained from the cells 
was hybridised with a labelled HO-1, COX-2, GAPDH or P-actin cDNA probe. Figures A, C and E 
show a representative single blot that has been probed for C, COX-2 mRNA, then P-actin mRNA 
followed by A, HO-1 mRNA and finally E, GAPDH mRNA. All blots are displayed above the 
respectiveP-actin expression. The RNA was quantified and normalised against P-actin expression in 
the cells, the normalised data was then expressed as an increase in the basal level of gene expression (0 
hours). The mean value obtained from 6 independent experiments that were probed for B, HO-1 
mRNA. D, COX-2 mRNA and F, GAPDH mRNA is also shown. The data displayed in B, D and F 
also shows the ± standard deviation for each treatment. Statistical analysis was performed using a two- 
tailed t-test and significant differences between treatments and an untreated control (0) at the P<0.05 
level are denoted by (*). Note the increase in basal gene expression (y-axis) is displayed using a 
different scale in each of figures B, D, and F. Because of the space required to display a single 
representative Northern blot for each experiment, such raw data will not appear throughout the 
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3.4.2 The effect of incubation time with the iron chelators salicylaldehyde 
isonicotinoyl hydrazone (SIH) and desferrioxamine mesylate (DFO).
The iron chelators DFO and SIH were applied to growing FEK-4 fibroblast cells at a 
final concentration of 500 and 100pM respectively. DFO and SIH both show 
effective perturbation of iron homeostasis at these concentrations (figure 3.3) and are 
widely used at these concentrations [Kvam et al., 2000; Tsafack et al., 1996], DFO or 
SIH were added to the cell culture media when the cells reached a confluence of 60%. 
After an incubation period with the iron chelator of 2, 4, 6, 8, 18 or 24 hours for SIH 
treatments and 2, 6, 18 or 24 hours for DFO treatments, the cells were lysed and the 
total cellular RNA was extracted.
3.4.2.1 The modulation of HO-1 mRNA expression in FEK-4 cells by using 
different incubation periods with the iron chelators DFO and SIH
The cells were treated as described in 3.4.2, after which the RNA was analysed using 
a 1400bp cDNA probe for HO-1 and a (3-actin cDNA probe as an internal reference 
(described in 2.10). Figure 3.7 displays the resultant modulation of HO-1 following 
the stated incubation periods with A) SIH and, B) DFO. The data in figures 3.7A and 
B indicate that the iron chelators SIH and DFO do not significantly (p<0.05) alter the 
basal expression of HO-1 mRNA.
F ig u r e  3 .7 . C h a n g e s  in  H O -1  m R N A  e x p r e s s io n  r e s u lt in g  fr o m  th e  tr e a tm e n t  o f  F E K -4  c e lls  w ith  
D F O  a n d  S IH  fo r  d if fe r e n t  in c u b a tio n  in te r v a ls . F E K -4  sk in  fibrob last c e l ls  w ere  incub ated  w ith  
(A ) 5 0 0 p M  D F O  and separately  (B ) lOOpM SIH  for a n  in cu b ation  p er io d  o f  either 2 , 4 , 6 , 8, 18 or  2 4  
hours for SIH  treatm ents or 2 , 6 , 18 and  2 4  hours for  D F O  treatm ents. A fter  the d esired  in cu b ation  
period , the m ed iu m  w a s rem o v ed  and tota l R N A  w a s extracted  from  the c e lls . T he R N A  w a s  
hyb rid ised  w ith  a H O -1 c D N A  probe and qu antified  u s in g  densitom etry . T h e figure represents the
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mean of 3 independent and reproducible experiments. A paired t-test was used to compare differences 
between the untreated control and treatments with the iron chelators. No significant differences 
(p<0.05) were observed. Note the increase in basal gene expression (y-axis) is displayed using a 
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3.4.2.2 The modulation of COX-2 mRNA expression in FEK-4 cells by various 
incubation periods with the iron chelators DFO and SIH
FEK-4 skin fibroblast cells were treated with the iron chelators DFO and SIH as 
described in 3.4.2. Total cellular mRNA was extracted from the cells, separated and 
transferred to a nylon membrane. The RNA on the membrane was hybridised with a 
1800bp cDNA COX-2 probe. Excess probe was removed and the remaining bound 
probe was quantified by densitometry. The relative density for each different 
treatment was normalised using an internal standard, in this case p-actin mRNA 
expression. Figure 3.8 displays the mean value obtained form three independent 
experiments. Incubation of FEK-4 cells with SIH for 18 and 24 hours resulted in a 3 
fold increase in the expression of COX-2 mRNA. However, COX-2 mRNA 
expression peaked at 13 fold after an 18 hour pre-incubation with 500p,M DFO. A 
paired t-test revealed a significant difference (p<0.05) in the expression of COX-2 
mRNA after an (A) 18 and 24 hour incubation with SIH, and after (B) 6, 18 and 24 
hour incubations with DFO.
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F ig u re  3 .8 . C h a n g e s  in  C O X -2  m R N A  e x p r ess io n  r e su lt in g  fr o m  th e  tr ea tm e n t o f  F E K -4  ce lls  
w ith  D F O  and  S IH  fo r  d iffe re n t  in c u b a tio n  in te rv a ls . FEK-4 skin fibroblast cells were incubated 
with (A) 500pM DFO and separately (B) lOOpM SIH for an incubation period of either 2, 4, 6, 8, 18 or 
24 hours for SIH treatments or 2, 6, 18 and 24 hours for DFO treatments. After the desired incubation 
period, the media was removed and total RNA was extracted from the cells. The RNA was hybridised 
with a COX-2 cDNA probe and quantified using densitometry. The figure displays the mean of 3 
independent and reproducible experiments. A paired t-test was used to compare differences between 
the untreated control and treatments with the iron chelators, significant differences (p<0.05) are 
denoted by: (*). Note the increase in basal gene expression (y-axis) is displayed using a different scale 
in both figures A and B.
A
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Fold increase in COX-2 mRNA 
expression (p-actin normalised)
3.4.2.3 The modulation of GAPDH mRNA expression in FEK-4 cells by various 
incubation periods with the iron chelators DFO and SIH
Normal, growing FEK-4 skin fibroblast cells were prepared as described in 3.4.2. 
The RNA extracted from the cells was hybridised with a 1400bp radiolabelled 
GAPDH cDNA probe and normalised with the data obtained using a p-actin cDNA 
probe, as described in 2.10. The data from 3 independent experiments was quantified 
by densitometry and analysed for significant differences between the untreated 
control and chelator treatments using a paired t-test. Figure 3.9 displays a significant 
difference (p<0.05) between an untreated control and cells treated with both (A) DFO 
and (B) SIH, separately, 18 and 24 hours after the addition of these chelators to the 
tissue culture medium.
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F ig u re  3 .9 . C h a n g e s  in  G A P D H  m R N A  e x p r ess io n  r e su lt in g  fr o m  th e  tr e a tm e n t o f  F E K -4  cells  
w ith  D F O  a n d  SIH  fo r  d iffe re n t  in c u b a tio n  in te rv a ls . FEK-4 skin fibroblast cells were incubated 
with (A) 500pM DFO and separately (B) lOOpM SIH for an incubation period of either 2, 4, 6, 8, 18 or 
24 hours for SIH treatments or 2, 6, 18 and 24 hours for DFO treatments. After the desired incubation 
period, the media was removed and total RNA was extracted from the cells. The RNA was hybridised 
with a GAPDH cDNA probe and quantified using densitometry. The figure displays the mean of 3 
independent experiments. A paired t-test v/as used to compare differences between the untreated 
control and treatments with the iron chelators, significant differences (p<0.05) are denoted by: (*). 





if  a  
®  0.5
0 1 2  3 5 6 7 8 9  10 11 12 13 14 15 16 17 18 19 20  21 22 23  244
Time (hours) after the addition of SIH
153
Fold increase in GAPDH mRNA 
expression (p-actin normalised)
3.5 The modulation of gene expression in 1BR-3 cells by different 
concentrations and incubation periods with DFO.
The cells used for these experiments were primary skin fibroblast cells of the cell line 
1BR3 (described in section 2.1) that contained 1.99pM ± 0.41 of intracellular low 
molecular mass iron, (compared with FEK-4 cells which contained 1.21jiM ± 0.45 
(Zhong, 2001)). To assess whether differences existed in the expression of GAPDH, 
HO-1 and COX-2 mRNA when 1BR-3 cells were treated with the iron chelator DFO, 
growing 1BR-3 cells were pre-treated for either 2, 6 or 18 hours with a moderate 
(lOOpM) or high (500pM) dose of DFO. Growing cells were lysed and prepared for 
the analysis of mRNA expression using the Northern blot technique. Figure 3.10 
shows a similar pattern of COX-2 and GAPDH mRNA regulation to that observed in 
figures 3.8 and 3.9. Figure 3.10A displays a slight (2 fold) significant (p<0.05) 
increase in the expression of HO-1 mRNA 18 hours after the addition of DFO to cells. 
Figure 3.10B displays a significant (p<0.05) 1.6 fold increase in COX-2 mRNA 
expression from 2 hours after the addition of DFO. The expression of COX-2 
increases in a dose dependent manner and at 18 hours after the addition of DFO, both 
100 and 500pM DFO cause a significant (p<0.05) 2.7 fold increase in COX-2 mRNA 
expression. Figure 3.10C displays the expression of GAPDH mRNA in response to 
DFO pre-treatment. GAPDH mRNA expression is increased by treating the cells with 
a high (500pM) dose of DFO 6 and 18 hours after its addition. At 18 hours after the 
addition of a high dose of DFO, GAPDH mRNA expression is increased 4 fold. A 
similar 4 fold increase is observed when cells are pre-treated for 18 hours with a 
moderate (lOOpM) dose of DFO.
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Figure 3.10. The effect of a moderate and high dose of DFO on gene expression.in 1BR-3 cells.
1BR-3 skin fibroblast cells were grown to a confluence of 60% and pre-treated for 18 hours with either 
lOOpM or 500pM DFO or iron saturated DFO (FO). mRNA was analysed for (A) HO-1 mRNA, (B) 
COX-2 mRNA or (C) GAPDH mRNA. The data displayed are the mean o f 4 independent 
experiments. Significant differences between treatments and an untreated control are denoted by (*). 
Significant differences at the level p<0.05 were assessed using a paired t-test. Note the increase in basal 
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3.6 Cell viability in response to the addition or removal of iron from FEK-4 
skin fibroblast cells.
Alterations in normal cellular iron homeostasis may interfere with many different 
cellular processes that could potentially cause a degree of toxicity to normal healthy 
cells. To assess whether any such toxicity arose when an exogenous iron chelator or 
sources of iron were added to skin fibroblast cells, flow cytometry was employed. 
This relies on the principle that the binding of an antibody coupled to a fluorescent 
dye to cells indicates whether an individual cell is (1) normal and alive, (2) in a state 
of apoptosis where individual cells programme their own death or (3) a state of 
necrosis where groups of cells undergo a passive disintegration.
3.6.1 The effect of iron chelation on the viability of growing FEK-4 cells
When two chemically different iron chelators (DFO and SIH) were applied to 
growing FEK-4 cells, we observed an increase in the expression of COX-2 and 
GAPDH mRNA. This increase was observed in response to a range of concentrations 
of DFO showing a statistically significant difference at concentrations as low as 5pM 
(figure3.6 B & C). Figures 3.8A and 3.9A display the increase in COX-2 and 
GAPDH mRNA in response to the pre-treatment of cells with the iron chelator SIH. 
It is important to ensure that any increases in COX-2 and GAPDH mRNAs are not 
artefacts of a general toxicity that the chelators may exert upon the cells. To assess 
this, growing FEK-4 cells were incubated for 18 hours with either DFO or SIH or the 
iron-saturated forms of these chelators, FO and Fe-SIH. Populations of cells were 
then removed from the plate in an appropriate buffer and analysed using a FACS 
Vantage machine (as described in 2.13). The data from three independent 
experiments were analysed, and table 3.2 displays the sample population of 10,000
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cells as a percentage of live, apoptotic and necrotic cells displaying the (±) standard 
deviation for each category on the right of each respective column. Although there 
appears to be a slight increase in the percentage of apoptosis and necrosis in cells 
treated with a high (500pM) concentration of DFO a paired t-test did not reveal any 
significant differences between the untreated control cells and cells pre-treated with 
iron chelators or iron saturated chelators.
T a b le  3 .2 .  C h a n g e s  in  ce ll v ia b ility  fr o m  p r e - tr e a t in g  c e l ls  w ith  a n  ir o n  c h e la to r . G ro w in g  F E K -4  
sk in  fibrob last c e lls  w ere  pre-treated  for 18 hours w ith  1 00  or 5 0 0 p M  D F O , 2 0 0 p M  SIH  or iron- 
saturated iron  ch elators (5 0 0 p M  F O  or 2 0 0 p M  F e-S IH ). A fter  18 hours, c e lls  w ere  h arvested  and  
in d iv id u a lly  a n a ly sed  u s in g  a F A C S  vantage  m ach in e . T h e figure d isp la y s the m ean  o f  3 in d ep en dent 
experim en ts as w e ll  as the (± )  standard d ev ia tio n  o n  the r igh t o f  ea ch  co lu m n . A  paired  t-test w a s  u sed  













Control 87.1 5.27 1.24 0.488 11.7 5.76
lOOpM
DFO 91.2 0.375 0.885 0.559 7.93 0.933
500pM
DFO 84.5 2.02 3.49 3.50 12 1.485
500pM
FO 91.4 1.62 1.04 0.474 7.57 2.09
200pM
Fe-SIH 87.4 4.37 0.845 0.346 11.8 4.72
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3.6.2 The effect of iron loading on the viability of growing FEK-4 cells
To assess the effect of chemically different forms of iron (haemin and ferric citrate) 
on the expression of the oxidant stress-modulated genes, HO-1 and COX-2, it was 
essential to firstly examine any toxicity that these compounds may exert upon the 
cells at the concentrations used for this study. If a type of iron is toxic to cells, it may 
alter the expression of oxidative stress-modulated genes independently of the 
oxidative stress generated by UVA irradiation. FEK-4 cells were incubated with 
either lOpM haemin or lOOpM ferric citrate for 18 hours prior to analysis using a 
FACS vantage machine (as described in 2.13). The data from three independent 
experiments was analysed, and table 3.3 displays the sample population of 10,000 
cells as a percentage of live, apoptotic and necrotic cells displaying the (±) standard 
deviation for each category on the right of each respective column. A paired t-test did 
not reveal any significant differences between the untreated control cells and cells 
pre-treated with haemin and ferric citrate.
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Table 3.3. Changes in cell viability from pre-treating cells with different sources of iron.
G ro w in g  F E K -4  sk in  fibrob last c e lls  w ere  pre-treated for 18 hours w ith  lO p M  h a em in  or lOOpM  ferric  
citrate. A fter  18 hours, c e lls  w ere  h arvested  and in d iv id u a lly  a n a ly sed  u s in g  a F A C S  van tage  m ach ine. 
T h e figure d isp la y s  the m ea n  and  (± ) standard d ev ia tio n  o f  3 in d ep en dent exp erim en ts. A  paired  t-test, 
u sed  to  com pare d ifferen ces b e tw e e n  the untreated con tro l and  treatm ents w ith  ferric citrate and  
haem in , r ev ea led  n o  s ig n ifica n t d ifferen ces .
Live cells ±SD Apoptotic ±SD Necrotic ±SD
(% total cells cells





87.1 5.27 1.24 0.488 11.7 5.76
lOOpM
Fe-Cit 91.0 0.396 1.03 0.834 7.95 0.438
lOpM
Hemin 90.9 0.502 0.81 0.764 8.28 1.27
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3.7 The modulation of gene expression by haemin and an iron salt
Normal skin fibroblast cells of the cell line FEK-4 were grown to a confluence of 
60% on 10cm plates. Both haemin and ferric citrate were applied separately to cells 
in order to increase the level of intracellular low molecular mass iron (as shown in fig 
3.5). Haemin is a ferric form of the haem molecule whereas ferric citrate forms a 
polymer or relatively high molecular mass oligomer [Bates et al., 1967], which is less 
effective at increasing the level of intracellular low molecular mass iron in skin 
fibroblast cells in comparison to haemin [Zhong, 2001]. Haemin and ferric citrate 
were separately added to growing FEK-4 fibroblasts at a final concentration of 10pM 
and lOOpM respectively. Haemin and ferric citrate were incubated with the cells for 
either 1, 2, 3, 4, 5, 6, 7, 8 or 18 hours after which the media, containing the source of 
iron, was removed and the cells were lysed for analysis by Northern blot analysis. 
Radiolabelled cDNA probes for HO-1 and COX-2 were bound to the mRNA present 
on nylon membranes containing the RNA and any excess probe was removed. The 
signal was measured by densitometry and normalised against the constitutively 
expressed gene p-actin. Data obtained from incubating cells with lOOpM ferric 
citrate and 10pM haemin displayed a 0.84 ± 23 and 0.97± 19 increase in GAPDH 
mRNA expression respectively when P-actin was used to normalise this data. Despite 
this, to minimise variations in experimental procedures, and to allow comparisons 
between iron loaded cells and cells subjected to iron chelators, all data were 
normalised against the constitutive expression of p-actin mRNA (as discussed later in 
section 3.20). The data in figure 3.11 are displayed as an increase in the basal level 
of gene expression of cells that had not been subjected to an exogenous source of 
iron. Statistical analysis was performed using a paired t-test to reveal any changes in 
the expression of HO-1 or COX-2 mRNA in response to treatments with the different
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sources of iron. The results shown are the mean of three independent experiments. In 
figure 3.11(AI) a significant (p<0.05) 11-fold peak in the expression of HO-1 is 
observed 4 hours after the addition of lOpM haemin. (AH) A significant (p<0.05) 
increase in HO-1 expression is also observed in cells treated with lOOpM ferric 
citrate, but the increase is much less, showing a 2.1 fold increase in mRNA expression 
after a 7-hour incubation with the ferric citrate. Any alterations in the expression of 
COX-2 mRNA were not statistically significant at the p<0.05 level in response to the 
different sources of iron. (BI) The expression of COX-2 mRNA in response to 
lOOpM ferric citrate showed no significant (p<0.05) change when compared to the 
basal (control) expression of COX-2 mRNA in untreated cells. However, (BII) there 
was a slight but significant (p<0.05) 1.3 fold increase in COX-2 mRNA expression 3 
hours after the addition of lOpM haemin to skin fibroblast cells.
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F ig u re  3 .1 1 . T h e  e ffe c t  o f  h a e m in  and  ferr ic  c itr a te  o n  th e  e x p r ess io n  o f  C O X -2  and  H O -1  
m R N A  in F E K -4  sk in  fib r o b la s t  ce lls . Growing FEK-4 skin fibroblast cells were treated with either 
(AI &BI) lOpM haemin or (All & BII) lOOpM ferric citrate for an incubation period of either 1, 2, 3, 
4, 5, 6, 7, 8 or 18 hours. Cells were then lysed and the total cellular RNA was hybridised with a 32 P 
labelled (A &B) HO-1 or (C & D) COX-2, cDNA probe. The resultant complexes were quantified and 
normalised according to P-actin mRNA expression. The data displayed are the mean of 3 independent 
experiments. Significant differences between iron treated cells and an untreated control were assessed 
using a paired t-test. Significant differences at the level p<0.05 are denoted by: (*). Note the increase 
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Fold increase in COX-2 mRNA 
expression (p-actin normalised)
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3.8 Absorption spectrum of the iron chelator DFO.
The iron chelator DFO was used to pre-treat cells that would subsequently be exposed 
to UVA. It was important therefore to ensure that the compound did not absorb any 
radiation in the UVA (320-380nm) region since this might prevent UVA reaching the 
cells. Spectrophotometric analysis was performed using a Kontron (Uvikon 720LC) 
spectrophotometer programmed to perform a wavelength scan from 290-425nm. 
DFO was diluted in water and measured against a control blank of water. Figure 3.12 
displays the wavelengths at which the iron chelator DFO absorbs light. Fig 3.12 
shows that DFO does not absorb any light in the UVA region used to irradiate cells.
F ig u re  3 .1 2 . T h e  a b so rp tio n  sp e c tr u m  o f  th e  iro n  c h e la to r  D F O . DFO was diluted in water to a 
final concentration of 500fiM and the absorbance was measured as described in 2.12. The figure 
displays the relative absorbance on the Y-axis, and the wavelength on the X-axis. The UVA region of 
the electromagnetic spectrum is shown in the area between the lines labelled (UVA 320-380nm). The 





















3.9 The modulation of UVA mediated gene expression by DFO.
When skin fibroblast cells of the cell line FEK-4 and 1BR-3 were irradiated with a 
moderate dose (250kJ/m2) of UVA radiation an increase in the expression of HO-1 
and COX-2 mRNA was observed (figure3.2). To assess the role of low molecular 
mass iron in this response the iron chelator DFO was added to normal growing FEK-4 
skin fibroblast cells prior to irradiation with UVA. Both cell lines on 10cm plates 
were pre-treated with DFO or the iron saturated form of DFO (FO) and exposed to a 
dose of 250kJ/m2 UVA radiation. Cells were then lysed on the plates and total RNA 
was extracted for Northern blot analysis of (A) HO-1, (B) COX-2 and (C) GAPDH 
mRNA as described in section 2.10. The data in figure 3.13 display significant 
differences between treatments and a non-irradiated control (*), and differences 
between UVA irradiated treatments and a UVA irradiated control (V) (i.e. both 
control values had not been pre-treated with either DFO or FO). Figure 3.13 shows 
that (A) UVA radiation of cells results in a significant (p<0.05) 11.5-fold increase in 
HO-1 mRNA expression, but the addition of DFO does not cause a significant 
(p<0.05) change in such a UVA modulated increase. (B) When cells are pre-treated 
with 500pM DFO a significant 5.5-fold (p<0.05) increase in COX-2 mRNA is 
observed, this increase was enhanced (to 7-fold) when the cells were irradiated with 
UVA. (C) GAPDH mRNA is constitutively expressed in the presence of UVA, but 
the expression of GAPDH mRNA is significantly (p<0.05) increased 3.7 fold by pre­
treatment of cells with DFO.
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F ig u r e  3 .1 3 . T h e  m o d u la tio n  o f  UVA m e d ia ted  g e n e  e x p r e s s io n  b y  D F O . FEK-4 skin fibroblast 
cells were pre-treated for 18 hours with either 50pM and 500pM DFO or 50pM and 500pM of the iron 
saturated form of DFO (FO). Cells were lysed and the total RNA was extracted for Northern blot 
analysis o f (A) HO-1 mRNA, (B) COX-2 mRNA or (C) GAPDH mRNA. mRNA was quantified using 
a Phosphorimager and normalised according to P-actin mRNA expression. The data displayed are the 
mean of 4 independent experiments. Significant differences between UVA irradiated treatments and a 
UVA irradiated control are denoted by (V). Significant differences at the level p<0.05 were assessed 
using a paired t-test. Note the increase in basal gene expression (y-axis) is displayed using a different 
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3.10 COX-2 protein accumulation as a consequence of iron chelation
When the iron chelators (DFO and SIH) were applied to growing FEK-4 cells, an 
increase in the expression of COX-2 mRNA was observed. This increase was 
observed in response to a wide range of concentrations of DFO and SIH with the 
difference showing a statistical significance at concentrations as low as 5pM 
(figure3.6 B). Both the iron chelators, SIH and DFO, increased the expression of 
COX-2 mRNA but the response was more pronounced when cells were pre-treated 
with DFO in comparison to SIH. Fig 3.8B displays a highly significant (p<0.05) 13- 
fold increase in the expression of COX-2 mRNA 18 hours after pre-treatment of cells 
with 500pM DFO, (compared to a 3.25 fold increase in response to SIH (fig 3.8A)). 
Therefore, only DFO was used to determine whether the increase in mRNA 
accumulation led to a corresponding increase in the accumulation of COX-2 protein. 
Because the peak in mRNA accumulation occurred 18 hours after the addition of 
DFO, protein was measured at a later time point of 24 hours in response to a range of 
concentrations of DFO. The increased incubation period allowed the translation of 
COX-2 mRNA. Protein expression was measured using Western blot analysis as 
described in section 2.11. Primary antibodies were bound to the COX-1 or COX-2 
protein and a secondary antibody, which bound to the primary antibody, produced 
measurable chemiluminesence. In order to establish that changes in iron homeostasis 
were dependent solely upon iron chelation, the iron-saturated form of DFO was also 
added to the cells (FO). As shown in Figure 3.14, the addition of DFO at 
concentrations of 100 and 500pM increased the accumulation of COX-2 protein in 
FEK-4 skin fibroblast cells. A positive expression control consisting of the co­
addition of 50ng/ml TNFa and 0.5ng/ml IL-1 for 24 hours showed a high level of 
COX-2 protein expression. In contrast, when membranes were re-probed for the
171
expression of COX-1 protein, the expression was highly consistent between all 
treatments. This result demonstrated that COX-1 is constitutively expressed in FEK-4 
cells and that samples were evenly loaded, showing that alterations in the expression 
of COX-2 were a consequence of the different chemicals added to the cells. Although 
normalising COX-2 expression according to the expression of COX-1 demonstrates 
that samples were evenly loaded and that COX-1 is constitutively expressed, it may 
be considered necessary to perform a second normalisation with an appropriate 
housekeeping gene such as p-actin.
F ig u re  3 .1 4 . T h e  e x p r ess io n  o f  C O X -2  p r o te in  a fte r  p r e -tr e a tm e n t o f  ce ils  w ith  D F O . FEK-4 cells 
were pre-treated for 24 hours using the iron chelator, DFO, at concentrations of 2.5, 20, 100 and 
500fiM. 500pM of iron-saturated DFO (FO) was added for the same period, and cells were separately
pre-treated for 24 hours with 50ng/ml TNFa in combination with 0.5ng/ml IL-1. The
chemiluminescent signal obtained from both COX-1 and COX-2 protein is displayed. The figure is 




3.11 The effect of nitric oxide synthase inhibitors on the increased expression 
of COX-2 mRNA by DFO.
It is known that the iron chelator DFO can increase the transcriptional activity of an 
enzyme named inducible nitric oxide synthase (iNOS) (Dlaska and Weiss, 1999). 
Furthermore, it has been shown that the product of this enzyme, nitric oxide, increases 
the induction of cyclooxygenase-2 (Honda et al., 2000). Because an increase in 
COX-2 mRNA (fig 3.6) and protein (fig 3.14) is observed, it is important to establish 
whether this is a result of the production of nitric oxide by DFO. Normal growing 
FEK-4 cells on 10cm plates were pre-treated for 18.5 hours with NMMA and in an 
independent experiment with 1400W. NMMA is an effective nitric oxide synthase 
(NOS) inhibitor, whereas 1400W is a selective inhibitor of the inducible form of the 
enzyme (iNOS) (Garvey et al., 1996). 30 min after the addition of either NMMA or 
1400W, DFO was also added to the cells and incubated for 18 hours. Cells were 
lysed and the cellular RNA extracted. The RNA was transferred to a nylon membrane 
and hybridised with a radiolabelled COX-2 cDNA probe, followed by a p-actin 
cDNA probe for normalisation. Figure 3.15 indicates that the increase in COX-2 
mRNA induced by the addition of DFO is not a consequence of nitric oxide 
production. Both NMMA and 1400W had no significant (p<0.05) effect on the DFO- 
induced accumulation of COX-2 mRNA (DFO (500) + NMMA (500)) and (DFO 
(500) + 1400W (100)).
Figure 3.15. The effect of NOS inhibitors on DFO modulated COX-2 mRNA expression. The
nitric o x id e  sy n th a se  inh ib itors N M M A  and 1 4 0 0 W  w ere  a d d ed  separately  to  g ro w in g  F E K -4  c e lls  at 
concen tra tion s o f  5 0 0  and lOOpM , resp ectiv e ly . A fter  3 0  m in  either 500 |uM  D F O  or iron  saturated  
D F O  (F O ) w a s add ed  eith er a lo n e  or in  com b in a tio n  w ith  the p r e v io u sly  a d d ed  N O S  inh ib itors. A fter  a 
further 18 hours c e lls  w ere  ly se d  for N orthern  b lo t  a n a ly sis . T h e data d isp la y ed  are the m ean  o f  6
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independent observations and show the (±) standard deviation. Statistical analysis was performed 
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3.12 The effect of cobalt chloride on gene expression.
Both cobaltous salts and iron chelators, such as DFO, are known to increase the 
activity of a transcription factor that is normally associated with low oxygen 
concentrations, namely hypoxia inducible factor-1 (HIF-1) (Wang and Semenza, 
1993). To investigate whether the DFO-induced increase in GAPDH mRNA and 
COX-2 mRNA (fig 3.6) could be mimicked by the addition to cells of a cobaltous 
salt, cobalt chloride was added to normal growing FEK-4 skin fibroblasts. Total RNA 
was extracted from cells and analysed using Northern blot analysis as described in 
section 2.10. The mRNA from cells pre-treated with cobalt was probed for the 
mRNA of the genes for HO-1, COX-2 and GAPDH and normalised according to the 
mRNA expression of p-actin. Tables 3.4A, B and C include some of the data shown 
in figure (3.9) for comparison. Taken together the data show that the treatment of 
cells with cobalt chloride results in a highly significant (p<0.05) 44 fold increase in 
HO-1 mRNA, whereas DFO has no significant (p<0.05) effect on HO-1 mRNA 
expression. In contrast the expression of COX-2 mRNA is significantly (p<0.05) 
enhanced by 8 fold following the addition of DFO but is not significantly altered by 
the addition of cobalt chloride. However, GAPDH mRNA is significantly (p<0.05) 
increased by both cobalt chloride and DFO by 3.47 and 3.49 fold, respectively.
175
T a b le  3 .4 .  T h e  e f fe c t  o f  c o b a lt  c h lo r id e  o n  g e n e  e x p r e s s io n . N o rm a l g ro w in g  F E K -4  sk in  fibrob last 
c e lls  w ere  pre-treated  for  18 hours w ith  either 5 0 0 p M  c o b a lt ch loride  (C o C l2) or 5 0 0 p M  D F O . T ota l 
m R N A  w a s extracted  and h y b rid ised  w ith  a p robe d irected  tow ards (A )  H O -1 m R N A , (B )  C O X -2  
m R N A  and (C ) G A P D H  m R N A . m R N A  ex p ress io n  w a s qu an tified  u s in g  d en sito m etry  and  
n o rm a lised  a ga in st P -actin  m R N A  ex p ression . T h e ta b les sh o w  the m ea n  o f  5 ind ep en dent  
ob serv a tio n s for  c o b a lt treatm ents and 6  for D F O  treatm ents. T h e figure a lso  d isp la y s the ±  standard  
d ev ia tion . S tatistica l a n a ly sis  w a s p erform ed  u s in g  a tw o -ta iled  t-test and  sig n ifica n t d ifferen ces  
b e tw e e n  the treatm ents and an untreated control at the P < 0 .0 5  le v e l are d en o ted  b y  (* ).
A
Addition Increase in HO-1 mRNA ± Standard deviation
Control 1 -
500foM C0 CI2 44.4* 3.14
500|iM DFO 1.61 0.621
B
Addition Increase in COX-2 mRNA ± Standard deviation
Control 1 -
500|aM C0 CI2 1.53 0.579
500|aM DFO 8* 2.13
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c
Addition Increase in GAPDH mRNA ± Standard deviation
Control 1 -
500|iM CoCl2 3.47* 0.406
500|iM DFO 3.49* 0.994
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3.13 HIF-1 DNA binding resulting from the pre-treatment of cells with DFO 
and SIH.
Figures 3.9 and 3.6C display a significant increase in the accumulation of GAPDH 
mRNA. We investigated the possibility that this increase may be due to an increase 
in the activity of a nuclear transcription factor named hypoxia inducible factor-1 
(HIF-1) which has been shown to become active in response to iron chelation as well 
as hypoxia (Wang and Semenza, 1993). To determine whether the iron chelators 
DFO and SIH modulate HIF-1 DNA binding in primary skin fibroblast cells (FEK-4), 
we assayed the nuclear extracts of cells pre-treated for 18 hours with either DFO or 
SIH using the bandshift technique (EMSA). HIF-1 DNA binding was measured using 
an end-radiolabelled W18 oligonucleotide (18 base pair), containing a HIF-1 DNA 
binding site derived from the erythropoetin gene (Wang and Semenza, 1995) as 
described in section 2.8. Supershift analysis using a HIF-1 a  specific antibody, 
confirmed that the complex contained HIF-1, while the iron saturated form of DFO 
and SIH (FO and Fe-SIH, respectively) confirmed that the increases in HIF-1 DNA 
binding were a result of the chelation properties of both DFO and SIH. The findings 
shown in figure 3.16 indicate that the iron chelator DFO caused a dose dependent 
increase in HIF-1 DNA binding and SIH induces HIF-1 DNA binding in a similar 
manner.
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F ig u re  3 .1 6 . T h e  e ffec t o f  D F O  and  S IH  o n  H IF -1  D N A  b in d in g . Nuclear extracts prepared from 
FEK-4 cells, (A), were pre-incubated with 2.5, 20, 50, 100 and 500pM DFO or 500pM iron saturated 
DFO (FO) for 18 hours or (B), 100 and 200[iM SIH. 500pM DFO was used as a reference comparison 
for the induction of HIF-1 DNA binding. Iron saturated Fe-SIH was added at a concentration of 
200pM. Supershift analysis using a HIF-1 a  specific antibody is shown by the bands labelled HIF-1 a  
Ab, the constitutive binding (described by Kvietikova et al 1995) is shown by the band labelled 
constitutive, and the non-specific binding is also displayed. (A), also displays the excess radiolabelled 
free probe. Figures are representative of n=4 experiments
A
DFO(pM) 0 2.5 20 50 100 500 500 500 500 0
Antibody — —  — —  —  —  + — + —
Excess probe —  — —  —  —  —  —  + +
FO (pM) 0 0 0 0 0 0 0 0 0  500
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BDFO OiM) 0 0 0 0 0 0 500 500 0 0
SIH ftiM) 0 0 200 200 100 100 0 0 0 0
Antibody — + — + — + — + — +
Fe-SIH (pM) 0 0 0 0 0 0 0 0 100 100





3.14 The modulation of HIF-1 promoter activity by DFO and SIH.
Figures 3.16A and B display an increase in the DNA binding of the transcription 
factor HIF-1 in response to the application of the iron chelators DFO and SIH to 
growing cells. Because this was an important observation, we assessed the effect that 
these chelators had on the HIF-1 promoter with which the transcription factor HIF-1 
interacts. This was performed using a luciferase reporter assay construct. The 
hypoxia responsive luciferase gene construct pGLTfERH contained a transferrin 
HRE-enhancer upstream of a heterologous simian virus 40 promoter and was kindly 
provided by Dr. Roland Wenger (Rolfs et al., 1997). This construct was transiently 
transfected into growing FEK-4 cells along with the p-galactosidase expression vector 
(pCMVpGal). By performing a co-transfection it allowed differences in transfection 
and growth to be corrected by dividing the luciferase value by the respective value 
obtained for p-galactosidase activity. Using this technique, we observe that DFO 
strongly increases reporter activity in a dose dependent manner (Table 3.5). Cobalt 
chloride (a known stimulator of HIF-1 activity) and the weaker iron chelator, SIH, 
also induced HIF-1 reporter activity but to a lesser extent than the strong iron 
chelator: DFO. When cells were pre-treated with ferric citrate or the iron saturated 
form of DFO, no significant (p<0.05) increase was observed in HEF-1 reporter activity 
(Table 3.5).
T a b le  3 .5 .  T h e  e f fe c t  o f  D F O  a n d  S IH  o n  H IF -1  p r o m o te r  a c t iv ity .  L u c ifera se  reporter constructs  
co n ta in in g  on e  c o p y  o f  the transferrin H R E , w ere  transien tly  tran sfected  in to  F E K -4  c e lls  5 hours prior  
to  the add ition  o f  D F O , F O , ferric citrate, F e-H B S er , SIH  or co b a lt  ch lorid e  for  41  hours. C ob alt 
ch loride  is  k n o w n  to  stron g ly  ind uce  H IF-1 a ctiv ity . T ab le  3 .3  sh o w s  the m ean s and  ±  S D  o f  three  
ind ep en dent exp erim en ts. D iffer e n c es  in  the tra n sfection  e f f ic ie n c y  and extract preparation w ere  
corrected  b y  n orm alisa tion  o f  the correspon d ing  P -g a la cto sid a se  a c tiv itie s . A  paired  t-test rev ea led  a
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s ig n ifica n t d ifferen ce  b e tw e en  contro l and treatm ent w ith  D F O , SIH  and cob a lt ch lorid e  (* ), (p < 0 .0 5  
lev e l).




50|uM DFO 28.66* 5.10
150(iM DFO 37.03* 4.03
150|oM FO 0.93 0.55
500|iM DFO 51.40* 12.89
lOOfiM ferric citrate 0.82 0.08
50|aM SIH 7.36* 1.99
50|aM cobalt chloride 29.41* 1.71
182
3.15 Alterations in iron homeostasis induced by the novel iron chelator HBSer.
We have shown previously that the iron chelators DFO and SIH increase the activity 
of the transcription factor HIF-1 (fig 3.16 and table 3.4) and consequently alter the 
expression of genes that contain a hypoxia responsive element (HRE) such as 
GAPDH (fig 3.9 and 3.6C). We therefore included a novel iron chelator (N-(2- 
hydroxybenzyl)-L-serine (HBSer)), with a lower affinity for iron, into our study to 
assess whether its different properties could alter the hypoxic response.
3.15.1 Alterations in IRP/1RE binding by the iron chelator HBSer
To demonstrate that HBSer could remove intracellular low molecular mass iron, an 
IRP/IRE bandshift assay (EMSA) was used to assay the cytosolic extracts of FEK-4 
skin fibroblast cells that had been pre-treated for 18 hours with a range of 
concentrations of HBSer. HBSer was used at a range of high concentrations (between 
500pM and 7.5mM) due to its poor cell penetration. Interaction of an 
oligonucleotide, containing the human IRP-1 specific motif, with the IRP-1 protein 
present in cytosolic extracts of chelator pre-treated cells was used to estimate the level 
of intracellular ‘free’ iron within cells. A basal level of IRP/IRE binding is 
represented by (control) and was determined from cells that had not been pre-treated 
with iron chelators. Figure 3.17 shows that after an 18 hour incubation with the iron 
chelator HBSer, IRP-1 binding increases in a dose-dependent manner.
F ig u r e  3 .1 7 . T h e  e f fe c t  o f  H B S e r  o n  in tr a c e llu la r  ir o n  h o m e o s ta s is .  IR P/IR E  b in d in g  w a s  
m easu red  u s in g  the c y to so lic  extracts from  F E K -4  sk in  fibrob last c e lls  and  a ra d io la b elled  IR E probe. 
C ells  w ere  pre-treated for 18 hours w ith  e ither 5 0 0 p M , Im M , 2 m M , 5 m M  or 7 .5 m M  H B S er  as w e ll  as 
5 0 0 p M  D F O  for com parison . 5 m M  o f  the iron  saturated H B S er  d id  n o t increase  IR P/IR E  b in d in g
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activity. The positions of the IRP/IRE complex are indicated on the figure. The displayed EMSA 




3.15.2 Measurement of intracellular ferritin levels in cells pre treated with 
HBSer
The data in section 3.15.1 show that HBSer increase IRP/IRE binding activity, an 
indication that HBSer has the potential to decrease intracellular iron. To support the 
evidence that HBSer chelates LMrFe, the abundance of the intracellular iron storage 
protein, ferritin, was measured. Ferritin is a target gene of the IRPs, which are in turn 
directly modulated by the presence, or absence of iron (see section 1.4.4.1). Growing 
FEK-4 skin fibroblast cells were pre-treated for 18 hours with HBSer. Cytosolic 
extracts were obtained as described in section 2.5.1 and the ferritin content of the 
chelator-treated cells was analysed using the Enzymun-Test® Ferritin kit (Roche, 
UK) as described in section 2.14. The binding of ferritin epitopes to anti-ferritin 
antibodies allowed a secondary bound chromagen (which absorbs light at 420nm) to 
be compared with a range of pre-prepared standards of known ferritin concentration. 
The resultant value for ferritin protein was normalised according to the total protein 
content of each sample and expressed as ng of ferritin per pg of total protein. Figure 
3.18 displays a value representing the ferritin content of cells pre-treated with HBSer 
and DFO (the value for which is also shown previously in figure 3.4). Figure 3.18 
displays a 42% and 66% decrease in intracellular ferritin when cells are pre-treated 
with HBSer and DFO, respectively.
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F ig u re  3 .1 8 . T h e e ffe c t o f  D F O  an d  H B S e r  o n  in tr a c e llu la r  fe rr it in  lev e ls . Growing FEK-4 cells 
were pre-treated for 18 hours with either lOOpM DFO or 5mM HBSer. Cytosolic extracts were 
analysed using a ferritin ELISA technique as described in section 2.14. The data shown is the mean of 
three independent experiments and displays the ± standard deviation. Statistical analysis was 
performed using a paired t-test. Significant differences (at the p< 0.05 level) compared to the untreated 
control are indicated by (*).
control DFO (100)
Iron chelator (100^M or 5mM)
HBSer (5)
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3.16 HBSer does not alter HIF-1 DNA binding activity
Conventional iron chelators such as DFO and SIH are shown to increase the DNA 
binding activity of the transcription factor HIF-1 (fig 3.16). To investigate whether 
the novel iron chelator HBSer could also induce this response a bandshift assay 
(EMSA) was employed. HBSer was dissolved in NaOH and neutralised using HC1 as 
described in 2.3.5. Nuclear extracts were obtained form normal growing FEK-4 cells 
that had been pre-treated with either DFO or HBSer. HIF-1 DNA binding was 
measured using an end-radiolabelled W18 oligonucleotide (18 base pair), containing a 
HIF-1 DNA binding site derived from the erythropoetin gene (Wang and Semenza, 
1995). Supershift analysis was performed using a HIF-1 a  specific antibody, which 
confirmed that the complex contained HIF-1. Figure 3.19 shows that HIF-1 DNA 
binding remains unchanged from the basal level of expression when cells are pre­
treated with a range of concentrations of HBSer. This is in contrast to DFO, which 
strongly induces HIF-1 DNA binding and is displayed as a positive control.
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F ig u r e  3 .1 9 . T h e  e ffe c t  o f  H B S e r  o n  H IF -1  D N A  b in d in g . FEK-4 cells were pre-treated for 18 
hours with 0.5 and 7.5mM HBSer, and 500}iM DFO. 500pM DFO was used as a reference 
comparison for the induction of HIF-1 DNA binding. Nuclear extracts were hybridised with a 
radiolabelled HIF-1 DNA probe as described in 2.8. Supershift analysis using a HIF-1 a  specific 
antibody is shown by the bands labelled HIF-1 a  Ab, the constitutive binding (described by Kvietikova 
et al 1995) is shown by the band labelled constitutive, and the non-specific binding is also displayed. 
The figure is highly representative of n=4 experiments.
DFO (pM) 0 0 0 0 500 500 500
HBSer (mM) 0 0.5 7.5 7.5 0 0 0
Antibody —  — — + — + ---------
Excess probe — — — — — — +





3.17 HBSer does not alter HIF-1 promoter activity
Using a HIF-1 bandshift assay (EMSA) (figure 3.19) it was shown that the novel iron 
chelator HBSer does not increase HIF-1 DNA binding. To further investigate this 
finding a reporter gene construct was used (pGLTfERH) that contains a single HRE 
derived from the transferrin 5’ enhancer. This construct was transiently transfected 
into growing FEK-4 cells along with the P-galactosidase expression vector 
(pCMVpGal). By performing a co-transfection with a reference plasmid differences 
in transfection and growth can be corrected by normalising any changes in luciferase 
activity in accordance with the respective p-galactosidase activity. Cellular extracts 
from chelator pre-treated cells were assayed using the luciferase assay system 
according to the manufacturers instructions (Promega) as described in section 2.9. 
Using the hypoxia responsive construct we observe that HBSer and iron saturated 
HBSer (Fe-HBSer) do not significantly (p<0.05) alter the basal level of reporter 
activity (table 3.6) whereas cobalt chloride (a known stimulator of HIF-1 activity) 
increased HIF-1 reporter activity reporter activity. To allow the comparison of 
HBSer-induced HIF-1 activity with that induced by cobalt chloride, DFO and FO, 
table 3.6 also displays the data previously displayed in table 3.5. When DFO is added 
in combination with HBSer (500pM DFO + 7.5mM HBSer) a significant (p<0.05) 
increase in HIF-1 activity is still observed.
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T a b le  3 .6 .  L u c ife r a se  r e p o r te r  a c t iv ity  in  r e s p o n s e  to  ir o n  c h e la to r s . L uciferase  reporter constructs  
co n ta in in g  on e  c o p y  o f  the transferrin H R E , w ere  transien tly  transfected  in to  F E K -4  c e lls  5 hours prior  
to  the add ition  o f  D F O , F O , H B S er, F e-H B S er  or cob a lt ch lo rid e  for  41  hours. C ob a lt ch loride  is  
k n o w n  to  stro n g ly  ind uce  H IF-1 activ ity . T here is  n o  inh ib itory  e f fe c t  o n  H IF-1 a c tiv ity  b y  H B S er  i f  it 
is  add ed  in  com b in a tio n  w ith  D F O . T h e  tab le  d isp la y s  the m ea n  (±  S D ) o f  three ind ep en dent 
experim en ts. D iffer e n c es  in  d ie  tra n sfectio n  e f f ic ie n c y  and extract preparation w ere  corrected  b y  
n o rm alisa tion  o f  the correspon d ing  P -g a la c to sid a se  a c tiv ities . A  paired  t-test rev ea led  a sig n ifica n t  
d ifferen ce  b e tw e en  an  untreated  con tro l and treatm ent w ith  D F O  and co b a lt ch lorid e  (* ), (p < 0 .0 5  
lev e l).




150}iM DFO 37.03* 4.03
150}iMFO 0.93 0.55
500nM DFO + 5mM HBSer 63.78* 13.88
2.5mM HBSer 0.29 0.04
5mM HBSer 0.20 0.12
5mM Fe-HBSer 0.50 0.38
50(iM cobalt chloride 29.41* 1.71
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3.18 The effect of HBSer on the viability of growing FEK-4 cells
To ensure that the novel iron chelator HBSer was not toxic to cells, growing FEK-4 
cells were incubated for 18 hours with either 7.5mM HBSer or 7.5mM of the iron- 
saturated form of HBSer (Fe-HBSer). Adding iron citrate to HBSer in a 2:1 molar 
ratio produced Fe-HBSer. Populations of cells were then detached from the plate in 
an appropriate buffer and analysed using a FACS vantage machine (as described in 
2.13). The data from three independent experiments were analysed. Table 3.7 
displays the percentage of live, apoptotic and necrotic cells. ± standard deviation is 
shown on the right of each column. A paired t-test did not reveal any significant 
differences between the untreated control cells and cells pre-treated with HBSer or 
iron saturated HBSer.
T a b le  3 .7 .  C h a n g e s  in  c e ll v ia b ility  r e s u lt in g  fr o m  p r e - tr e a t in g  c e lls  w ith  H B S e r . G row in g  F E K -4  
sk in  fib rob last c e lls  w ere  pre-treated  for 18 hours w ith  7 .5 m M  o f  e ith er H B S er  or the iron  saturated  
form  o f  H B S er  (F e-H B S er). A fter  18 hours, c e lls  w ere  harvested  and  in d iv id u a lly  a n a ly sed  u s in g  a 
F A C S  v a n tage  m ach ine. T h e figure d isp la y s the m ea n  o f  3 ind ep en d en t experim en ts. A  paired  t-test 
w a s u sed  to  com pare d ifferen ces b e tw e en  the untreated  con tro l and treatm ents w ith  H B S er  and F e-  
H B S er.
Live cells ±SD Apoptotic ±SD Necrotic ±SD
(% total cells cells





87.1 5.27 1.24 0.488 11.7 5.76
7.5mM
HBSer 91.4 1.46 0.84 0.438 7.83 1.90
7.5mM
Fe-HBSer 89.8 2.23 0.945 0.445 9.26 2.66
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3.19 Absorption spectrum of the iron chelator HBSer
The aim of this experiment was to determine whether HBSer could absorb radiation in 
the UVA (320-380nm) region and absorb UVA that is destined for the cells. 
Spectrophotometric analysis was performed using a Kontron (Uvikon 720LC) 
spectrophotometer programmed to perform a wavelength scan from 290-425nm. 
HBSer was diluted in NaOH and neutralised with HC1 as described in section 2.3.5. 
The absorbance of HBSer was measured against a control blank that contained NaOH 
and HC1 in the same proportions used to solubilise HBSer. Figure 3.20 displays the 
absorption spectrum of the iron chelator HBSer and shows that HBSer does not 
absorb any radiation in the UVA region used to irradiate cells.
Figure 3.20. The absorption spectrum of the iron chelator HBSer. HBSer was made as a stock 
solution and diluted to a final concentration of 7.5mM for analysis. The absorbance was measured as 
described in section 2.12. The figure displays the relative absorbance on the Y-axis, and the 
wavelength on the X-axis. The UVA region of the electromagnetic spectrum is shown in the area 































3.20 The modulation of GAPDH and P-actin mRNA by the iron chelators 
DFO, SIH and HBSer
It has been shown that the iron chelators DFO and SIH (fig 3.6C and 3.9) modulate 
the mRNA expression of GAPDH, a gene that is usually constitutively expressed in 
cells. It is important to demonstrate that the constitutively expressed housekeeping 
gene of choice (p-actin) is not modulated by iron chelation in FEK-4 skin fibroblast 
cells. Growing FEK-4 skin fibroblast cells were pre-treated for 18 hours with DFO, 
SIH or HBSer. Cells were then lysed and the total RNA extracted. The quantity of 
RNA was accurately calculated and a defined amount of each sample was introduced 
into an agarose gel that contained ethidium bromide. The ethidium bromide allowed 
the RNA to be visualised under a UV transilluminator, and subsequent quantification 
of this luminesence was performed using a Syngene darkroom (SYDR) (Synoptics 
Ltd). After the RNA had been quantified using image quant software (Synoptics Ltd), 
the RNA was transferred to a nylon membrane and hybridised with a P-actin cDNA 
probe, followed by a GAPDH cDNA probe, in order to allow quantification and 
comparison of the respective RNA. Quantification of the mRNA for p-actin and 
GAPDH was performed using a Phosphorimager (Molecular Dynamics, Sunnyvale, 
CA.). Figure 3.21 and table 3.8 show that only GAPDH mRNA is modulated by the 
iron chelators DFO. Pre-treatment of cells with 100pM DFO results in a 2.47 fold 
increase in GAPDH mRNA.
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Figure 3.21. The modulation of GAPDH and P-actin mRNA by DFO, SIH and HBSer. Normal, 
growing FEK-4 cells were pre-treated for 18 hours with either lOOpM DFO, lOOpM SIH or 7.5mM 
HBSer. Total RNA was visualised using ethidium bromide in an agarose gel, and the mRNA for 
GAPDH and P-actin was measured using the respective radiolabelled cDNA probes. The figure shows 
both the 18s and 28s RNA for each sample visualised under a UV transilluminator, and also the 
GAPDH and P-actin mRNA visualised using a Phosphorimager. The displayed data is highly 






T a b le  3 .8 .  T h e  m o d u la t io n  o f  G A P D H  a n d  P -a c tin  m R N A  b y  D F O , S IH  a n d  H B S e r . F E K -4  c e lls  
w ere  pre-treated  for 18 hours w ith  e ither lOOpM  D F O , lOOpM  SIH  or 7 .5 m M  H B S er. T o ta l R N A  w a s  
v isu a lise d  u s in g  eth id iu m  brom id e in  an agarose g e l,  and  the m R N A  for G A P D H  and P -actin  w a s  
m easu red  u s in g  the resp ectiv e  ra d io la b elled  c D N A  prob es. T h e  tab le  is  co m p rised  o f  the m ea n  data  
from  tw o  in d ep en d en t experim en ts and d isp la y s the ex p ress io n  o f  18s R N A , G A P D H  and P -actin  








18s RNA 1 0.95 0.86 1.15 0.90
p-actin 1 0.82 0.78 1.05 0.93
GAPDH 1 2.47 2.11 0.82 0.79
195
3.21 Modulation of basal and UVA-induced gene expression by HBSer
To assess whether the iron chelator HBSer could modulate the mRNA expression of 
the genes for GAPDH, HO-1 and COX-2, in the presence or absence of UVA 
radiation, growing FEK-4 cells on 10cm plates were pre-treated for 18 hours with a 
range of concentrations of HBSer. Growing FEK-4 cells were pre-treated for 18 
hours with either DFO or HBSer and either lysed for mRNA analysis or irradiated 
with a moderate dose (250kJ/m2) of UVA radiation. Cells subjected to UVA 
radiation were incubated for a further 4 hours prior to lysis and mRNA extraction. 
Total RNA was separated on an agarose gel and transferred to a nylon membrane 
which was then hybridised with a COX-2 cDNA probe, and in turn a HO-1, GAPDH 
and p-actin cDNA probe. mRNA levels were quantified using a Phosphorimager and 
the data obtained for p-actin mRNA was used to normalise all data. Figure 3.22A 
shows that UVA induces a significant (p<0.05) 23 fold up-regulation of HO-1 mRNA 
expression which is not significantly altered by the addition of either DFO or HBSer. 
In contrast figure 3.22B shows that COX-2 mRNA is strongly up-regulated (10 fold) 
by the iron chelator DFO, but not by HBSer. When cells were pre-treated with HBSer 
no (p<0.05) significant alterations were observed from the basal expression of COX-2 
mRNA which is in complete contrast to the effect observed in response to DFO. The 
UVA control, unexpectedly, shows a very low up-regulation of COX-2 mRNA. The 
expression of GAPDH mRNA shown in figure 3.22C indicates that GAPDH cannot 
be modulated by the novel iron chelator HBSer, or UVA radiation, but as shown 
previously (fig 3.6C and 3.9) is significantly (p<0.05) up-regulated by the addition of 
DFO.
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Figure 3.22. The modulation of HO-1, COX-1 and GAPDH mRNA by the iron chelator HBSer.
Growing FEK-4 cells on 10cm plates were pre-treated for 18 hours with either 5mM, 7.5mM HBSer or 
500pM DFO. After 18 hours selected plates (of cells) were further subjected to a moderate dose 
(250kJ/m2) of UVA radiation and incubated for a further 4 hours. Total cellular mRNA was extracted 
and analysed with a cDNA probe for (A) HO-1 mRNA, (B) COX-2 mRNA and (C) GAPDH mRNA. 
All data was normalised in accordance with the expression of P-actin mRNA. The data displayed are 
the mean of 3 independent observations and show the ± standard deviation. Significant differences 
between treatments and an non-irradiated control are denoted by (*), and also differences between 
UVA irradiated treatments and a UVA irradiated control are denoted by (V). Significant differences at 
the level p<0.05 were assessed using a paired t-test. Note the increase in basal gene expression (y-axis) 
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197
Fold increase in GAPDH mRNA 
expression (p-actin normalised)
O NJ W
o b i - t o i t o a i o i b i - u
VOoo
Fold increase in COX-2 mRNA 
expression (p-actin normalised)
4. Discussion
4.1 An iron chelator that does not induce HIF-1 activity.
Iron chelators used for clinical and experimental iron chelation, have been shown to 
activate HIF-1 [Wang and Semenza, 1993, Wanner et al., 2000 & Dalle et al., 2000]. 
This occurs as an unwanted side effect of their strong affinity for intracellular low 
molecular mass iron. Confirming this, we have shown that DFO and SIH induce HIF- 
1 transactivation in FEK-4 skin fibroblast cells. Here, for the first time, we have 
shown that it is possible to remove intracellular low molecular mass iron by using a 
novel exogenous iron chelator that does not induce HIF-1.
The HIF response is critical to the induction of target genes that enable organisms to 
adapt to low oxygen concentrations. These genes include inducible nitric oxide 
synthase, glyceraldehyde 3-phosphate dehydrogenase, caeruloplasmin (an acute phase 
protein) and the transferrin receptor [Bianchi et al., 1999, Ren et al., 2000, Gleade and 
Ratcliffe, 1998 & Zhu and Bunn, 1999]. However, the induction by iron chelators of 
genes associated with hypoxia complicates the interpretation of cellular processes that 
arise solely from the chelation of intracellular iron. Another important consideration 
when using strong iron chelators that increase HIF-1 activity, is that iron chelator- 
induced HIF-1 DNA binding and activity has been associated with the protection of 
cells against certain forms of oxidative-stress [Siren et al., 2000, Digicaylioglu et al., 
2001 & Zaman et al., 1999]. Consequently, any protection against oxidative damage 
that is observed following the addition of iron chelators may be due either to the 
induction of HIF-1 responsive genes or to the chelation of reactive forms of iron.
It has recently been concluded that hypoxic regulation of HIF-la occurs at the post- 
translational level. The mechanism for the rapid degradation of HIF-la appears to
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proceed via a ubiquitin-proteosome pathway as discussed in section 1.5.3.1, and 
shown in figure 4.1. The Von-Hippel-Lindau prolyl hydroxylase (pVHL) enzyme 
fulfils a critical function in HIF-la degradation and has an absolute requirement for 
molecular oxygen as co-substrate and weakly binds ferrous iron for use as a co-factor. 
Accordingly, when one such enzyme was prevented from binding iron, the activity of 
the recombinant enzyme was completely inhibited both in vivo and in vitro. This 
evidence supports the proposal that iron chelators remove the ferrous iron atom that is 
loosely bound at the centre of the 2-oxyglutarate dependent dioxygenases (discussed 
later) (figure 4.1) [Epstein et al., 2001]. A cobalt salt also inhibited the activity and 
this possibly reflects displacement of iron within the protein [Epstein et al., 2001]. .
In this study, we have characterised a novel iron chelator (HBSer) that effectively 
binds intracellular low molecular mass iron, but does not induce HIF-1 transactivation 
and subsequent glyceraldehyde 3-phosphate dehydrogenase transcription. Our data 
show that the iron chelator, HBSer, increases IRP/IRE binding in a dose dependent 
manner, thereby indicating a depletion of intracellular iron. The function of HBSer as 
an intracellular iron chelator is further indicated by our observation that HBSer, as 
well as DFO and SIH, significantly decrease the level of intracellular ferritin in FEK- 
4 skin fibroblast cells. Low molecular mass iron exists as both ferrous and ferric ions 
within cells, in a state of equilibrium that is dependent on reductants and oxidants 
contained within the cells. Irrespectively of the ability of certain iron chelators to 
strongly bind ferrous iron, the chelation and therefore safe sequestration of ferric iron 
within cells means that the aforementioned equilibrium is disturbed in favour of the 
oxidation of ferrous iron to form ferric ions which may also become available to an 
iron chelator. In effect, the level of both ferric and ferrous iron is depleted and since 
the IRPs only detect ferrous iron, this may in part explain how we observe an increase
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in IRP/IRE binding and a subsequent decrease in ferritin. Taken together, our data 
demonstrate that it is possible to use an exogenous iron chelator to modulate genes 
associated with iron homeostasis and dissociate this from effects associated with 
hypoxia. Although most iron chelators have multiple biological properties in addition 
to their ability to chelate iron [Halliwell, 1989], we believe that the most likely 
explanation as to why HBSer (used at non-toxic concentrations) does not activate 
HIF-1 DNA binding and promoter activity in the same way as DFO and SIH is due to 
its lower affinity for iron. HBSer is therefore similar to endogenous iron-binding 
proteins in that it can acquire low molecular mass iron, but its affinity for iron is not 
high enough to remove the iron associated with proteins such as the pVHL enzyme 
(which controls the hypoxic response). This is an essential property of proteins with a 
central role in cellular iron homeostasis.
We propose that chelators of this type may be particularly valuable for assessing 
changes in gene expression or other biological effects that arise solely from iron 
chelation. They have the potential to deplete the immediate and transient release of 
LMrFe and protect cells from iron-mediated oxidative stress without the induction of 
several genes associated with the hypoxic response.
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Figure 4.1. A simplified diagrammatic representation showing two ways in which degradation of 
the HIF-1 a  protein is prevented. pVHL represents the prolyl hydroxylase enzyme. The figure 
has been adapted from a presentation by P. J. Ratcliffe, 2002.
An iron chelator (such as 
DFO or SIH) is shown 
removing ferrous iron 





oxygen (shown here 
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4.2 An iron chelator that does not increase COX-2 mRNA and protein
accumulation
It has been proposed that iron chelation increases COX-2 mRNA, protein and PGE2 
activity by depleting cellular iron [Tanji et al., 2000]. However, the study by Tanji et 
al. demonstrated an increase in COX-2 activity when using a conventional iron 
chelator that is known to increase HIF-1 activity. Before Tanji et al published their 
findings we were aware that non-toxic doses of strong iron chelators such as DFO and 
SIH were capable of increasing COX-2 mRNA and protein accumulation. We were 
also aware that such chelators had the undesirable effect of leading to the activation of 
the HIF-1 response. In contrast to the findings of Tanji et al. we have shown that 
depleting intracellular iron using a non-toxic dose of the novel iron chelator (HBSer), 
which does not increase HIF-1 activity, fails to significantly increase the 
accumulation of COX-2 mRNA.
An explanation for this observation may be that conventional iron chelators such as 
DFO (used at concentrations of 2.5 to 500pM) and SIH strongly induce HIF-1 
transactivation in FEK-4 skin fibroblast cells. Such a response induces target genes 
that allow an organism to protect itself from the harmful effects of low oxygen 
concentrations (hypoxia). An array of genes, containing responsive elements, are 
induced by the HIF response, including the genes for inducible nitric oxide synthase, 
caeruloplasmin (an acute phase protein), the transferrin receptor, phosphoglycerate 
kinase-1 and haemoxygenase-1 [Bianchi et al., 1999, Ren et al., 2000, Gleade and 
Ratcliffe, 1998 & Zhu and Bunn, 1999]. However, the induction of genes that are 
directly modulated by hypoxia may have pronounced effects on cellular processes, 
which, in turn, may directly or indirectly alter the subsequent expression of genes that 
do not contain a hypoxia responsive element, such as COX-2.
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As previously mentioned, the enzyme, inducible nitric oxide synthase (iNOS), 
contains in its promoter region a hypoxia responsive element [Meilillo et al, 1995]. 
When the transcription factor HIF-1 is present and bound to this element, it mediates 
an increase in the production of this enzyme, which enables the synthesis of nitric 
oxide (*NO) from its substrate L-arginine. In support of this, it was shown that the 
iron chelator DFO could increase the transcriptional activity of inducible nitric oxide 
synthase (iNOS) [Dlaska and Weiss, 1999]. *NO is a paramagnetic molecule and a 
free radical that can readily diffuse between and within cells. Much research has 
concentrated on NO* because of its multiple effects in different biological systems 
such as the nervous system and vascular system. *NO readily binds to certain 
transition metals, and many of its physiological effects, including its vasodilatory 
effect, are a direct result of its initial binding to ferrous haem groups of the enzyme 
guanalate cyclase [as reviewed in Halliwell and Gutteridge, 1999]. The production of 
*NO can be induced by HIF-1 transactivation and furthermore the production of *NO 
in rheumatoid synovial cells is known to induce COX-2 expression [Honda et al.,
2000]. It was, therefore, important to demonstrate that the increase in COX-2 mRNA 
that is observed using skin fibroblast cells in response to strong iron chelators (such as 
DFO and SIH) was not a consequence of increased *NO production caused by an 
increase in HIF-1 activity. This was subsequently demonstrated using two inhibitors 
of nitric oxide activity, namely N-(3-(aminomethyl)benzyl)acetamidine)also known 
as 1400W which is a slow, tight-binding specific inhibitor of human inducible nitric 
oxide synthase (Garvey et al., 1996), and N-methyl-L-arginine (NMMA) a well 
established non-specific inhibitor of nitric oxide synthases which, when added in 
excess compared to the enzymes normal substrate L-arginine acts as a substrate 
analogue. When both inhibitors were added to cells prior to the addition of the iron
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chelator DFO they failed to prevent the up-regulation of COX-2 mRNA suggesting 
that *NO does not have a role this response.
An alternative explanation for the up-regulation of COX-2 by the iron chelator DFO 
may, in the future, be derived from work performed on the hypoxic induction of 
COX-2. Hypoxia has long been known to act as a potent stimulus for the induction of 
the enzyme COX-2 and this induction is believed to occur via the modulation of 
nuclear factor-icB (NF-kB) p65 transcription factor in human vascular endothelial 
cells [Schmedtje et al., 1996]. Further research has recently shown that the 
transcription factor, specificity protein-1 (Sp-1), in association with NF-kB is 
responsible for the increased expression of COX-2 in hypoxic vascular endothelium 
[Xu et al., 2000]. In addition, the observation that COX-2 expression is increased in 
comeal epithelial cells in response to hypoxia [Bonazzi et al., 2000] indicates that this 
is not a response that is specific to vascular endothelial cells.
Our studies with COX-2 further strengthen our postulation that chelators such as 
HBSer, which do not increase HIF-1 activity, may be particularly valuable for 
assessing changes in gene expression that arise solely from iron chelation, since they 
have the potential to deplete LMrFe without the induction of genes such as GAPDH 
and COX-2 associated with the hypoxic response.
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4.3 A UVA induced immediate and transient release of LMrFe has no effect on 
gene expression
Immediately after a moderate dose (250kJ/m2) of UVA (320-380nm) radiation, 
human skin cells (FEK-4) have been shown to undergo an immediate and transient 
release of low molecular mass iron (LMrFe) [Pourzand et al., 1999] and this iron may 
act as a pro-oxidant that contributes to the cellular damage caused by UVA radiation 
[Brenneisen et al., 1998, Pourzand et al., 1999]. In an attempt to decrease this 
transient release of LMrFe, normal growing FEK-4 cells were treated with the iron 
chelators desferrioxamine (DFO) and salicylaldehyde isonicotinoyl hydrazone (SIH). 
However, although the intracellular iron pool decreased, an increase in the DNA 
binding activity of the hypoxia inducible factor-1 (HIF-1) was observed. The 
induction of HIF-1 activates the expression of several genes associated with hypoxia 
and iron homeostasis and obscures the interpretation of any data that attempts to show 
gene modulation by the experimental sequestration of LMrFe. To avoid such 
complications our study incorporated the use of the novel iron chelator (HBSer) that 
does not increase HIF-1 activity nor protect cells by absorbing UVA (320-380nm) 
radiation. HBSer, therefore, allowed us to observe changes in gene expression that 
arose solely from the sequestration of LMrFe. Using this approach, we have shown 
that the addition of the iron chelator HBSer to FEK-4 skin fibroblast cells does not 
significantly alter the increased expression of HO-1 or COX- mRNA that is induced 
by UVA radiation.
The increased levels of LMrFe in FEK-4 cells were measured before and after a 
moderate dose (250kJ/m2) of UVA radiation. Zhong, has previously shown using the 
calcein assay for intracellular LMrFe [Breuer et al., 1995, Cabantchik et al., 1996] 
that the level of LMrFe in FEK-4 skin fibroblast cells can rise significantly by 2.14 ±
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0.51 fold after UVA (250kJ/m2) irradiation to a value of 2.46pM ± 0.67 [Zhong, 
2002]. Iron in the low molecular mass chelatable form (LMrFe) has been implicated 
as a species that may directly or indirectly alter the expression of various genes 
(discussed in detail in section 1.4.4.2). To assess whether LMrFe could mimic the 
UVA-induced expression of HO-1 and/or COX-2, cells were loaded with lOpM 
haemin and 100pM ferric citrate. The addition of iron citrate at a concentration in 
excess of 40 times greater than that found in FEK-4 cells after irradiation only caused 
a maximal 2.1 fold increase in HO-1 mRNA accumulation and a 1.35 fold increase in 
COX-2 mRNA accumulation. Even if the iron binding capacity of the cell culture 
media (42 pM) is taken into account, there is still 68pM of iron available for cellular 
uptake [3.3.1]. Haemin, however, is a substrate for the haemoxygenase enzymes. 
Heamoxygenase-1 (HO-1) contains a promoter element termed the haem responsive 
element (HRE) that increases transcription of the HO-1 gene in the presence of haem. 
When present the enzyme catalyses the degradation of haem to yield, among other 
products, LMrFe and has been implicated in a process that results in free iron export 
from cells [Ferris et al., 1999]. As expected, we observed a strong 11-fold increase in 
HO-1 mRNA expression but no significant alteration in the expression of COX-2 
mRNA.
Taken together our findings show that the immediate and transient release of LMrFe 
that occurs following UVA irradiation does not appear to directly or indirectly affect 
the expression of either HO-1 or COX-2 (figure 4.2). To date, there has been no 
evidence to support the involvement of LMrFe in the UVA-induced modulation of 
HO-1 and COX-2, a finding that is consistent with several previous studies which 
have shown that species other than iron have a major role in the modulation of genes 
by UVA. For example, work from this group has demonstrated that singlet oxygen
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and not the hydroxyl radical is responsible for the induction of the haemoxygenase 
gene by UVA/near-visible light [Keyse and Tyrrell, 1990; Basu-Modak and Tyrrell, 
1993]. A further study by Basu-Modak et al. demonstrated a role for lipid metabolites 
in the induction of haemoxygenase-1 by UVA radiation [Basu-Modak et al., 1996]. 
Later, Ryter and Tyrrell proposed that singlet molecular oxygen ( ^ 2 ) (along with 
other ROS) generated during photochemical processes, such as UVA radiation 
exposure, is a general effector of UVA-induced eukaryotic gene expression (figure 
4.2) [Ryter and Tyrrell, 1998].
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F ig u r e  4 .2 . A  d ia g r a m m a tic  r e p r e se n ta t io n  o f  U V A  g e n e r a te d  r e a c t iv e  o x y g e n  sp e c ie s  (R O S ) a n d  
lo w  m o le c u la r  m a ss  ir o n  (L M r F e )  r e le a se  a n d  th e ir  in v o lv e m e n t  in  th e  m o d u la t io n  o f  H O -1  a n d
C O X -2 .
UVA
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T h e  f ig u r e  sh o w s  th a t  L M r F e  d o e s  n o t  a p p e a r  to  a f fe c t  th e  U V A  m e d ia te d  e x p r e s s io n  o f  H O -1
a n d  C O X -2  e ith e r  d ir e c t ly  o r  in d ir e c t ly  b y  th e  g e n e r a t io n  o f  R O S .
4.3.1 Cellular uptake of chelators and iron complexes
4.3.1.1 The cellular uptake of iron chelators
Most biochemists are aware that DFO does not readily diffuse into cells because of its 
large hydrophilic structure. However, Lloyd et al. (1991), confirmed that DFO does 
not enter cells by passive diffusion, but enters by pinocytosis. Once internalised, 
DFO will remain in the lysosomes [Lloyd et al., 1991] where it has the potential to 
accumulate to high concentrations and complex with intralysosomal iron [Cable and 
Lloyd, 1999]. Because DFO is strongly hydrophilic, and therefore dissolved in water 
when added to cells, it is taken-up by the process responsible for the uptake of
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droplets of extracellular fluid and proteins attached to the cell membrane, namely 
pinocytosis.













The iron chelator HBSer, like DFO, is a hydrophilic iron-chelating molecule that 
shows similar incorporation kinetics to those observed when pre-treating cells with 
DFO. It is reasonable to speculate that because HBSer has a large amino acid-based, 
hydrophilic structure, it is also likely to enter cells in a similar way to DFO.
The iron chelator SIH however is a lipophilic molecule that enters cells very rapidly. 
In fact, when SIH is used in the Calcein assay (for intracellular LMrFe [Breuer et al., 
1995, Cabantchik et al., 1996]) it enters cells immediately after addition to the cell 
medium. This occurs because small-uncharged molecules such as SIH can readily 
pass through the phospholipid bilayers that comprise cell membranes.
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4.3.1.2 The cellular uptake of iron
There are several factors that must be considered when applying iron to growing cells. 
One such consideration is the redox state of the iron, which determines how the iron 
is transported into the cell. Ferric iron may only be taken into the cell when bound to 
transferrin via the transferrin receptor. However, FEK-4 skin fibroblast cells contain 
very few transferrin receptors and this is a very inefficient way to deliver iron to these 
cells [Pourzand et al., 2000]. In contrast, ferrous iron in solution at a stabilising pH 
value may be rapidly absorbed into cells in a transferrin independent manor via 
divalent metal transporting proteins (present in cell membranes) discussed in detail in 
section 1.4.1.1.
Iron was applied to growing FEK-4 skin fibroblasts in two main forms throughout this 
study, namely haemin and ferric citrate, and limitations of these two approaches are 
discussed below.
Ferric citrate:
1. When ferric citrate complexes are prepared from ferric chloride and sodium 
citrate (as described in section 2.3.2) the pH values of the solution become 
acid. If the pH is not immediately adjusted to a neutral or alkaline pH value, 
an electron transfer takes place between the citrate and the ferric salt to 
produce ferrous ions. The electron transfer starts to take place soon after the 
ferric citrate is prepared in solution [Gutteridge, 1991]. When such a solution 
is used to treat FEK-4 cells the formation of ferrous ions is advantageous as 
these ions may be transported into FEK-4 cells using a transferrin-independent 
mechanism.
2. The practice of using citrate as a ‘chelate’ ligand for ferric ions may 
complicate studies because of the polynuclear behaviour of this chelate. At a
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citrate to iron ratio of 1:1 ferric citrate forms polymers, and at ratios above 
20:1 polymerisation is suppressed by the formation of ferric dicitrate [Bates et 
al., 1967]. Such polymers are relatively high molecular weight complexes, 
which are incapable of transferring ferric iron to the metal binding sites of 
transferrin.
The ability of ferric citrate to form ferrous iron may be pivotal in allowing growing 
FEK-4 cells to uptake iron using transferrin-independent mechanisms. However, the 
formation of relatively high molecular weight complexes and their inability to enter 
cells could explain why high concentrations of ferric citrate are less effective than low 
concentrations of haemin at increasing intracellular iron.
Haemin
1. The level of intracellular haem may be increased by the addition of haemin or 
the inhibition of globin synthesis [Ponka and Neuwirt 1969]. Although the 
precise mechanism for haemin uptake is not clear, it is known that the 
movement of haemin into cells is rapid and does not require serum proteins 
[Sinclair and Granick, 1976]. The uptake of haemin is markedly augmented 
by delivering the haemin in a solution of dimethyl sulphoxide (DMSO) [Ebert 
et al., 1983] as described in section 2.3.1. Internalised haem is then 
transported to the microsomal haemoxygenase degradation site to yield 
equimolar amounts of LMrFe, bilirubin and carbon monoxide. Using such an 
approach we have elevated the level of intracellular LMrFe by the addition of 
low concentrations of haemin to growing FEK-4 cells.
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4.4 The expression of COX-2 in response to cobalt chloride
Cobalt chloride is known to mimic hypoxia by increasing the activity of the 
transcription factor HIF-1 [Bunn and Poyton, 1996]. We have shown that in FEK-4 
skin fibroblast cells the iron chelators DFO and SIH (which mimic hypoxia in a 
similar way) increase mRNA accumulation of the enzyme COX-2. In contrast, a 
cobalt chloride-induced state of hypoxia did not elicit an increase in COX-2 mRNA 
accumulation.
The ultimate determinant of HIF-1 activity is known to be a prolylhydroxylase 
enzyme (pVHL), which has a pivotal role in the degradation of the HIF-1 a  protein 
under conditions of normoxia. To fulfil its function, of degrading HIF-1 a, pVHL has 
an absolute requirement for molecular oxygen and a co-factor requirement for ferrous 
ions. Accordingly, in the absence of either oxygen or iron, the in vitro activity of 
pVHL is abrogated [Epstein et al., 2001]. This essential requirement for iron explains 
why iron chelators such as DFO and SIH are capable of increasing HIF-1 activity (fig 
4.1). Furthermore, the addition of excess cobaltous ions to cells has been shown to 
increase HIF-1 activity by displacing the ferrous ions associated with the HIF- 
regulatory enzyme (pVHL) [Epstein et al., 2001]. Based on evidence published in 
several studies showing an increase in COX-2 expression in response to hypoxia 
[Schmedtje et al., 1996, Shan et al., 1998 & Chiarugi et al., 1999] and the use of 
cobalt chloride to mimic hypoxia and increase COX-2 mRNA [Navarra et al., 2001 & 
Lui et.al., 1999], we attempted to demonstrate a similar effect in FEK-4 cells. 
However, although the addition of cobalt chloride increased HIF-1 activity and 
subsequent HO-1 and GAPDH mRNA expression, we did not observe a significant 
increase in COX-2 mRNA expression, which demonstrates that FEK-4 skin fibroblast
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cells may be classified alongside several other cell types in which the addition of 
cobalt chloride does not increase the expression of COX-2.
The up-regulation of GAPDH and HO-1 mRNA by cobalt chloride occurs through 
increased HIF-1 activity. Both HO-1 and GAPDH contain hypoxia responsive 
elements in their promoter region, allowing them to be transcribed in response to 
hypoxia. However, although the up-regulation of HO-1 in response to cobaltous ions 
was dramatic, no such response was observed when cells were treated with DFO. 
This occurs because the hypoxic (HIF-1 dependent) induction of HO-1 has an 
absolute requirement for LMrFe in both vascular endothelial cells and human dermal 
fibroblast cells [Ryter et al., 2000, Panchenko et al., 2000].
We therefore hypothesised that the up-regulation of COX-2 by cobalt chloride but not 
by iron chelation occurs only in specific types of cells. This postulate is based on 
evidence provided by Lui et al. In their study using three different prostate cancer 
cells lines; LNCaP, PC-3 and PC3ML, they investigated the up-regulation of vascular 
endothelial growth factor (VEGF) by cobalt chloride-stimulated hypoxia, and the role 
of COX-2 [Lui et.al., 1999]. COX-2 mRNA expression could not be induced by 
cobalt chloride in LNCaP cells, but was strongly induced in PC3ML cells. The 
expression of the VEGF gene, modulated under the direct control of the HIF-1 
transcription factor, was increased in all three of the cell lines. In this case, 
comparisons may be made between their finding and our study showing that a HIF-1 
dependent increase in GAPDH and HO-1 occurs, but that no increase in COX-2 
expression is observed. The postulate that the modulation of COX-2 activity is cell 
specific is supported by several other studies [Haider et al., 2002, Navarra et al.,
2001] that display a differential modulation of COX-2 in response to cobalt chloride. 
In a study by Haider et al., they demonstrated that COX-2 activity could be decreased
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by the addition of cobalt chloride to micro vessel endothelial cells [Haider et al.,
2002], but in contrast to the study by Haider et al., Navarra et al., demonstrated an 
increase in COX-2 activity in human trophoblast cells [Navarra et al., 2001] 
suggesting that the cobalt chloride induced expression of COX-2 is wholly dependent 
on the type of cell.
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4.5 p-actin is an appropriate housekeeping gene for Northern blot analysis of 
iron chelator treated cells
A ‘housekeeping’ gene is one that is constitutively expressed in vivo. This property is 
exploited in studies of gene regulation because the amount of mRNA they produce 
remains constant and can therefore be utilised as an internal reference standard for 
semi-quantative studies of inducible genes. About 30,000 housekeeping genes are 
known in mammals, and these have been identified by the presence of CG-rich 
islands that are indicative of these types of genes [Alberts et al., 1989]. GAPDH and 
18s rRNA are examples that are widely used for this purpose. However, for the 
purpose of this study, P-actin was a preferred housekeeping gene in experiments 
requiring the use of an iron chelator, p-actin was used because GAPDH is known to 
contain several hypoxia responsive elements in its promoter region and has been 
shown to be modulated by the transcription factor HIF-1 [Escoubert et al. 1999]. 
Since we demonstrated that the activity of HIF-1 is significantly up-regulated by both 
DFO and SIH it was not advisable to use GAPDH to normalise such data. In order to 
observe any alterations in the mRNA accumulation of GAPDH, HO-1 and COX-2 in 
response to iron chelators it was necessary to demonstrate that the mRNA 
accumulation for p-actin was not modulated by iron chelation, p-actin has previously 
been reported to slightly decrease in rat skeletal cells exposed to hypoxia [Webster, 
1987], however when the accumulation of p-actin mRNA was measured in FEK-4 
skin fibroblast cells and compared to the constitutive presence of 18S and 28S RNA 




UVA irradiation of skin fibroblast cells causes an increase in the expression of 
oxidative stress-modulated genes such as HO-1 and COX-2. When cells are exposed 
to UVA light several reactive species are generated such as singlet oxygen and 
superoxide, and these could act as primary triggers for gene activation [Ryter and 
Tyrrell, 1998]. In addition, secondary reactive species such as those derived from the 
oxidation of cell lipids (lipid peroxidation), stimulated by the UVA radiation, may 
also contribute to the modulation of gene expression [Basu-Modak et al., 1996]. 
When skin fibroblast cells are exposed to a dose of UVA irradiation they release low 
molecular mass iron (LMrFe) within the cell [Pourzand et al., 1999]. Such iron is 
frequently regarded as a pro-oxidant form of iron that is likely to increase the damage 
characteristically seen during the UVA irradiation of cells. Here we investigate the 
possibility that following the UVA irradiation of cells, it is the released LMrFe that 
acts as a key signal for the gene activation of HO-1 and COX-2.
The experimental design adopted to address this proposal was based on influencing 
iron levels within cells that were exposed to UVA irradiation and subsequently 
measure gene expression. This involved both depleting cells of iron using iron 
chelators, as well as supplementing cells with iron complexes. Previous work has 
shown that when FEK-4 fibroblast cells are pre-treated, 18 hours before irradiation, 
with a single dose of DFO (IOOjiM) it almost completely abolished the UVA-induced 
increase in free chelatable iron in cells [Pourzand et al., 1999], however, when a range 
of concentrations of DFO were applied to cells in the absence of UVA, we observed 
an increase in the expression of GAPDH and COX-2 mRNA. Re-examining this 
observation in fibroblast cells using a wide range of concentrations of DFO, we 
observed there to be an increase in the activity of the transcription factor HIF-1 and
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the subsequent modulation of HIF-1 associated genes such as GAPDH and COX-2. 
To demonstrate that this was not due to a unique pharmacological property of DFO, 
we repeated all experiments using a chemically different iron chelator with a similar 
iron binding constant, namely SIH. SIH produced an increase in HIF-1 activity with 
subsequent gene expression of GAPDH and COX-2 similar to that of DFO.
Cells contain a pool of LMrFe that is accessible to most iron chelators able to enter 
the cell. This pool is in equilibrium with loosely bound forms of iron able to activate 
enzymes such as aconitase, IRP-1 and also ribonucleotide reductase, and as proposed 
here, may also activate and modulate the expression of genes. Strong iron chelators 
such as DFO and SIH can chelate these forms of iron, and as we have shown here, 
removal of such iron will activate HIF-1.
In an attempt to separate the chelation of the labile iron pool from the more specific 
chelation of enzyme and gene-activating iron we used a novel iron chelator, namely 
HBSer, which has a considerably lower iron binding constant than either DFO or SIH. 
As expected, HBSer was able to deplete intracellular LMrFe, but did not induce HIF- 
1 activity, strongly suggesting that chelatable forms of iron available to DFO and SIH, 
but not HBSer, are involved in gene modulation within cells.
Such forms of chelatable iron do not appear to be responsible for the increased 
expression of HO-1 or COX-2 following UVA irradiation of skin fibroblast cells, 
since pre-treatment of cells with HBSer prior to UVA irradiation, did not alter the 
UVA induced level of HO-1 or COX-2 expression.
As an essential control, the aforementioned experiments were repeated without UVA 
irradiation, but with the addition of iron complexes to the cell. Two different 
chemical forms of iron were presented to skin fibroblast cells, namely haemin and 
ferric citrate. Both effectively increased intracellular levels of LMrFe to levels
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similar to those seen following UVA irradiation. However, they did not increase the 
expression of either COX-2 or HO-1 such as we observe following UVA irradiation 
of cells.
In summary, it has been shown for the first time that following UVA-irradiation of 
cells, the release of LMrFe that is known to take place, is not responsible for the 
enhanced expression of either HO-1 or COX-2. In addition, we have also shown that 
it is possible to remove intracellular low molecular mass iron using an exogenous iron 
chelator without the induction of HIF-1.
Building upon these observations, we propose to undertake studies to explore the 
modulation of gene expression by both iron and hypoxia. This is discussed in detail 
in the following section.
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6 Future studies
6.1 The modulation of COX-2 by hypoxia
The expression of cyclooxygenase-2 (COX-2) is modulated by iron chelation in FEK- 
4 skin fibroblast cells; we propose this occurs as a result of the hypoxic response that 
iron chelators are known to mimic (discussed in section 4.2). We have also shown 
that mimicking hypoxia using cobalt chloride does not significantly alter the 
expression of COX-2 mRNA and therefore propose that this may be a response that is 
specific to certain cells types (discussed in section 4.4). To strengthen the proposal 
that the up-regulation of COX-2 by strong iron chelators is a consequence of the 
hypoxic response and not iron chelation, it would be necessary to expose the 
aforementioned cells to low oxygen concentrations (hypoxia) and observe the 
modulation of COX-2 mRNA. If hypoxic exposure increases COX-2 mRNA 
expression in FEK-4 cells it would strengthen a proposal of this thesis that there is to 
date a lack of evidence to support the involvement of LMrFe chelation in the 
induction of COX-2. To demonstrate this response growing FEK-4 skin fibroblast 
cells would be exposed to hypoxia, using a hypoxic cell incubator, over various time 
points. Cells would then be lysed and total RNA or protein extracted for Northern or 
Western blot analysis to determine whether COX-2 mRNA and protein accumulation 
could be induced by hypoxia. This study would aim to support evidence showing that 
the induction of COX-2 by iron chelators (such as DFO) is not a consequence of the 
removal of iron [Tanji et al., 2000], but most probably dependent on the increase in 
HIF-1 activity. To further support this evidence we aim to pre-treat cells with a series 
of iron chelators with different affinities for iron that like HBSer do not increase HIF- 
1 activity. COX-2 accumulation would be measured following treatment of cells with
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these different iron chelators. If as we expect, COX-2 expression is increased by 
hypoxia, it would be necessary to demonstrate whether LMrFe alters the hypoxic 
induction of COX-2. Growing FEK-4 skin fibroblast cells would be pre-treated with 
a non-HIF-1 inducing iron chelator (such as HBSer) and a source of iron, such as 
ferric citrate, prior to hypoxic exposure. Following cell lysis and analysis of COX-2 
mRNA and protein (using Northern and Western blot analysis) it should be possible 
to assess whether the absence or presence of LMrFe can potentiate or diminish the 
expression of COX-2 in response to hypoxia.
6.2 Investigation of the role of LMrFe in the induction of HO-1
The role of LMrFe in the UVA-induction of the enzyme haemoxygenase-1 is 
discussed in section 4.3. Here we present additional evidence that suggests the 
removal of LMrFe from cells, using an iron chelator that does not mimic a hypoxic 
response or absorb UVA, does not significantly alter the expression of HO-1. In 
contrast to the aforementioned situation, the modulation of HO-1 expression in 
response to hypoxia is known to have an absolute requirement for LMrFe. For 
example, iron chelators that strongly increase HIF-1 activity cannot subsequently 
increase HO-1 expression (tab. 3.3 and discussed in 4.4). In support of a requirement 
for LMrFe in the induction of HO-1 by hypoxia Ryter et al. report a strong 
dependence on the presence of LMrFe for the hypoxic induction of HO-1 protein and 
activity in bovine aortic endothelial cells [Ryter et al., 2000]. Secondly, Panchenko et 
al. have demonstrated a similar abrogation of the induction of HO-1 in response to 
hypoxia using the iron chelator DFO human dermal fibroblast cells [Panchenko et al., 
2000].
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However, the aforementioned studies have used ‘strong’ iron chelators that increase 
HIF-1 activity i.e. DFO and o-phenanthroline [Ryter et al., 2000, Panchenko et al.,
2000], whereas the hypoxic induction of HO-1 has been shown to be abrogated in the 
absence of LMrFe. It is important to see whether such an effect is still observed if we 
use an iron chelator that does not increase HIF-1 activity. A bandshift assay (EMSA) 
and reporter gene assay would be employed to demonstrate any alterations in HIF-1 
DNA binding and promoter activity induced by hypoxia in the presence or absence of 
iron. Cells would be pre-treated for 18 hours with HIF-1 and non-HIF-1 inducing 
iron chelators and then exposed to hypoxia. The cells would be lysed and the nuclear 
extracts assayed using a HIF-1 bandshift assay (EMSA) to assess HIF-1 DNA binding 
activity. A similar experiment would measure HIF-1 luciferase reporter activity as 
described in 2.9.
6.3 The affinity of chelators for different forms of iron
We have postulated that the novel iron chelator HBSer does not increase HIF-1 
activity due to its lower affinity for iron. To firmly establish whether this finding is 
unique to HBSer or applicable to other low affinity chelators it would be necessary to 
employ other chelators with a low affinity for iron. Such iron chelators may include 
the compounds synthesised by Galey et al. These iron chelators include ER3080 and 
ER2579 that have a low affinity for ferric iron Ka 26.8 and 18.1 respectively. Doses 
of 12 and 60pM respectively protect cells against both hydrogen peroxide and tert- 
butyl hydroperoxide toxicity [Galey et al., 1998]. The compound ER2579 has been 
specifically designed to increase its affinity for ferric iron from Ka 18.1 to Ka 26.8 
when it becomes hydroxylated within the cell by hydrogen peroxide generated during 
an oxidative insult such as UVA radiation.
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Furthermore, to further establish why HBSer does not increase HIF-1 activity it is 
essential to measure the affinity of HBSer for ferrous ions. Unfortunately, the Ka for 
ferrous ions of HBSer is at present unknown. Conventional therapeutic cellular iron 
chelators are normally designed to chelate ferric iron present in excess of normal 
requirements. During iron-overload low molecular mass iron inside cells has been 
shown to be attached to weak ligands such as phosphate and citrate. When iron 
chelators remove ferric iron, they can disturb the equilibrium between ferric and 
ferrous ions causing more ferrous ions to become oxidised to the ferric state, i.e. the 
reaction is forced strongly top the right:
In addition, iron chelators such as DFO also have a low affinity for ferrous ions (Ka 
<108 M). This is important to consider, because only ferrous iron activates and needs 
to be removed from functional proteins such as the pVHL enzyme and the IRP iron- 
sulphur cluster. To assess whether the activation of pVHL is dependent on the 
affinity of an iron chelator for ferrous ions, it would be necessary to establish the 
affinity of HBSer and a series of other similar chelators for ferrous iron. By applying 
these chelators to cells and measuring HIF-1 activity it may be possible to establish 
whether the affinity of an iron chelator for ferrous ions is low enough to prevent 
ferrous iron from being abstracted from the pVHL enzyme.
6.4 Do iron chelators, that do not increase HIF-1 activity, alter other cellular 
processes that are affected by ‘strong’ iron chelators?
A key proposal in our postulate is that the lower iron chelating potential of HBSer 
allows it to remove iron from the cell’s LMrFe pool but not from functional proteins
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such as the 2-oxyglutarate dependent dioxygenase (pVHL). Aside from the ability of 
a strong iron chelator to induce HIF-1 they are also known to have several unrelated 
effects on cells that must be considered when using such agents. For example, iron 
chelators are known to act as effective antiproliferative agents because they can 
inhibit the activity of the non-haem iron containing ribonucleotide reductase enzyme 
critical for the conversion of ribonucleotides to deoxyribonucleotides. A decrease in 
deoxyribonucleotide concentration is thought to prevent DNA synthesis, which then 
results in Gi/S arrest. The aforementioned enzyme, ribonucleotide reductase, is 
comprised of two dissimilar proteins, often referred to as R l, which contains 
polythiols, and R2, which contains non-haem iron and a free tyrosyl radical. Both the 
Rl and R2 contribute to the active site of the enzyme. However, it appears that iron 
chelators exhibit their inhibitory effect through the prevention of incorporation of iron 
into the holoenzyme rather than high affinity binding of the non-haem iron [Li et al.,
2001]. However, treating cells with a lower affinity iron chelator that is designed to 
mimic an iron-binding protein will allow the effective depletion of the intracellular 
LMrFe pool, but may not remove functional iron associated with proteins and 
enzymes.
We would expect that different cellular proteins, requiring iron for their activity, 
would hold their iron with differing affinities in equilibrium with the cells LMrFe 
pool. In order to assess this we would pre-treat cells with iron chelators that range in 
their affinity for iron and assay changes in the activity of the 2-oxyglutarate 
dependent dioxygenase (pVHL) using EMSA (bandshift) and reporter analysis, IRP-1 
and ribonucleotide reductase using bandshift and Western blot analysis respectively.
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Table 6.1. The chelator binding constant for iron111 of a range of different iron chelators.
Chelator binding- 
constant for iron111








human Apo- Log 20.2
transferrin
nitrilotriacetic acid Log 15.9
(NTA)
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P r o te in s  A , B , C  a n d  D  a r e  in  a n  a r b itr a r y  o r d e r  a s  th e ir  a f f in it ie s  fo r  ir o n  in  F E K -4  c e l ls  a r e  n o t








• Abraham, N.G., Drummond, G.S., Lutton, J.D. and Kappas, A. (1996) The 
biological significance and physiological role of heme oxygenase. Cell 
Physiol Biochem. 6, 129-168.
• Adamec, J., Arias, E.E., Mangravita, G.C., Ferreira, G.C., Twesten, R.D. and 
Isaya, G. (2001) Antioxidant properties of yeast frataxin stimulate iron usage 
and inhibit Fenton chemistry. Bioiron 2001. abstr No. 108
• Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., Watson, J.D. (1994) 
Molecular biology of the cell. Third ed. Garland Publishing.
• Ames, B.N. (1983) Dietary carcinogens and anti-carcinogens. Science. 221, 
1256-1263.
• Anderson, G.J., Frazer, S.J., Wilkins, S.J., Becker, E.M., McKie, A.T. and 
Vulpe, C.D. (2002) Hepcidin expression inversely correlates with the 
expression of duodenal iron transport molecules and iron absorption in rats. 
Biometals meeting 2002, Kings College London. Abstract number S23.
• Applegate, L.A., Frenk, E., Gibbs, N., Johnson, B., Ferguson, J. and Tyrrell,
R. M. (1994) Cellular sensitivity to oxidative stress in the photosensitivity 
dermatitis/actinic reticuloid syndrome. J. Invest. Dermatol. 102, 762-767.
• BasuModak, S. and Tyrrell, R.M. (1993) Singlet oxygen -  a primary effector 
in the ultraviolet-A/near visible light induction of the human heme oxygenase 
gene. Cane. Res. 53, 4505-4510.
• BasuModak, S., Lusher, P. and Tyrrell, R.M. (1996) Lipid metabolite 
involvement in the activation of the human heme oxygenase-1 gene. Free Rad. 
Biol. Med. 20, 887-897.
• Bates, G.W., Billips, C. and Saltman, P. (1967) The kinetics and mechanism 
of iron (III) exchange between chelates and transferrin. J. Biol. Chem. 242, 
2810-2815.
• Bellocq, A., Israel-Beit, D., Cadranel, J., Perez, J., Fouqueray, B., Kanfer, A., 
Girot, R. & Baud, L. (1999) Reduction of tumor necrosis factor a  expression 
and signalling in peripheral blood mononuclear cells from patients with 
thalassaemia or sickle cell anaemia upon treatment with desferrioxamine. 
Cytokine. 11, 168-172.
226
• Benjamin, I.J. and McMillan, D.R. (1998) Stress (heat shock) proteins. Circ. 
Res. 83, 117-132.
• Bergeron, E J . and Brittenham, G.M. (Eds) (1994) The development of iron 
chelators for clinical use. CRC press, Inc.
• Bianchi, L., Tacchini, L. & Cairo, G. (1999) HIF-1-mediated activation of 
transferrin receptor gene transcription by iron chelation. Nucleic Acids. Res. 
21, 4223-4227.
• Biesalski, H.K. (1996) Effects of controlled exposure of sunlight on plasma 
and skin levels of beta carotene. Free Rad. Res. 24, 215-219.
• Bissett, D.L., Chatteijee, R. and Hannon, D.P. (1991) Chronic ultraviolet 
radiation-induced increase in skin iron and the photoprotective effect of 
topically applied iron chelators. Photochem. Photobiol. 54, 215-223.
• Black, H.S., de Gruijl, F.R., Forbes, P.D., Cleaver, J.E., Anathaswamy, H.N, 
de Fabo, E.C, Ullrich, S.E. and Tyrrell, R. M. (1997) Photocarcinogenesis: an 
overview. J. Photochem. Photobiol. B. 40, 29-47.
• Blake, D.R., Winyard, P. and Lunec, J. (1985) Cerebral and ocular toxicity 
induced by desferrioxamine. Quant. J. Med. 56, 345-355.
• Bolann, B.J. and Ulvik, R.J. (1990) The limited ability of superoxide to 
release iron from ferritin. Eur. J. Biochem. 193, 899-904.
• Bonazzi, A., Mastyugin, V., Mieyal, P.A., Dunn, M.W. and Schwartzman, M. 
(2000) Regulation of cyclooxygenase-2 by hypoxia and peroxisome 
proliferators in the corneal epithelium. J. Bio. Chem. 275, 2837-2944.
• Bose, B., Soriani, M. and Tyrrell, R.M. (1999) Activation of expression of the 
c-fos oncogene by UVA irradiation in cultured human skin fibroblasts. 
Photochem. Photobiol. 69 ,489-493.
• Bothwell, T.H., Charlton, R.W., Cook, J.D. and Finch, C.A. (1979) Iron 
metabolism in man. Blackwell, Oxford, 1-157.
• Bradford M.M. (1976) A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilising the principle of protein-dye binding. 
Anal. Biochem. 72, 248-254.
• Brenneisen, P., Wenk, J., Koltz, L.O., Wlaschek, M., Briviba, K., Kreig, T., 
Sies, H. and Scharffetter-Kochanek, K. (1998) Central role of ferrous/ferric 
iron in the ultraviolet B irradiation-mediated signaling pathway leading to
227
increased interstitial collagenase (Matrix degrading metalloprotease (MMP)-l) 
and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal 
fibroblasts. J. Biol. Chem. 273, 9:5279-5287.
• Breuer, W., Epsztejn, S., Millgram, P., Cabantchik, Z.I. (1995) Transport of 
iron and other transition metals into cells as revealed by fluorescent probe.
Am. J. physiol. 268, C1354-C1361
• Bruls, W.A., Slaper, H., van der Leun, J.C. and Berrens, L. (1984) 
Transmission of human epidermis and stratum comeum as a function of 
thickness in the ultraviolet and visible wavelengths. Photochem. Photobiol.
40, 485-494.
• Bunn, H.F. and Poyton, R.O. (1996) Oxygen sensing and molecular adaptation 
to hypoxia. Physiol. Rev. 76, 839-885.
• Cabantchik, Z.I., Glickstein, H. and Milgram, P. (1996) A fluorescence assay 
for assessing chelation of intracellular iron in a membrane model system and 
mammalian cells. Anal. Biochem. 233, 221-227.
• Cabantchik, Z.I., Glickstein, H., Milgram, P., Breuer, W. (1996) A 
fluorescence assay for assessing chelation of intracellular iron in a membrane 
model system and mammalian cells. Anal. Biochem. 233, 221-227
• Cable, H. and Lloyd, J.B. (1999) Cellular uptake and release of two 
contrasting iron chelators. J. Pharm. Pharmacol. 51, 131-134.
• Cairo, G. and Pietrangelo, A. (2000) Iron regulatory proteins in pathobiology. 
Biochem. J. 352, 241-250.
• Casella, L., Gullotti, M., Pintar, A., Messori, A., Rockenbauer, A. & Gyor, M. 
(1987) Iron (III) tyrosinate models. Synthesis and spectroscopic and 
stereochemical studies of iron (III) complexes of N-salicylidene-l-amino acids. 
Iorg. Chem. 26,1031-1038.
• Chedekel, M.R. and Ziese, L. (1997) Melanins: Sunscreens development, 
evaluation and regulatory aspects. Marcel Decker, Inc., NY., USA, 117-137
• Chiarugi, V., Magnelli, L., Chiarugi, A. and Gallo, O. (1999) Hypoxia induces 
pivotal tumor angiogenesis control factors including p53, vascular enodhelial 
growth factors and the NF-kB-dependent inducible nitric oxide synthase and 
cyclooxygenase-2. J. Cane. Res. and Clin. Res. 125, 525-528.
• Crest Co. Ltd. (1997) website on aspects of UVA. USA.
228
• Crichton, R.R. (1991) Inorganic biochemistry of iron metabolism. Ellis 
Harwood; Chichester.
• Crisponi, G., Nurchi, V.M., Silvagni, R. and Faa, G. (1999) Oral iron chelators 
for clinical use. Polyhedron. 18, 3219-3226.
• Daghman, N.A., McHale, C.M., Savage, G.M., Price, S., Winter, P.C., 
Maxwell, A.P. & Lappin, T.R.L. (1999) Regulation of erythropoetin gene 
expression depends on two different oxygen sensing mechanisms. Mol. Gen. 
andMetab. 67,113-117.
• Dalle, B., Payen, E. & Beuzard, Y. (2000) Modulation of transduced 
erythropoietin expression by iron. Exp. Hematol. 28, 760-764.
• Dancis, A., Roman, D.G., Anderson, G.J., Hinnebusch, A.G. and Klausner, 
R.D. (1992) Ferric reductase of Saccharomyces cervisiae: Molecular 
characterisation, role in uptake, and transcriptional control by iron. Proc.
Natl Acad. Sci. USA. 89, 3869-3873.
• Darnell, G. and Richardson, D.R. (1999) The potential of iron chelators of the 
pirydoxal isonicotinoyl hydrazone class as effective antiproliferative agents 
III: the effect of the ligands on molecular targets involved in proliferation. 
Blood. 94, 2:781-792.
• Darr, D., Combs, S., Dunston, S., Manning, T. and Pinnell, S. (1992) Topical 
vitamin C protects porcine skin from ultraviolet radiation-induced damage. Br. 
J. Dermatol. 127, 247-253.
• de Gruijl, F.R. (2000) Photocarcinogenesis: UVA vs UVB. Methods Enzymol. 
319, 359-366.
• Dennery, P.A., Spitz, D.R., Yang, G., Tatorov, A., Lee, C.S., Shegog, M.L. 
and Poss, K.D. (1998a) Oxygen toxicity and iron accumulation in the lungs of 
mice lacking heme-oxygenase-2. J. Clin. Invest. 101 ,1001-1011.
• Dennery, P.A., Yang, G., Tatorov, A. and Poss, K.D. (1998) Decreased 
markers of oxidative injury after hyperoxia in the absence of lung heme- 
oxygenase-1 in vivo. Am. J. Rispir. Crit. Care Med. 157, A891-A900.
• DeWitt, D.L. and Smith, W.L. (1988) Primary structure of prostaglandin G/H 
synthase from sheep vascular gland determined from the complementary 
cDNA sequence. Proc. Natl. Acad. Sci. USA. 85, 1412-1416.
229
• Digicaylioglu, M. & Lipton, S.A. (2001) Erythropoetin-mediated 
neuroprotection involves croos-talk between Jak2 and NF-kB signalling 
cascades. Nature. 412, 641-647.
• Dlaska, M. and Weiss, G. (1999) Central role of transcription factor NF-IL6 
for cytokine and iron-mediated regulation of murine inducible nitric oxide 
synthase expression. J. Immunol 162, 6171-6177.
• Donati, Y.R.A., Solsman, D.O. and Polla, B.S. (1990) Oxidative injury and 
the heat shock response. Biochem. Pharmacol. 40, 2571-2577.
• Dore, S., Takahashi, M., Ferris, C.D., Hester, L.D., Guastella, D. and Snyder, 
S.D. (1999) Bilirubin, formed by activation of heme oxygenase-2 protects 
neurons against oxidative stress injury. Proc. Natl. Acad. Sci. USA. 96, 2445- 
2450.
• Eide, D., Daviskaplan, S., Jordan, I., Sipe, D. and Kaplan, J. (1992)
Regulation of iron uptake in saccharomyces-cerevisiae-the ferrireductase 
Fe(II) transporter are regulated independently. J. Biol. Chem. 267, 20774- 
20781.
• Elbert, P.S., Frykholm, B.C, Hess, R.A. and Tschudy, D.P. (1983) 
Characteristics of hematin uptake in malignant, embryonic and normal cells. 
Cancer Biochem. Biophys. 6, 157-165.
• Elbirt, K.K. and Bonkovsky, H.L. (1999) Heme oxygenase: recent advances in 
understanding its regulation and role. Proc. Assoc. Am. Physicians. I l l ,  438- 
447.
• Ellison, R.T., Giehl, T J . and Laforce, F.M. (1998) Damage of the outer- 
membrane of enteric gram negative bacteria by lactoferrin. Infect. Immune. 56, 
2774-2781.
• Epstein, A.C.R., Gleade, J.M., McNeill, L.A., Hewitson, K.S., O’Rourke, J., 
Mole, D.R., Mukheiji, M., Metzen, E., Wilson, M.I., Dhanda, A., Tian, Y., 
Masson, N., Hamilton, D.L., Jaakola, P., Barstead, R., Hodgkin, J., Maxwell, 
P.H., Pugh, C.W., Schofield, C.J. and Ratcliffe, P J . (2001) C. elegans EGL-9 
mammalian homologs define a family of dioxygenasees that regulate HIF by 
prolyl hydroxylation. Cell. 107,43-54.
• Epsztejn, S., Kakholn, O. and Glickstein, H. (1997) Fluorescence analysis of 
the labile iron pool of mammalian cells. Anal. Biochem. 248, 31-40.
230
• Escoubert, B., Planes, C. & Clerici, C. (1999) Hypoxia increases 
glyceraldehyde-3-phosphate dehydrogenase transcription in rat alveolar 
epithelial cells. Biochem. Biophys. Res. Commun. 266, 156-161.
• Fandrey, J., Frede, S., Ehleben, W., Porwol, T., Acker, H. & Jelkmann, W. 
(1997) Cobalt chloride and desferrioxamine antagonise the inhibition of 
erythropoetin production by reactive oxygen species. Kidney Int. 51, 492-496.
• Feinberg, A.P. and Vogelstein, B. (1984) A technique for radiolabelling DNA 
restriction endonuclease fragments to high specific activity. Anal. Biochem. 
137, 266-267.
• Ferris, C.D., Jaffrey, S.R., Sawa, A., Takahashi, M., Brady, S.D., Barrow, 
R.K., Tysoe, S.A., Wolosker, H., Baranano, D.E., Dore, S., Poss, K.D., and 
Snyder, S.H. (1999) Haem oxygenase-1 prevents cell death by regulating 
cellular iron. Nature Cell Biol. Vol.l, July 1999:152-157.
• Fogg, S., Agarwal, A., Nick, H.S. & Visner, G.A. (1999) Iron regulates 
hypoxia-dependent human heme oxygenase 1 gene expression in pulmonary 
endothelial cells. Am. J. Respir. Cell Mol. Biol. 20, 797-804.
• Frederick, J.E., Snell, H.E. and Haywood, E.K. (1989) Skin cancers and
ultraviolet radiation. Photochem. Photobiol. 50, 443-450.
• Freeman, S.E., Gange, R.W., Matzinger, E.A. and Sutherland, B.M. (1986) 
Higher pyrimidine dimmer yields in skin of normal humans with higher UV- 
sensitivity. J. Invest. Dermatol. 86, 34-36.
• Freeman, S.E., Hacham, H., Gange, R.W., Maytum D.J., Sutherland, J.C. and 
Sutherland, B.M. (1989) Wavelength dependence of pyrimidine dimmer 
formation in DNA of human skin irradiated in situ with ultraviolet light. Proc. 
Natl. Acad. Sci. 86, 5605-5609.
• Fuller, C.J.; Faulkner, H.; Bendich, A.; Parker, R.S. and Roe, D.A. (1992)
Effect of carotene supplementation on photosuppression of delayed-type 
hypersensitivity in normal young men. Am. J. Clin. Nutr. 56, 684-90.
• Gaboriau, F., Morliere, P., Marquis, I., Moysan, A., Geze, W. and Dubertret, 
L. (1993) Membrane damage induced in culture human skin fibroblasts by 
UVA irradiation. Photochem. Photobiol. 58, 515-520.
231
• Galey, J.B., Destree, O., Dumats, J., Pichaud, P., Marche, J., Genard, S., 
Braccioli, G., Capitaine, L., Plessix, H., Brambilla, L. and Cantoni, O. (1998) 
Protection of U937 cells against oxidative injury by a nove series of iron 
chelators. Free Rad. Biol Med. 25, 881-890.
• Garavelli, M; Bemardi, F; Olivucci, M.; Robb, M. (1998) A DFT study of the 
reactions between Singlet -Oxygen and a Carotenoid model. J. Am. Chem.
Soc. 120, 10210-10222.
• Garvey, E.P., Oplinger, J.A., Furfine, E.S., Kiff, R.J., Laszlo, F., Whittle, 
BJ.R. and Knowles, R.G. (1996) 1400W is a slow, tight binding, and highly 
selective inhibitor of inducible nitric oxide synthase in vitro and in vivo. J. 
Biol. Chem. 272, 4959-4963.
• Getherbeck, S., Buettner, R. and Krutmann, J. (1997) Ultraviolet A radiation- 
induced expression of human genes: molecular and photobiological 
mechanisms. Biol. Chem.3Sl, 1231-1236.
• Getherbeck, S., OlaizolaHom, S., Schmitt, H., Grewe, M., Jahnke, A., 
Johnson, J.P., Briviba, K., Seis, H. and Krutmann, J. (1996) Activation of 
transcription factor AP-2 mediates UVA-radiation and singlet oxygen-induced 
expression of the human intracellular adhesion molecule 1 gene. Proc. Natl. 
Acad. Sci. USA. 93,14586-14591.
• Gey, K.F., Puska, P., Jordan, P. and Moser, U.K. (1991) Inverse correlation 
between plasma vitamin E and mortality from ischemic heart disease in cross­
cultured epidemiology. Am. J. Clin. Nutr. 53, 326S-334S.
• Giacomoni, P.U. (2001), Sun Protection in Man, ESP Vol. 3. Elsevier.
• Girotti, A.W. (1990) Photodynamic lipid peroxidation in biological systems. 
Photochem. Photobiol. 51, 497-501.
• Gleade, J.M. & Ratcliffe, P.J. (1998) Hypoxia and the regulation of 
physiologically relevant gene expression. Mol. Med. Today. March 122-125.
• Goessling, L.S., Mascotti, D.P. and Thach, R.E. (1998) Involvement of heme 
in the degradation of iron-regulatory protein 2. J. Biol. Chem. 273 ,12555- 
12557.
• Goldberg, M.A., Dunning, S.P. & Bunn. H.F. (1988) Regulation of the 
erythropoetin gene: evidence that the oxygen sensor is a heme protein.
Science. 242, 1412-1415
232
• Gollnick, Hopfenmueller, W.; Hemmes, C.; Chun S.C.; Schmid C.; 
Kundermeier K.; Biesalski H.K. (1996) Systemic beta carotene plus topical 
UV sunscreen are an optimal protection against harmful effects of natural UV 
sunlight. Results of the Berlin-Eilath study. Eur. J. Dermatol 6, 200-205.
• Griffiths, H.R., Mistry, P., Herbert, K.E. and Lunec, J. (1998) Molecular 
effects of ultraviolet light-induced genotoxicity. Crit. Rev. in Clin. Lab. Sci. 
35, 189-237.
• Gutteridge, J.M.C. (1986) Iron promoters of the Fenton reaction and lipid 
peroxidation can be released from haemoglobin by peroxides. FEBS Lett. 201, 
291-295.
• Gutteridge, J.M.C. (1987) The antioxidant activity of hapatoglobin towards 
haemoglobin-stimulated lipid peroxidation. Biochem. Biophys. Acta, 917,219- 
223.
• Gutteridge, J.M.C. (1991) Hydroxyl radiacl formation from the auto reduction 
of a ferric citrate complex. Free Rad Biol. Med. 11, 401-406.
• Gutteridge, J.M.C. (1995) Signal, messenger and trigger molecules from free 
radical reactions and their control by antioxidants. Iron signalling 
mechanisms -  from transcription factors to oxidative stress. Ed. L. Packer and 
K. Wirtz. NATOASIseries. 92, 157-161. Springer-Verlag. Berlin.
• Gutteridge, J.M.C. and Hou, Y. (1986) Iron complexes and their reactivity in 
the bleomycin assay for radical-generating loosely-bound iron. Free Rad. Res. 
Commun. 2, 143-151.
• Gutteridge, J.M.C. and Quinlan, G.J. (1992) Antioxidant protection against 
organic and inorganic oxygen radicals by normal human plasma: the important 
primary role for iron-binding and iron-oxidising proteins. Biochem. Biophys. 
Acta. 1159, 248-254.
• Gutteridge, J.M.C. and Smith, A. (1988) Antioxidant protection by 
haemopexin of haem-stimulated lipid peroxidation. Biochem. J. 256, 861-865.
• Gutteridge, J.M.C., Halliwell, B., Treffry, A. and Harrison, P.M. (1983) Effect 
of ferritin-containing fractions with different iron loading on lipid 
peroxidation. Biochem. J. 209, 557-560.
233
• Gutteridge, J.M.C., Paterson, S.K., Segal, A.W. and Halliwell, B. (1981) 
Inhibition of lipid peroxidation by the iron-binding protein lactoferrin. 
Biochem. J. 199, 259-261.
• Gutteridge, J.M.C., Rowley, D.A. and Halliwell, B. (1981) Superoxide- 
dependent formation of hydroxyl radicals in the presence of iron salts. 
Detection of free iron in biological systems by using bleomycin-dependent 
degradation of DNA. Biochem. J. 199, 263-265.
• Haider, A., Olszanecki, R., Gryglewski, R., Schwartzman, M.L., Lianos, E., 
Kappas, A., Nasjletti, A. and Abraham, N.G. (2002) Regulation of 
cyclooxygenase by the heme-heme oxygenase system in microvessel 
endothelial cells. J. Pharmacol. And exp. Therap. 300,188-194.
• Halliday, J.W. and Powell, L.W. (1992) Hereditary hemochromatosis and 
other diseases associated with iron overload. Iron and human disease. Ed. 
Halberg, L. and Asp, G. 131-160, CRC press: Boca Raton.
• Halliwell, B. (1989) Protection against tissue damage in vitro by 
desferrioxamine: what is the mechanism of action?. Free Rad. Biol. Med. 7, 
645-651.
• Halliwell, B. and Gutteridge, J.M.C. (1986) Oxygen free radicals and iron in 
relation to biology and medicine: some problems and concepts. Arch. 
Biochem. Biophys. 246, 501-514.
• Halliwell, B. and Gutteridge, J.M.C. (1999) Free radicals in biology and 
medicine. 3rd ed, Oxford University Press, Oxford, UK.
• Hancock, J. and Neill, S. (1999) Reactive oxygen species as potential 
signalling molecules in both plants and animals. The Biochemist. Aug, 23-27
• Hanson, D.L. and deLeo, V.A. (1989) Long wave ultraviolet radiation 
stimulates arachidonic acid release and cyclooxgenase activity in mammalian 
cells in culture. Photochem. Photobiol. 49, 423-30.
• Hanson, E.S., Foot, L.M. and Leibold, E.A. (1999) Hypoxia post 
transcriptionally activates iron-regulatory protein 2. J. Biol. Chem. 274, 5047- 
5052.
234
• Henderson, B. R.; Menotti, E. and Kuhn, L. C. (1996) Iron regulatory proteins 
1 and 2 bind distinct sets of RNA target sequences. J. Biol. Chem. 271: 4900- 
4908.
• Hendrick, J.P. and Hart, F.V. (1993) Molecular chaperon functions of heat- 
shock proteins. Annu. Rev. Biochem. 62, 349-384.
• Hermes-Lima, M., Nagy, E., Ponka, P. & Hermes-Lima, M. (1998) The iron 
chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 
DNA against hydroxyl radical mediated strand breaks. Free Rad. Biol. Med. 
25, 875-880.
• Hershko, C. and Rachmilevitz, E.A. (1975) Non-transferrin plasma iron in 
patients with transfusional iron overload. Proteins of iron storage and 
transport in biochemistry and medicine. Ed Crichton, R.R. 427-432. North 
publishing Co. Amsterdam.
• Hightower, L.E. (1980) Abnormal proteins as the trigger for the induction of 
stress responses. J. Cell. Phys. 102,407-412.
• Honda, S., Migita, K., Hirai, Y., Ueki, Y., Yamasaki, S., Urayama, S., Yoijro, 
K., Takaaki, F., Kawakami, A., Kimachi, M., Kita, M., Ida, H., Aoyagi, T. and 
Eguch, K. (2000) Induction of COX-2 expression by nitric oxide in 
rheumatoid synovial cells. Biochim. Biophys. Res. Comm. 268, 928-931.
• Hu, M.L. and Tappel, A.L. (1992) Potentiation of oxidative damage to 
proteins by UVA and protection by antioxidants. Photochem. Photobiol. 56, 
357-363.
• Immenschuh, S. and Ramadori, G. (2000) Gene regulation of heme 
oxygenase-1 as a therapeutic target. Biochem. Pharmacol. 60, 1121-1128.
• Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., 
Asara, J. M., Lane, W. S. & Kaelin Jr, W. G. (2001) HIFa targeted for VHL- 
mediated destruction by proline hydroxylation: Implications for O2 sensing. 
Science. 292, 464-468.
• Iwasaki, K., Kitizawa, M. and Sakamoto, K. (2001) Reduction of UV-induced 
NF-kB activation by an amino acid based iron chelator. Reviewed manuscript, 
provided by Ajinomoto Co., Inc., Japan.
235
• Jaakkola, P., Mole, D.R., Tian, Y., Wilson, M.I., Gielbert, J., Gaskell, S J., 
Von Kriegsheim, A., Hebestreit, H.F., Mukheiji, M., Schofield, C J., Maxwell, 
P.H., Pugh, C.W. & Ratcliffe, PJ. (2001) Targeting of HIF-l-a to the von 
Hipple-Lindau ubiquitylation complex by C^-regulated prolyl hydroxylation. 
Science. 292, 468-472.
• Ji, Y., Xu, Q. and Schmedtje, J.F. (1998) Hypoxia induces high-mobility- 
group protein I(Y) and transcription of the cyclooxygenase-2 gene in human 
vascular endothelium. Circ. Res. 83, 295-304.
• Jurkiewicz, B.A. and Buettner, G.R. (1996) EPR detection of free radicals in 
UV-irradiated skin: mouse versus human. Photochem. Photobiol. 64, 918-22.
• Kadir, F.H.A, Al-Massad, K.F., Fatemi, S J.A., Singh, H.K., Wilson, M.T. and 
Moore, G.R. (1991) Electron transfer between horse ferritin and 
ferrihaemoproteins. Biochem. J. 278, 817-820.
• Kasid, U.N., Dritschilo, A., Rhim, J.S. (1987) Human epidermal keratinocytes 
retain radiation resistance following in vitro immortalisation and malignant 
transformation. Radiation. Res. I l l ,  567-571.
• Keyse, S.M. and Emslie, E.A. (1992) Oxidative stress and heat shock induce a 
human gene encoding a protein-tyrosine phosphatase. Nature. 359, 644-647.
• Keyse, S.M. and Tyrrell, R.M. (1989) Heme oxygenase is the major 32-kDa 
stress protein induced in human skin fibroblasts by UVA radiation, hydrogen 
peroxide, and sodium arsenite. Proc. Natl. Acad. Sci. USA. 86, 99-103.
• Keyse, S.M. and Tyrrell, R.M. (1990) Induction of the heme oxygenase gene 
in human skin fibroblasts by hydrogen peroxide and UVA (365 nm) radiation: 
evidence for the involvement of the hydroxyl radical. Carcinogenesis. 11, 
787-791.
• Kitazawa, M. & Iwasaki, K. (1996) Suppresion of iron catalysed free radical 
generation by iron tyrosinate models. Biochim. Biophys. Acta. 220, 36-41.
• Kitazawa, M. & Iwasaki, K. (1999) Reduction of ultraviolet light-induced 
oxidative stress by amino acid-based iron chelators. Biochim. Biophys. Acta. 
1473, 400-408.
• Klausner, R.D., Rouault, T.A. and Harford, J.B. (1993) Regulating the fate of 
mRNA; the control of cellular iron metabolism. Cell. 72,19-28.
236
• Koltz, L.O., Pellieux, C., Briviba, K., Pierlot, C., Aubry, J.M. and Sies, H. 
(1999) Mitogen-activated protein kinase (p38-, JNK-, ERK-) activation 
pattern induced by extracellular and intracellular singlet oxygen and UVA. 
Eur. J. Biochem. 260, 917-922.
• Kvam, E. and Tyrrell, R.M. (1997) Induction of oxidative DNA damage in 
human skin cells by UV and near visible radiation. Carcinogenesis. 18, 2379- 
84.
• Kvam, E., Hejmadi, V., Ryter, S., Pourzand, C. and Tyrrell, R.M. (2000) 
Heme oxygenase activity causes transient hypersensitivity to oxidative 
ultraviolet A radiation that depends on release of iron from heme. Free Rad. 
Biol. Med. 28, 1191-1196.
• Kvam, E., Noel, A., Basu-Modak, S. and Tyrrell, R.M. (1999) 
Cyclooxygenase dependent release of heme from microsomal hemeproteins 
correlates with induction of heme oxygenase 1 transcription in human 
fibroblasts. Free Radic. Biol. Med. 26, 511-7.
• Kvietikova, I.; Wenger, R. H.; Marti, H. H. and Gassmann, M. (1995) The 
transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia- 
inducible factor (HIF-1) DNA recognition site. Nucleic acid Res. 23, 4542- 
4550.
• Lamb, N.J., Mumby, S., Quinlan, G.J., Evans, T.W. and Gutteridge, J.M.C. 
(1999) Haem oxygenase shows pro-oxidant activity in microsomes and 
cellular systems: implications for the release of low molecular mass iron. 
Biochem. J. 344, 153-158.
• Laughton, M.J., Moroney, M.A., Hoult, J.R.S. & Halliwell, B. (1989) Effects 
of desferrioxamine on eicosanoid production in two intact cell systems. 
Biochem. Pharmacol. 38, 189-193.
• Lautier, D., Luscher, P. and Tyrrell, R.M. (1992) Endogenous glutathione 
levels modulate both constitutive and UVA radiation/hydrogen peroxide 
inducible expression of the human heme oxygenase gene. Carcinogenesis. 3, 
227-232.
• Lee, P.J., Jiang, B.H., Chin, B.Y., Iyer, N.V., Alam, J., Semenza, G.L. & 
Choi, M.K. (1997) Hypoxia-inducible factor-1 mediated transcriptional
237
activation of the haemoxygenase-1 gene in response to hypoxia. J. Biol.Chem. 
272,5375-5381.
• Ley, R.D., Applegate, L.A., Fry, RJ. and Sanchez, A.B. (1991) 
Photoreactivation of ultraviolet radiation-induced skin and eye tumors of 
Monodelphis domestica. Cancer Res. 51, 6539-6542.
• Li, J., Zheng, L.J., King, I, Doyle, T.W. and Chen, S.H. (2001) Synthesis and 
antitumor activities of ribonucleotide reductase: 3-amino-4-methylpyrimidine- 
2-coaboxaldehyde-thiosemicarbazone (3-Amp), 3-amino-pyrimidine-2- 
carboxaldehyde-thiosemicarbozone (3-AP) and its water-soluble prodrugs. 
Current Med. Chem. 8, 121-133.
• Lieu, P.T., Heiskala, M., Peterson, P.A. and Yang, Y. (2001) The roles of iron 
in health and disease. Mol Aspects Med. 22,1-87.
• Lloyd, J.B., Cable, H. and Rice-Evans, C. (1991) Evidence that 
desferrioxamine cannot enter cells by passive diffusion. Biochem. Pharmcol. 
1 4 ,1361-3.
• Lowe, N.J., Meyers, D.P., Weider, J.M., Luftman, D., Borget, T., Lehman, 
M.D., Johson, A.W. & Scott, I.R. (1995) Low doses of repetitive ultraviolet A 
induce morphological changes in human skin. J. Invest. Dermatol. 105, 739- 
743.
• Lui, X.U., Kirschenbaum, A., Yao, S., Steams, M.E., Holland, J.F., Claffey,
K. and Levine, A.C. (1999) Up-regulation of vascular endothelial growth 
factor by cobalt chloride-stimulated hypoxia is mediated by persistent 
induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. 
Clin. Exp. Met. 17, 687-694.
• Lui, Y., Cox, S.R., Morita, T. and Kourembanas, S. (1995) Hypoxia regulates 
vascular endothelial growth factor gene expression in endothelial cells. Circ. 
Res. 77, 638-643.
• Maines, M.D. (1988) Heme oxygenase: function, multiplicity, regulatory 
mechanisms and clinical applications. FASEB. J. 2, 2557-2568.
• Maines, M.D. (1997) The heme oxygenase system: a regulator of second 
messenger genes. Annu. Rev. Pharmacol. Toxicol. 37, 517-554.
• Mathews-Roth M.M. (1982) Photosensitization by porphyrins and prevention 
of photosensitization by carotenoids. J. Natl. Cancer Inst. 69,279-285.
238
• Mathews-Roth, M.M, Krinsky, N.I. (1987) Carotenoids affect development of 
UV-B induced skin cancer. Photochem. Photobiol. 46, 507-509
• Mathews-Roth, M.M. (1987) Photoprotection by carotenoids. Fed. Proc. 46, 
1890-1896.
• Mattera, R., Strone, G.P., Bahhur, N. and Kuryshev, Y.A. (2001) Increased 
release of arachidonic acid and eicosanoids in iron-overloaded 
cardiomyocytes. Circulation. 102,2395-2401.
• McCormick, J.P., Klita, S., Terry, J., Schrodt, M. & Einstark, A. (1982) 
Formation by hydrogen-peroxide or 254nm radiation of a near-UV 
chromophore from peptide bound cysteine. Photochem. Photobiol. 36: 367- 
369.
• McCoubrey, W.K., Huang, TJ. and Maines, M.D. (1997) Isolation and 
characterisation of a cDNA from the rat brain that encodes hemoprotein heme 
oxygensae-3. Eur. J. Biochem. 247, 725-732.
• Melillo, G., Musso, T., Sica, A., Taylor, L.S., Cox, G.W. and Varesio, L. 
(1995) A hypoxia-responsive element mediates a novel pathway of activation 
of the inducible nitric oxide synthase promoter. J. Exp. Med. 182, 1683-1693.
• Meplan, C., Richard, M.J. and Hainaut, P. (2000) Redox signalling in the 
control of the P53 pathway. Biochem. Pharmacol. 59, 1:25-33.
• Mitchell, J.A. & Warner, T.D. (1999) Cyclo-oxygenase-2: pharmacology, 
physiology, biochemistry and relevance to NSAID therapy. Brit. J. 
Pharmacol. 128, 1121-1132.
• Morliere, P., Salmon, S., Aubailly, M., Risler, A. and Santus, R. (1997) 
Sensitization of skin fibroblasts to UVA by excess iron. Biochim. Biophys. 
Acta. 1334, 283-290.
• Mukhopadhyay, C.K., Mazumder, B., & Fox, P.L. (2000) Role of hypoxia- 
inducible factor-1 in transcriptional activation of caeruloplasmin by iron 
deficiency. J. Biol.Chem. 275, 21048-21054.
• Mullner, E.W., Neupert, B. and Kuhn, L.C. (1989) A specific messenger-RNA 
binding-factor regulates the iron dependent stability of cytoplasmic transferrin 
receptor messenger-RNA. Cell. 58, 373-382.
• Navarra, P., Miceli, F., Tringali, G., Minici, F., Pardo, M.G., Lanzone, A., 
Mancuso, S. and Apa, R. (2001) Evidence for a functional link between the
239
heme-oxygenase-carbon monoxide pathway and corticotrophin-releasing 
hormone released from primary cultures of human trophoblast cells. J. Clin. 
Endo. And Metab. 86, 317-323.
• Neilands, J.B. (1995) Siderophores, structure and function of microbial iron 
transport compounds. J. Biol. Chem. 270, 26723-26726.
• Neuzil, J. and Stocker, R. (1994) Free and albumin-bound bilirubin are 
effective co-antioxidants for alpha-tocopherol, inhibiting plasma and low 
density lipoprotein lipid peroxidation. J. Biol. Chem. 269 ,12-19.
• O’Connell, M.J. and Peters, T.J. (1987) Ferritin and haemosiderin in free 
radical generation, lipid peroxidation and protein damage. Chem. Phys. Lipids. 
45, 241-249.
• O’Connell, M.J., Baum, H. and Peters, TJ. (1986) Haemosiderin-like 
properties of free radical modified ferritin. Biochem. J. 240, 297-300
• Otterbein, L.E., Mantell, L. and Choi, A.M. (1999) Carbon monoxide provides 
protection against hypoxic lung injury. Am. J. Physiol. 276, L688-694.
• Panchenko, M.V., Harrison, W.F. and Korn, J.H. (2000) Induction of heme 
oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. Am. J. 
Physiol. Cell Physiol. 278, C92-C101.
• Parkes, J.G., Lui, Y., Sima, J.B. & Templeton, D.M. (2000) changes in gene 
expression with iron loading and chelation in cardiac myocytes and non- 
myocitic fibroblasts. J. Mol. Cell. Cardiol. 32, 233-246.
• Pelham, H. (1988) Heat shock proteins: coming in from the cold. Nature. 332, 
776-777.
• Ponka, P. and Neuwirt, J. (1969) Regulation of iron entry into reticulocytes. I. 
Feedback inhibitory effect of heme on iron entry into reticulocytes. Blood. 33, 
609-615.
• Poss, K.D and Tonegawa, S. (1997) Heme oxygenase 1 is required for 
mammalian iron reutilization. Proc Natl Acad Sci USA. 9 4 ,10919-24.
• Poss, K.D. and Tonegawa, S. (1997) Reduced stress defence in heme- 
oxygenase-1 deficient cells. Proc. Natl. Acad. Sci. USA. 94, 10925-10930.
• Poswig, A., Wenk, J., Brenneisen, P., Wlaschek, M., Hommel, C., Quel, G., 
Faiss K., Dissemond, J., Briviba, K., Krieg, T. and Scharffetter-Kochanek, K.
240
(1999) Adaptive antioxidant response of manganase-superoxide dismutase 
following repetitive UVA irradiation. J. Invest. Dermatol. 112,13-18.
• Pourzand, C., Reelfs, O., Kvam, E. and Tyrrell, R.M. (2000) The iron 
regulatory protein can determine the effectiveness of 5-aminolevulinic acid in 
inducing protoporphyrin IX in human primary skin fibroblasts. J. Invest. 
Dermatol. 112, 419-425.
• Pourzand, C., Watkin, R.D., Brown, J.E., Tyrrell, R.M. (1999) Ultraviolet A 
radiation induces immediate release of iron in human primary skin fibroblasts: 
the role of ferritin. Proc. Natl. Acad. Sci. USA. 96, 6751-6.
• Qui, R. and Zeng, R.L. (2001) Advances in signal transduction of reactive 
oxygen species. Prog. Biohem. Biophys. 28, 287-289.
• Quinlan, G.J., Chen, Y., Evans, T.W. and Gutteridge, J.M.C. (2001) Iron 
signalling regulated directly through oxygen: implications for sepsis and the 
acute respiratory distress syndrome. Clin. Sci. 100, 169-182.
• Recalcati, S., Taramelli, D., Conte, D. and Cairo, G. (1998) Nitric oxide- 
mediated ferritin synthesis in J774 macrophages by inflammatory cytokines: 
role of selective iron regulatory protein-2 down regulation. Blood. 9 1 ,1059- 
1066.
• Reelfs, O. (2000) The role of iron and reactive oxygen species (ROS) in the 
activation of the transcription factor NF-kB by solar ultraviolet A (UVA) in 
primary human skin fibroblasts. Ph.D. thesis, University of Bath, UK.
• Reeve, V.E. and Tyrrell, R.M. (1999) Heme oxygenase induction mediates the 
photoimmunoprotective activity of UVA radiation in the mouse. Proc. Nat. 
Acad. Sci. USA. 96, 9317-9321.
• Richardson, D.R. (1997) Potential of iron chelators as effective 
antiproliferative agents. Can. J. Physiol. Pharmacol. 7 5 ,1164-1180.
• Rischer, C.E. and Easton, T.A. (1992) Focus on human biology.
HarperCollins publishing Inc.
• Rolfs, A., Kvietikova, I., Gassmann, M. & Wenger, R.H. (1997) Oxygen- 
regulated transferrin expression is mediated by hypoxia-inducible factor-1. J. 
Biol.Chem. 272,20055-20062.
241
• Rosen, G.D., Birkenmeier, T.M., Raz, A. and Holtzman, M J. (1989) 
Identification of a cyclo-oxygenate-related gene and its potential role in 
prostaglandin formation. Biochem. Biophys. Res. Comm. 164, 1358-1365.
• Ryter, S., Kvam, E., Richman, L., Hartmann, F. and Tyrrell, R.M. (1998a) A 
chromatographic assay for heme oxygenase activity in cultured human cells: 
application to artificial heme oxygenase overexpression. Free Rad. Biol. Med. 
24, 959-971.
• Ryter, S.W. and Tyrrell, R.M. (1998) Singlet oxygen (*02): A possible 
effector of eukaryotic gene expression. Free Rad. Biol. Med. 2 4 ,1520-1534.
• Ryter, S.W. and Tyrrell, R.M. (2000) The heme synthesis and degradation 
pathways: role in oxidant sensitivity. Heme oxygenase has both pro- and 
antioxidant properties. Free Rad. Biol. Med. 28, 289-309.
• Ryter, S.W., Minliang, S., Lai, C. and Su, C. (2000) Regulation of endothelial 
heme oxygenase activity during hypoxia is dependent on chelatable iron. Am. 
J. Physiol. Heart Circ. Phisiol. 279, H2889-H2897.
• Sandau, K, B., Zhou, J., Kietzmann, T. & Brune, B. (2001) Regulation of the 
hypoxia-inducible factor l a  by the inflammatory mediators nitric oxide and 
tumor necrosis factor-a in contrast to desferrioxamine and phenylarsine oxide 
J. Biol.Chem. 276, 39805-39811.
• Schallreuter, K.U. and Wood, J.M. (1986) The role of thioredoxin reductase in 
the reduction of free radicals at the surface of the epidermis. Biochem.
Biophys. Res. Commun. 136, 630-7.
• Schmedtje, J.F., Ji, Y., Lui, W., DuBois, R. and Runge, M. (1996) Hypoxia 
induces cyclooxygenase-2 via the NF-kB p65 transcription factor in human 
vascular endothelial cells. J. Biol. Chem. 272, 601-608.
• Schreiber, E.; Matthias, P.; Mueller, M. M. & Schaffner, W. (1989) Rapid 
detection of octamer binding-proteins with mini-extracts, prepared from a 
small number of cells. Nucleic Acid Res. 17, 6419.
• Schulman, H.M., Hermes-Lima, M., Wang, E-M. & Ponka, P. (1995) In vitro 
antioxidant properties of the iron chelator pyridoxal isonicotinyl hydrazone 
and some of its analogues. Redox Report. 1, 373-378.
242
• Sinclair, P.R and Gamick, S. (1976) The transport of hemin and 
protoporphyrin across the plasma membrane of chick embryo liver cells in 
culture. Ann. Clin. Res, 17, 250-258.
• Siren, A.L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, 
P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., Mennini, T., 
Heumann, R., Cerami, A., Ehrenreich, H. & Ghezzi, P. (2000) Erythropoietin 
prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. 
Natl. Acad. Sci. USA 98, 4044-4049.
• Soriani, M., Rice-Evans, C. and Tyrrell, R.M. (1998) Modulation of the UVA 
activation of haem oxygenase, collagenase and cyclooxygenase gene 
expression by epigallochatechin in human skin cells. FEBS Letters. 439, 253- 
257.
• Stocker, R. (1990) Induction of haem oxygenase as a defence against 
oxidative stress. Free Rad. Res. Commun. 9, 101-112.
• Stocker, R. and Ames, B.A. (1987) Potential role of conjugated bilirubin and 
copper in the metabolism of lipid peroxides in bile. Proc. Natl. Acad. Sci.
USA. 84,8130-8134.
• Stocker, R., Yamamoto, Y., McDonagh, A.F., Glazer, A.N. and Ames, B.N. 
(1987) Bilirubin is an antioxidant of possible physiological importance. 
Science. 235, 1043-6.
• Stocker, R., Yamamoto, Y., McDonagh, A.F., Glazer, A.N. and Ames, B.A. 
(1987) Bilirubin is an antioxidant of possible physiological importance. 
Science. 235, 1043-1046.
• Strenborg, H.J. & Van der Leun, J.C. (1990) Tumorigenesis by a long 
wavelength UVA source. Photochem. Photobiol. 51, 325-330.
• Suttner, D.M. and Dennery, P.A. (1999) Reversal of HO-1 related 
cytoprotection with increased expression is due to reactive iron. FASEB. J. 13, 
1800-1809.
• Symons, M.C.R. and Gutteridge, J.M.C. (1998J Free radicals and iron: 
chemistry, biology and medicine. Oxford University Press, Oxford, UK.
• Tanji, K., Imaizumi, T., Matsumiya, T., Itaya, H., Fujimoto, K., Cui, C.F., 
Toki, T., Ito, E., Yoshida, H., Waksbayashi, K. and Satoh, K. (2001) 
Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression
243
and prostaglandin production in a human macrophage cell line. Biochim. 
Biophys. Acta. 1530, 227-235.
• Tebbe, B., Geilen, C.C., Eberle, J., Kodelja, V. and Orfanos, C.E. (1997) L- 
ascorbic acid inhibits UVA-induced lipid peroxidation and secretion of IL-1 
alpha and IL-6 in cultured human keratinocytes in vitro. J. Invest. Dermatol. 
108, 302-306.
• Tenhunen, R., Marver, H.S. and Schmid, R. (1968) The enzymatic conversion 
of heme to biliverdin by microsomal heme oxygenase. Proc. Natl. Acad. Sci 
USA. 61, 748-775.
• Tenhunen, R., Marver, H.S. and Schmid, R. (1969) The enzymatic conversion 
of hemoglobin to bilirubin. Trans. Assoc. Am. Physicans. 82, 363-271.
• Thiel, E.C. (1994) Iron regulatory elements (IREs): a family of mRNA non­
coding sequences. Biochem. J. 304 ,1-11.
• Thiele, J. and Eisner, P. (2001) Oxidants and antioxidants in cutaneous 
biology. Ed. G. Burg, Karger press, Zurich.
• Thiele, J.J., Traber, M.G., Polefka, T.G., Cross, C.E. and Packer, L. (1997) 
Ozone-exposure depletes vitamin E and induces lipid peroxidation in murine 
stratum comeum. J. Invest. Dermatol. 108,753-7.
• Thornton, R.D., Lane, P., Borghaei, R.C., Pease, E.A., Caro, J. & Mochan, E.
(2000) Interleukin 1 induces hypoxia-inducible factor 1 in human gingivial 
and synovial fibroblasts. Biochem. J. 350, 307-312.
• Trenam, C.W., Blake, D.R. and Morris, C J . (1992) Skin inflammation: 
Reactive oxygen species and the role of iron. J. Invest. Dermatol. 99, 675- 
682.
• Trenam, C.W., Dabbagh, A.J., Blake, D.R. and Morris, C J . (1992a) The role 
of iron in an acute model of skin inflammation induced by reactive oxygen 
species. Br. J. Dermatol. 126(3), 250-256.
• Tsafack, A., Loyevsky, M., Ponka, P. and Cabantchik, Z.I. (1996) Mode of 
action of iron (III) chelators as antimalarials. J. Lab. Clin. Med. 127, 574-582.
• Tyrrell, R.M. (1991) UVA (320-380nm) radiation as an oxidative stress. 
Oxidative stress: Oxidants and Antioxidants, Academic Press Ltd.
• Tyrrell, R.M. (1994) The molecular and cellular pathology of solar ultraviolet 
radiation. Mol. Aspects Med. 15, 1-77.
24 4
• Tyrrell, R.M. (1996) UV activation of mammalian stress proteins. EXS. 77, 
255-71.
• Tyrrell, R.M. (1996a) Activation of mammalian gene expression by the UV 
component of sunlight -  from models to reality. Bioassays. 1 8 ,139-148.
• Tyrrell, R.M. (1999) Redox regulation and oxidant activation of heme 
oxygenase-1. FreeRadic. Res. 31, 335-340.
• Tyrrell, R.M. and Pidoux, M. (1988) Correlation between endogenous 
glutathione content and sensitivity of cultured human skin cells to radiation at 
defined wavelengths in the solar UV range. Photochem. Photobiol. 47 ,405- 
412.
• Tyrrell, R.M., Pourzand, C.A., Brown, J., Hejmadi, V., Ryter, S. and Watkin, 
R.D. (2000) Cellular studies with UVA radiation: a role for iron. Rad. Protect. 
Dosimetry. 91, 37-39.
• Vile, G.F. and Tyrrell, R.M. (1993) Oxidative stress resulting from ultraviolet 
A irradiation of human skin fibroblasts leads to a heme oxygenase-dependent 
increase in ferritin. J. Biol. Chem. 268, 14678-14681.
• Vile, G.F. and Tyrrell, R.M. (1995) UVA radiation-induced oxidative damage 
to lipids and proteins in vitro and in human skin fibroblasts is dependent on 
iron and singlet oxygen. Free Radic. Biol. Med. 18, 721-730.
• Vile, G.F., Basu-Modak, S., Waltner, C. and Tyrrell, R.M. (1994) Heme 
oxygenase 1 mediates an adaptive response to oxidative stress in human skin 
fibroblasts. Proc. Natl. Acad. Sci. USA. 91, 2607-2610.
• Walling, C., Kurz, M. and Schugar, H.J. (1970) The iron (III)- 
ethylenediaminetetracetic acid -  peroxide system. Inorg. Chem. 9, 931-937.
• Wang, G.L. & Semenza, G.L. (1993) Desferrioxamine induces erythropoetin 
gene expression and hypoxia-inducible factor 1 DNA-binding activity: 
implications for a model of hypoxia signal transduction. Blood. 82, 3610- 
3615.
• Wang, G.L. & Semenza, G.L. (1995) Purification and characterisation of 
hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230-1237.
• Wanner, R.M., Spielmann, P., Stroka, D.M., Camenisch, I., Scheid, A., 
Houck, D.R., Bauer, C., Gassmann, M. & Wenger, R.H. (2000) Epolones
245
induce erythropoetin expression via hypoxia-inducible factor-la activation. 
Blood. 96, 1558-1565.
• Wayne, C.E. & Wayne, R.P. (1996), Photochemistry, Oxford science 
publications.
• Webster, K.A. (1987) Regulation of glycolytic enzyme RNA transcription 
rates by oxygen availability in skeletal muscle cells. Mol and Cell. Biochem. 
77,19-28.
• Wenger, R.H., Rolfs, A., Marti, H.H., Bauer, C., & Gassmann, M. (1995) 
Hypoxia, a novel inducer of acute phase gene expression in a human hepatoma 
cell line. J. Biol. Chem. 270, 27865-27870.
• Wu, K.K. (1995) Inducible cyclo-oxygenase and nitric oxide synthase. Adv. 
Pharmacol. 33, 179-207.
• Xu, Q., Ji, Y. and Schmedtje, J.F. (2000) Spl increases expression of 
cyclooxygenase-2 in hypoxic vascular endothelium. J. Biol. Chem. 275, 
24583-24589.
• Yamaguchi, T., Hashizume, T., Tanaka, M., Nakayama, M., Sugimoto, A., 
Ikeda, S., Nakajima, H. and Horio, F. (1997) Bilirubin oxidation provoked by 
endotoxin treatment is suppressed by feeding ascorbic acid to a rat mutant 
unable to synthesise ascorbic acid. Eu. J. Biochem. 245, 233-240.
• Ye, Z. and Connor, J.R. (1999) Screening of transcriptionally regulated genes 
following iron chelation in human astrocytoma cells. Biochim. Biophys. Acta. 
264, 709-713.
• Yoshida, T. and Kikuchi, G. (1978) Features of the reaction of heme 
degradation catalysed by the reconstituted microsomal heme oxygenase 
system. J. Biol. Chem. 253, 4230-4236.
• Yoshida, T., Noguchi, M. and Kikuchi, G. (1980) Oxygenated form of heme- 
heme oxygenase complex and requirement for second electron to initiate heme 
degradation from the oxygenated complex. J. Biol. Chem. 255,4418-4420.
• Yoshida, T., Noguchi, M. and Kikuchi, G. (1982) The step of carbon 
monoxide liberation in the sequence of heme degradation catalysed by the 




E L S E V I E R
Free Radical Biology & Medicine. Vol. 33, No. 3. pp. 356-363, 2002 
Copyright © 2002 Elsevier Science Inc. 
Printed in the USA. All rights reserved 
0891-5849/02/$-see front matter
P I I  S 0 8 9 1-5 8 4 9 (0 2 )()0884-5
Original Contribution
A NOVEL IRON CHELATOR THAT DOES NOT INDUCE HIF-1 ACTIVITY
M ark C reighton-G utteridge and Rex M . T yrrell 
Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
(Received 11 February 2002: Revised 11 April 2002; Accepted 18 April 2002)
A b s tr a c t— H um an sk in  ce lls  (FE K -4) have b een  show n to u n d erg o  an im m ed ia te  and  transien t re lease  o f  low  m olecu lar 
m ass iron (L M rFe) w hen sub jec ted  to  U V A  ( 3 2 0 -3 8 0  nm ) irrad ia tio n  and  th is iron  m ay act as a p ro -ox idan t and increase 
tissue in jury . In o rd er to  d ecrease  th is tran sien t re lease o f  L M rF e , ce lls  w ere  treated  w ith  the iron che la to rs  desferri- 
oxam ine (D F O ) and sa licy la ldehyde ison ico tin o y l hyd razone (SIH ). H ow ever, a lthough  the iron  pool d ecreased , an 
increase in the D N A  b ind ing  ac tiv ity  o f  the  h y p o x ia  inducib le  fa c to r-1 (H IF -1 ) w as ob se rv ed  w hen  D FO  and SIH  w ere 
adm in istered  to norm al g ro w in g  F E K -4  ce lls . T h e  in duction  o f  H IF-1 ac tiv a tes  the exp ress io n  o f  severa l genes 
associa ted  w ith  hypox ia  and  iron  h om eostasis. H IF-1 in duction  has also  been  associa ted  w ith  p ro tec tion  against certain  
form s o f  o x idative  stress. T h ere fo re , it is d ifficu lt to  use a  co n v en tio n a l H IF-1 ac tiv a tin g  iron  ch e la to r  (such  as D FO ) 
for m echanistic  stud ies o f  p ro tec tion  agains t iron -m ed ia ted  o x idative  stress  since  any  p ro tec tion  observed  cou ld  be a 
consequence  o f  e ith er the ch e la tio n  o f  L M rF e  o r  the induction  o f  p ro tec tive  g enes associa ted  w ith  the hypox ic  response. 
In o rder to observe  the effec t o f  iron ch e la tio n  o n  cell function  w ithou t the induction  o f  hy p o x ia  resp o n siv e  genes, cells 
w ere treated  w ith the novel iron  ch e la to r  jV -(2-hydroxybenzyl)-L -serine (H B S er). A lth o u g h  th is com p o u n d  is an 
effec tive  iron  ch e la to r u n d er the  cond itio n s em p lo y ed  in th is ex p erim en t, it d o es have a low er iron -b in d in g  constan t than 
e ith er D F O  o r SIH . T h is  m ay be the m ajo r d e term inan t o f  the  obse rv a tio n  that the co m p o u n d  does not induce H IF -I 
b ind ing  o r ac tiva te  HIF-1 resp o n siv e  transcrip tio n a l p rom oters . ©  2002  E lsev ie r Science  Inc.
K e y w o rd s— Iron che la to r. H ypox ia , H IF -1, G A P D H , D FO , G en e  ex p ress io n , O x id a tiv e  stress. Iron , F ree rad icals
IN TRODUCTIO N
A pool of low molecular mass iron (LMrFe) exists within 
cells which is essential for the synthesis of iron requiring 
enzymes and proteins and for the synthesis of DNA. 
Within biological systems, iron can change its oxidation 
state to form ferric, ferrous, and ferryl complexes. It is this 
ability to lose and accept electrons that makes iron a key 
biological catalyst and transporter of electrons. LMrFe 
has been implicated as contributing to pro-oxidant status 
in several pathological conditions such as atherosclero­
sis, ischemic injury, adult respiratory distress syndrome, 
and Alzheimer’s disease, as well as aspects of ageing 
[1,2]. LMrFe has also recently been implicated as an 
important contributor to the cellular damage caused by 
UVA (320-380 nm) irradiation [3,4]. UVA irradiation of 
cultured primary skin fibroblast cells (FEK-4) causes an
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immediate release of LMrFe and this iron release appears 
to be the result of the decompartmentalization of proteo­
lytic enzymes, from lysosomes within the cytoplasm, 
which then degrade ferritin [4]. In addition, heme oxy­
genase-1 (HO-1) is induced [5], which catalyzes the 
breakdown of any heme present to form biliverdin, car­
bon monoxide (CO), and LMrFe, and has been impli­
cated in a process that results in free iron export from 
cells [6],
Intracellular and extracellular LMrFe is considered a 
chelatable form of iron that can be sequestered by the 
administration of appropriate LMrFe chelators [7], It is 
essential that the iron chelator prevent the iron from 
redox cycling and thereby participating in catalytic reac­
tions that lead to the generation of reactive oxygen spe­
cies (ROS). The design of clinically used iron chelators 
has concentrated on their ability to bind iron (III) with 
high affinity, enabling them to be used for the treatment 
of body iron overload [7]. ‘High’ affinity iron chelators 
such as DFO, mimosine, SIH, and deferiprone, however, 
increase the activity of hypoxia inducible factor-1 (HIF-
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1), a nu clear  transcription factor [ 8 - 1 0 ] .  H IF -1 transac­
tiv a tio n  is  norm ally  increased  by a lo w  intracellu lar  
o x y g e n  ten sio n  (h y p o x ia ), but iron ch elators ha v e  been  
sh o w n  to  m im ic  the e ffe c t  o f  o x y g e n  d eprivation  on  a  
nu m ber o f  h y p o x ia  resp o n siv e  g e n e s  [1 1 -1 4 ] .
H IF -1  is  a  heterod im eric  D N A  binding c o m p le x  c o m ­
prised  o f  an a  and a j3 subunit, the latter b e in g  co n sti-  
tu tiv e ly  ex p ressed  and identical to  the aryl hydrocarbon  
recep tor  nu clear translocator (A R N T ). H y p o x ia  or iron  
ch e la tio n  resu lts in  the accu m ulation  o f  H I F - la ,  enab lin g  
it, u p on  d im eriza tio n , to  bind to a sp ec ific  D N A  seq u en ce  
w ith in  the h y p o x ia  resp o n siv e  e lem en t (H R E ) o f  an array 
o f  target g e n e s . S u ch  g en es in c lu d e  g ly cera ld eh y d e  
3 -p h o sp h a te  d eh y d ro g en a se  (G A P D H ), in d u c ib le  nitric  
o x id e  ( iN O S ), caeru lop lasm in , and the transferrin recep ­
tor [1 1 ,1 3 ,1 5 ,1 6 ] .  T arget g en es  m ay be d iv id e d  in  to  
three c la sse s:  ( i )  g e n e s  w h ich  represent an adaptation  o f  
the w h o le  org a n ism  to  h y p o x ia  such  as eryth rop oetin  
(E P O ), ( i i)  th o se  w h ich  are lo ca l actin g  factors su ch  as 
v ascu lar  en d o th elia l grow th  factor (V G E F ), and  ( iii)  
g e n e s  w h ich  h a v e  intracellu lar fun ction s su ch  as g ly c o ­
ly tic  e n z y m e s  [1 7 ,1 8 ] . T h e  induced  c h a n g e s  fa c ilita te  
adaptation  to  h y p o x ic  co n d ition s, and the in d u ction  o f  
su ch  g e n e s  m ay b e  protective  against iron to x ic ity  and  
o x id a tiv e  stress [ 1 4 ,1 9 - 2 1 ] .  T he lack  o f  a v a ila b ility  o f  a  
therapeutic iron ch ela tor  d esig n ed  to  d ecrea se  o x id a tiv e  
stress in d u ced  b y  m ild  and transient in crea ses in  cellu lar  
iron , prom pted  K itazaw a  and Iw asaki to  sy n th e s ize  an  
iron  ch ela tor  by co n d en s in g  and red ucin g  sa licy la ld e -  
h y d e  w ith  the L -a m in o  acid , serine [22 ]. T h e  product w as  
the tridentate iron chelator, /V -(2 -h yd roxyb en zy l)-L -  
ser in e  (H B S er). In v itro  experim en ts h a v e  sh o w n  that 
th is  co m p o u n d  is  a b le  to  inh ib it iro n -in d u ced  h yd roxy l 
radical form ation  in  the F enton  reaction  and sig n ifica n tly  
d ecrea se  U V -in d u ced  lip id  peroxid ation  [2 2 ]. T h e  a sso ­
c ia tio n  con stan t o f  H B S er  for iron (III) w a s ca lcu la ted  to  
b e  lo g  K  2 1 - 2 2 ,  substantia lly  lo w er  than that o f  D F O  
( lo g  K  ~  3 0 )  and SIH  (lo g  K  ~  2 9 )  and c lo s e  to  the  
affin ity  o f  so m e  p h y sio lo g ic a l iron-bind ing prote in s [22 ]. 
H B S er  has b een  in vestig a ted  as an iron ch e la to r  that m ay  
n o t increase  H IF -1 D N A  binding and prom oter activ ity . 
S u ch  a  property w o u ld  a llo w  the m easu rem en t o f  
ch a n g es  in  g e n e  ex p ressio n  as a  c o n se q u en ce  o f  the  
sequ estration  o f  lo w  m olecu lar  m ass iron in  th e  a b sen ce  
o f  the h y p o x ic  resp on se.
MATERIALS AND METHODS
A ll c h e m ic a ls  u sed  w ere  su pp lied  by B D H  L aboratory  
S u p p lie s  (P o o le , D o rset, U K ) u n less o th erw ise  stated. 
S to c k  so lu tio n s w ere  prepared under sterile  c o n d itio n s  in  
w ater, e x ce p t sa licy la ld eh y d e  iso n ico tin o y l hyd razone  
(SIH ; k in d ly  p rov id ed  by Dr. P. P onka), w h ic h  w as  




Fig. 1. Structure o f the tridentate iron chelator /V-(2-hydroxybenzyl)- 
L-serine (HBSer), kindly provided by Dr. Manabu Kitizawa and Dr. 
Keiji Iwasaki. The figure is modified from Kitizawa and Iwasaki [22].
ultim ate  concentration  o f  D M S O  d id  not e x c e e d  0.1% . 
F errioxam ine w as prepared by the add ition  o f  3 .6  m l o f  
2 0 0  m M  desferr ioxam in e m esy la te  (C ib a -G e ig y , B ase l, 
S w itzerlan d ) to  a  s ligh t e x c e s s  o f  2 0 0  m M  ferric c h lo ­
ride. T h e  e x c e ss  iron w a s reco v ered  by d ia ly z in g  the  
c o m p le x  against 2 0  m l hum an apotransferrin (5  g/1) 
so lu tio n  con ta in in g  0 .5  g  so d iu m  hyd rogen  carbonate for  
2  h. H B S er  (sh o w n  in F ig . 1) ( >  99%  pure) w a s k indly  
p ro v id ed  by  Dr. M anabu K itiza w a  and Dr. K eiji Iw asaki 
(A jin o m o to  C o ., Inc., T o k y o , Japan).
A  sto c k  so lu tion  o f  H B S er  w a s prepared by d isso lv in g  
the com p o u n d  in 1 M  so d iu m  hyd roxid e, fo llo w e d  by  
neutra lization  usin g  1 M  hyd roch lor ic  ac id  and  d ilu tion  
w ith  w ater. H B S er w a s then d ilu ted  in t issu e  culture  
m ed ia  and incubated w ith  the c e lls . B eca u se  o f  poor c e ll  
penetration  o f  the co m p o u n d , m illim o la r  concen trations  
are n ecessary .
Cells an d  conditions o f  culture
H um an sk in  fibroblasts o f  the c e ll lin e  F E K -4 , derived  
from  a  foresk in  exp lant, w ere  used . C e lls  w ere  cultured  
in  E a g le s  Earls M in im al E ssen tia l M ed iu m  (E M E M ; L ife  
T e ch n o lo g ie s , P a is ley , S co tla n d ) su pp lem en ted  w ith  
15%  v /v  feta l c a lf  serum  (P A A  L aboratories, Y e o v il,  
S o m erset, U K ) (in activa ted  at 5 6 °C  for 4 5  m in), g lu ­
tam in e  (L ife  T e ch n o lo g ie s )  (2 m M ), so d iu m  bicarbonate  
(L ife  T e ch n o lo g ie s )  (0 .2%  w /v ) , p en ic illin , and strepto­
m y c in  (L ife  T e ch n o lo g ie s )  (5 0  IU /m l each ). C e lls  w ere  
g ro w n  in  T 125 flasks (M B I F erm entas, H anover, M D , 
U S A ) and w ere p assaged  by trypsin ization  o n c e  a w eek , 
w h ich  in v o lv ed  rem oval o f  the m ed ia , a  s in g le  w ash  w ith  
P B S , and gen tle  d etachm en t by  incubation  for  5 - 1 0  m in  
at 3 7 °C  in 0 .25%  w /v  trypsin  (L ife  T ech n o lo g ie s) . T he  
c e lls  u sed  for exp erim en ts w ere  seed ed  at 2 .5  X 105 on  
a 10 c m  d ish  to  reach a  c o n flu en ce  o f  5 0 - 6 0 %  on the day  
o f  treatm ent. P lates w ere incubated  at 3 7 °C  in an atm o­
sp here o f  5% v /v  C 0 2. C e lls  w ere o n ly  u sed  betw een  
p a ssa g e s  10 to  15.
Treatments
T h e ‘co n d itio n ed ’ m ed ia  o n  the p late w a s rem oved  
and a portion (8  m l) w a s treated w ith  the iron chelator,
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iron-saturated ch elator, or  cob a lt ch lo r id e , and rep laced  
on  the c e lls . T h e c e l ls  w ere  then incub ated  for 18 h 
(e x ce p t for the reporter assay  ex p erim en ts, w h ich  re­
qu ired 41 h).
IRP/IRE bandshift assay
C ellu lar  c y to p la sm ic  extracts w ere  prepared accord­
ing  to  the m eth od  d escr ib ed  by Schreib er  et al. [23]. 
C y to p la sm ic  protein co n ten t w as ca lcu la ted  u sin g  the 
B radford assay  [2 4 ]. T h e  32P -la b eled  R N A  probe w as  
transcribed in vitro from  1 fig o f  lin ear ized  (BamHl- 
c le a v ed ) p lasm id  p G e m -3 Z f(+ ) ,  co n ta in in g  the w ild - 
typ e  IR E  (c lo n e  4 2 , H en derson  et al. [2 5 ])  from  the 5 '  
untranslated reg ion  o f  the hum an ferritin  h eavy  chain  
m R N A , as descr ib ed  in [2 5 ], i.e ., 2  fig o f  D N A  tem plate  
w a s transcribed u s in g  T 7  R N A  p o ly m era se  (P rom ega, 
M ad iso n , W I, U S A ) in the p resen ce  o f  2 .5  m M  each  
G T P , A T P , and U T P  (Pharm acia , U p p sa la , S w ed en ) and  
6 0  fiC i o f  [ a - 32P ]C T P  (A m ersham , B uck in gham sh ire, 
U K ; 8 0 0  C i/m m o l). R N A -p rotein  c o m p le x e s  w ere re­
so lv e d  in a  6%  w /v  acry lam id e  g e l dried  and ex p o sed . 
T h e resu lts w ere v isu a lized  and qu antified  by use o f  a  
phosphorim ager (M o lecu la r  D y n a m ics, Su n n y v a le , C A , 
U S A ) and u se  o f  the so ftw are  Im age Q uant 3 .3 . A n y  
ch a n g es in IR P/IR E  b in d in g  ind icate  that iron chelators  
interfere w ith  the ‘free ’ iron and its su b seq u en t interac­
tion  w ith  the iron-su lphur c lu ster  o f  the IR P -1 protein.
Isolation and analysis o f  RNA
C e lls  (2  X 106/1 0  cm  p late) w ere  stim ulated  and  
incubated  at 3 7 °C  in  E M E M  (as d escr ib ed  p rev io u sly ). 
T ota l cellu lar  R N A  w a s iso la ted  u s in g  the acid  guani- 
d in iu m  th iocyan ate-p h en o l-ex traction  m eth od . R N A  w as  
red isso lv ed  in  R N A se -fre e  w ater and quantified  by ab­
sorption  sp ectrop hotom etery . R N A  w a s e lectroph oresed  
(2 5  /x g /w ell) in a M O P S /fo rm a ld eh y d e-1.3%  w /v  aga­
rose  g e l and transferred to  a Z eta-P robe B lo ttin g  (B io -  
R ad, H ercu les, C A , U S A ) ny lon  m em brane by capillary  
b lotting . T h e G A P D H  c D N A  probe w a s prepared as a  
1 40 0  bp Hind III/E co  RI fragm ent o f  the m urine g ly cer-  
a ld eh yd e phosphate  d eh y d ro g en a se  g en e . T h e /3-actin  
c D N A  probe w as a P C R  product o f  5 4 5  bp from  hum an  
/3-actin c D N A , w h ich  en co m p a ssed  reg io n s 2 6 7  to  791  
o f  the /3-actin c D N A  (k in d ly  p rovided  by Dr. Q uinlan, 
R o y a l B rom pton H osp ita l, L on d on ). P C R  prim ers used  
w ere  obtained  from  L ife  T e ch n o lo g ie s . T h e  /3-actin  
prim ers used  w ere: 5 ' to  3 ' C A G  G A A  G G A  A G G  T T G  
G A A  G A G  and 3 ' to  5 ' G G C  A C C  A C  A  C C T  T C T  
A C A  A T G . c D N A  probes w ere 32P  lab eled  by the ran­
d o m  prim ed sy n th esis  m eth od  u sin g  a  h igh  prim e en ­
z y m e  kit (B oeh rin ger  M annh eim , M annh eim , G erm any)
and 32P  dC T P  (A m ersh am ) accord ing  to m anufacturers’ 
instructions. T h e lab eled  c D N A  probe w a s then purified  
u sin g  E lu tip -D  co lu m n s (S c h le id er  and S ch u e ll, D a sse l, 
G erm any). M em b ran es w ere  prehybrid ized  and hybrid­
ize d  in a 7%  w /v  S D S , 250 m M  N a 2H P 0 4, 1 m M  
ethy len ed iam inetetraaceta te  (E D T A ). T h e  32P -la b eled  
probe w a s added to  the hyb rid ization  so lu tio n . A fter  
hyb rid ization , n o n sp ec ifica lly  bound probe w a s w ash ed  
from  the m em brane u sin g  S D S  (at a  final concen tration  
o f  0 .1%  w /v )  and  20X S S P E  (3  M  N a C l, 0.2 M  
N a 2H P 0 4, 20 m M  E D T A , pH  7 .4 ). W a sh in g s w ere per­
form ed  tw ice  w ith  6 X  S S P E  for 5 m in  at 3 7 °C , tw ic e  
w ith  IX S S P E  for 15 m in at 3 7 °C  and tw ic e  w ith  2X 
S S P E  for 15 m in at 6 5 °C . T h e  m em branes w ere  sea led  in  
a p lastic  m em brane and e x p o se d  to  a p h osp horim ager  
screen . A fter  autoradiography, the c D N A  probe w as  
stripped from  the m em brane b y  b o ilin g  in  0 .3%  w /v  S D S  
( tw ic e  for 3 0  m in  ea ch  tim e), and b lots w ere  reprobed  
w ith  a /3-actin c D N A  probe u s in g  the m eth od  p rev io u sly  
descr ib ed . R N A  w a s  qu antified  u sin g  a ph osp h orim ager  
(M o lecu la r  D y n a m ics) and u se  o f  the so ftw a re , Im age  
Q uant 3 .3 .
HIF-1 bandshift assay
C ellu lar  nuclear extracts w ere  prepared accord in g  to  
th e  m eth od  descr ib ed  by Schreib er e t  al. [2 3 ]. N u clear  
protein  con ten t w a s ca lcu la ted  u sin g  the B radford assa y  
[2 4 ]. E lec tro p h o r etic  m o b ility  sh ift  a s s a y s  (E M S A s )  
w e r e  p erfo rm ed  by  in c u b a tin g  n u clea r  e x tra c ts  w ith  a  
w ild -ty p e  (W 1 8 )  o l ig o n u c le o t id e  c o n ta in in g  a w ild -  
ty p e  (W 1 8 )  H IF -1  b in d in g  s ite  d er iv ed  fro m  th e  E P O  
g e n e , s e n s e  5 'G C C C T A C G T G C T G T C T C A 3 ' and a n ­
t is e n se  5 'T G A G  A C  A G C  A C G T A G G G C 3 ' [2 6 ] .  T h e  
o lig o n u c le o t id e s  w ere  an n ea led  at a  concen tration  o f  2 5 0  
m M  in 2 5 0  m M  T ris (pH  7 .8 )  at 9 5 °C  for 15 m in  and  
then  c o o le d  to  room  tem perature and stored  at — 2 0 °C . 
P rob es w ere produ ced  by en d -la b e lin g  5 m M  o f  the  
o lig o n u c le o tid e s  u sin g  [ a - 32P] A T P  and K le n o w  p o ly ­
m erase  (L ife  T e ch n o lo g ie s ) . E n d -lab eled  probes w ere  
purified  from  unincorporated [ a - 32P] A T P  u sin g  a Sep h -  
a d ex  G 5 0  co lu m n  e lu ted  in a  15 0  fil v o lu m e  o f  water.
D N A -protein  binding reactions w ere carried out for 2 0  
m in at room  temperature in a  total volum e o f  2 0  fil, con ­
taining 10 fil (1 figjfil protein) o f  nuclear extract, 1 fil o f  
(0 .2  fig/fil) ‘com petitor’ D N A  (sequence, sen se  5 'G C -  
C C T A A A A G C T G T C T C A 3 ' and antisense 5 'T G A G A C A -  
G C T T T T A G G G C 3 '), 2 - 3  fil purified  probe (1 0 4 C P M ) 
in  10 m M  T ris-H C l (pH  8 ), 5 0  m M  N a C l, 0 .1  m M  
E D T A , 0 .5  m M  D T T , and 4%  v /v  g ly cero l and run on  
4%  w /v  nondenaturing p o ly a cry la m id e  g e ls . E lectro ­
p h o resis w a s perform ed at 3 0 0  V  in T ris/b orate /E D T A  
b u ffer (1 5  m M  T ris, 3 0  m M  b oric  acid , 0 .0 6  m M  E D T A )  
at 4 °C . For su persh ift a n a ly s is , 0 .6  fig o f  H I F - la  anti-
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body (Becton Dickinson, Mountain View, CA, USA) 
was added to the reaction mixture and incubated for 30 
min at 4°C. For competition experiments, a 100-fold 
excess of unlabeled annealed oligonucleotides was added 
to the reaction mixture with the labeled probe. The dried 
gels were visualized and quantified by use of the phos­
phorimager.
Transient transfection and reporter gene assay
The hypoxia responsive luciferase gene construct 
pGLTfERH contained a transferrin HRE-enhancer up­
stream of a heterologous simian virus 40 promoter and 
was kindly provided by Dr. Roland Wenger [27]. FEK-4 
cells on 3 cm plates were transiently transfected in 1 ml 
of Optimem-1 with glutamax-1 serum free media 
(Gibco) using 5 /u,l/ml lipofectin reagent (Life Technol­
ogies) and 2 pg of pGLTfERH DNA. Co-transfection 
with 0.25 pg of a reference plasmid, the /3-galactosidase 
expression vector (pCMV/3Gal), was performed simul­
taneously to enable differences in transfection and 
growth to be corrected. After 5 h, the Optimem media 
was replaced by normal EMEM serum containing media 
along with the chelators or controls and incubated for 
41 h. Cells were washed twice with ice-cold PBS and 
luciferase activity was measured using the luciferase 
assay system according to manufacturers instructions 
(Promega). Luciferase activity was determined using a 
TD-20/20 luminometer (Turner Designs, Palo Alto, CA, 
USA). /3-galactosidase activity was determined by incu­
bating 50 /ml cell extract with 150 /ml of reagent contain­
ing 2.5 mM CPRG (Boehringer Mannheim) and 1.25 
mM MgCl2. The activity of /3-galactosidase was calcu­
lated from the absorbance at 550 nm obtained in the final 
reaction.
RESULTS
DFO, SIH, and HBSer increase IRP/IRE binding 
activity
Changes in iron homeostasis resulting from the pre­
treatment of primary skin fibroblast cells (FEK-4) with 
three different iron chelators have been examined using 
an RNA bandshift assay (EMSA). Interaction of an oli­
gonucleotide, containing the human IRP-1 specific motif, 
with the IRP-1 present in cytosolic extracts of chelator 
pretreated cells was used to estimate the level of intra­
cellular ‘free’ iron within cells. Figure 2 shows that after 
an 18 h incubation with the hexadentate, hydrophilic iron 
chelator DFO (Fig. 2A), the tridentate, lipophilic iron 
chelator SIH (Fig. 2B), and the tridentate, hydrophilic 
novel iron chelator HBSer (Fig. 2C), IRP-1 binding 
increases in a dose-dependent manner (Fig. 2).
Free Probe





Fig. 2. Modulation of IRP/IRE binding in response to DFO, SIH, and 
HBSer treatments. Human FEK-4 cells were pretreated for 18 h with 
(A) DFO concentrations of 5, 50. 100, and 500 /xM, and 500 /xM 
iron-saturated DFO (FO); (B) SIH concentrations of 100 and 200 /xM 
as well as 500 /xM DFO. (Iron-saturated SIH was also used at 200 /xM). 
(C) Cells were pretreated for 18 h with 500 /xM, 1 mM, 2 mM, 5 mM, 
and 7.5 mM HBSer, as well as 500 /xM DFO. Five millimolar of the 
iron-saturated HBSer did not increase IRP/IRE binding activity. The 
positions of the IRP/IRE complex are indicated and the excess free 
probe is shown in (A). The displayed EMSA results are highly repre­
sentative of n = 4 independent experiments.
DFO and SIH induce HIF-1 DNA binding, whereas 
HBSer does not
To determine whether the three iron chelators induce 
HIF-1 DNA binding in primary skin fibroblast cells 
(FEK-4), we assayed the nuclear extracts of cells pre­
treated with DFO, SIH, or HBSer using the bandshift 
technique (EMSA). HIF-1 DNA binding was measured
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Fig. 3. The effect of DFO. SIH, and HBSer on HIF-1 DNA binding. 
Nuclear extracts prepared from FEK-4 cells were preincubated with 
(A) 2.5, 20, 50, 100, and 500 /xM DFO or 500 /xM iron-saturated DFO
using an end-radiolabeled W18 oligonucleotide (18 base 
pair), containing a HIF-1 DNA binding site derived from 
the erythropoetin gene [26], Supershift analysis using a 
HIF-la specific antibody confirmed that the complex 
contained HIF-1. These findings indicate that the iron 
chelators DFO (Fig. 3A) and SIH (Fig. 3B) strongly 
induce HIF-1 DNA binding, whereas pretreatment of 
cells with HBSer (Fig. 3C) does not change the basal 
level of HIF-1 DNA binding.
HBSer does not increase reporter gene activity
DFO and SIH induce HIF-1 DNA binding as observed 
by EMSA analysis, whereas HBSer does not. To further 
investigate differences in HIF-1 activation between the 
iron chelators, we used a reporter gene construct that 
contains a single HRE derived from the transferrin 5' 
enhancer. Using this construct we observe that HBSer 
does not alter basal reporter activity, whereas DFO 
strongly increases reporter activity (Table 1). Cobalt 
chloride (a known stimulator of HIF-1 activity) and the 
weaker iron chelator, SIH, also induced HIF-1 reporter 
activity but to a lesser extent than the strongest of the 
iron chelators DFO (Table 1).
GAPDH mRNA expression is increased by DFO and 
SIH but not by HBSer
GAPDH is normally constitutively expressed in eu­
karyotic cells. However, GAPDH expression has been 
shown to increase in response to hypoxia and as a result 
of increased HIF-1 transactivation. GAPDH mRNA ac­
cumulation was used as a ‘marker’ of HIF-1 activity in 
human primary skin fibroblast cells (FEK-4). Total cel­
lular mRNA was hybridized with a radiolabeled GAPDH 
cDNA probe and quantified using standard Northern blot 
analysis. All data were normalized using a radiolabeled 
/3-actin cDNA probe. Although hypoxia shows a weak 
transcriptional activation of /3-actin in rat skeletal mus­
cles [28], we did not observe such an increase with 
FEK-4 cells in response to iron chelation. DFO and SIH 
significantly increased the expression of GAPDH
(FO) for 18 h, or (B) 100 and 200 /xM SIH. Five hundred micromolar 
DFO was used as a reference comparison for the induction of HEF-1 
DNA binding. Iron-saturated SIH (Fe-SIH) was added at a concentra­
tion of 200 /xM. (C) The modulation of HIF-1 DNA binding 18 h after 
cells were treated with 0.5 and 7.5 mM HBSer, and 500 /xM DFO was 
measured. Supershift analysis using a HIF-la specific antibody is 
shown by the bands labeled HIF-la Ab, the constitutive binding 
(described by Kvietikova et al. [29]) is shown by the band labeled 
constitutive, and the nonspecific binding is also displayed. (A) also 
shows the excess radiolabeled free probe. Figures are highly represen­
tative of n =  4 experiments.
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Table 1. Luciferase Reporter Activity in Response to Iron Chelation
Treatment
Luciferase activity 
(fold increase) ±  SD
Control 1 _
50 /xM DFO 28.66* 5.10
150 /xM DFO 37.03* 4.03
150 /xM FO 0.93 0.55
500 juM DFO 51.40* 12.89
500 /aM  DFO +  5 mM HBSer 63.78* 13.88
2.5 mM HBSer 0.29 0.04
5 mM HBSer 0.20 0.12
5 mM Fe-HBSer 0.50 0.38
50 /aM SIH 7.36* 1.99
50 /aM  cobalt chloride 29.41* 1.71
Luciferase reporter constructs containing one copy of the transferrin 
HRE, were transiently transfected into FEK-4 cells 5 h prior to the 
addition o f  DFO, FO, HBSer, Fe-HBSer, SIH, or cobalt chloride for 
41 h. Cobalt chloride is known to strongly induce HIF-1 activity. There 
is not an inhibitory effect on HIF-1 DNA binding by HBSer if  it is 
added with DFO. Shown are the means and ±  SD of three independent 
experiments. Differences in the transfection efficiency and extract 
preparation were corrected by normalization o f the corresponding 
/3-galactosidase activities. A paired /-test revealed a significant differ­
ence between control and treatment with DFO, SIH, and cobalt chloride 
(*). ip <  -05 level).
m R N A , w h ereas pretreatm ent o f  c e lls  w ith  H B S er  had 
no e ffe c t  o n  the ex p ressio n  o f  G A P D H  (T ab le  2 ).
DISCUSSION
M o st co n v en tio n a l iron ch ela tors used  for  c lin ic a l and  
experim en ta l iron ch e la tio n  lea d  to  the a c tiva tion  o f  the  
HIF-1 resp o n se  [ 8 - 1 0 ] ,  presum ab ly  as an undesirab le  
sid e  e f fe c t  o f  their strong affin ity  for  intracellu lar iron. 
H ere, w e  ha v e  sh o w n  for th e  first tim e that it  is  p o ss ib le  
to  rem o v e  intracellu lar lo w  m olecu lar  m a ss iron using  
e x o g en o u s  iron chelators w ith o u t the ind uction  o f  H IF -1.
C on ven tion a l iron ch e la to rs su ch  as D F O  (u sed  at 
concen trations o f  2 .5  to  5 0 0  /u,M) and SIH  in d u ce  H IF-1  
transactivation in F E K -4  sk in  fibroblast c e lls  (T ab le  1). 
T he H IF  response is  critica l to  the ind uction  o f  target 
g en es that en ab le  org a n ism s to  adapt to lo w  o x y g e n  
concentrations. T h ese  g e n e s  in c lu d e  in d u cib le  nitric o x ­
ide syn th ase, g ly cera ld eh y d e  3-ph osp hate  d eh y d ro g e­
nase, caeru lop lasm in  (an acu te  phase protein ), and the  
transferrin receptor [ 1 1 -1 4 ] ,  H o w ev er , the ind uction  o f  
g en es a sso c ia ted  w ith  h y p o x ia  by iron chela tors ser io u sly  
co m p lica tes the interpretation o f  experim en ta l w ork  u s­
ing su ch  agents. F irstly , it is  d ifficu lt to  a n a ly ze  alter­
ations in  a  range o f  cellu la r  p r o c esses  that arise  fo llo w in g  
the ch e la tio n  o f  iron w ith in  c e l ls  w h en  the ch ela tor  it se lf  
m odu lates g e n e s  a sso c ia ted  w ith  iron and o x y g e n  h o ­
m eo sta sis  by the transactivation  o f  H IF -1 . A n other  c o m ­
plication  o f  u sin g  strong iron  chelators that increase  
HIF-1 a c tiv ity , is  that iron ch ela tor-in d u ced  H IF-1 D N A  
binding and activ ity  has been  asso c ia ted  w ith  the protec-
Table 2. Modulation o f GAPDH mRNA Expression by Iron
Chelators
Treatment
GAPDH mRNA expression 
(fold increase) ±  SD
Control 1 _
5 mM HBSer 0.70 0.17
7.5 mM HBSer 0.66 0.12
100 nM  SIH 3.61* 1.12
100 /xM Fe-SIH 0.79 0.22
20 /a M  DFO 2.45* 0.74
100 jxM DFO 3.47* 0.33
100 /xM FO 1.17 0.38
50 fiM  C oC l2 3.01* 0.35
Northern blot analysis o f cells pretreated for 18 h with HBSer, SIH, 
iron-saturated SIH, DFO, FO, and cobalt chloride. W hole cell RNA 
was extracted and hybridized with a  radiolabeled cDNA probe. Figure 
4 shows the means and ±  SD of three o r four independent experiments. 
Differences in RNA loading were corrected by normalization o f the 
corresponding /3-actin RNA accumulation, measured using a radiola­
beled /3-actin cDNA probe. A paired /-test revealed a significant dif­
ference between the untreated control and treatments with DFO, SIH, 
and cobalt chloride (*), (p <  .05 level).
tion o f  c e l ls  aga in st certain  form s o f  o x id a tiv e  stress  
[ 1 9 - 2 1 ] .  C o n seq u en tly , an y  protection  a ga in st ox id a tiv e  
stress that is ob serv ed  fo l lo w in g  the add ition  o f  iron 
chelators m ay b e  d u e e ith er  to  the in d u ction  o f  H IF-1  
resp o n s iv e  g e n e s  or to  the c h e la tio n  o f  iron.
In th is stu dy , w e  h a v e  ch aracterized  a  n o v e l iron 
chelator (H B S er) that e f fe c t iv e ly  binds in tracellu lar lo w  
m o lecu la r  m a ss iron, but d o e s  n o t in d u ce  H IF-1 transac­
tivation .
It has recen tly  been  c o n c lu d e d  that h y p o x ic  regu lation  
o f  H I F - la  o ccu rs at the p osttran slation al le v e l. In so m e  
c e ll  l in es , both  H I F - la  and H I F -1/3 appear to  be co n sti-  
tu tive ly  e x p ressed  at the m R N A  lev e l. H o w ev er , at the 
protein lev e l H I F - la  is  rap id ly  degraded  under norm oxic  
co n d itio n s , w h ich  is  in  c o m p le te  contrast to  the co n sti-  
tu tive ly  ex p ressed  H IF -1/3 su bu nit. T h e m ech a n ism  for  
the rapid degradation  o f  H I F - la  appears to  be a  ubiq- 
u itin -p roteosom e pathw ay. H I F - la  b in ds to  the v o n  H ip- 
p el-L in dau  tum or su p p ressor  protein  (p V H L ), w h ich  
form s the reco g n itio n  c o m p o n e n t o f  an E 3  ubiquitin  
l ig a se  c o m p le x  lead in g  to  ub iq u ity la tion  o f  H I F - la  [ 3 0 -  
32] and su bseq u en t p roteasom al destruction . Further re­
search has led  to  the iso la tio n  and c la ssifica tio n  o f  the  
H IF -V H L -p ro ly l h y d ro x y la ses , resp o n sib le  for  regulat­
ing  the in teraction  o f  p V H L  w ith  H I F - la  and p rovides  
strong e v id e n c e  that they  b e lo n g  to  an ex ten d ed  super  
fam ily  o f  2 -o x o g lu ta ra te -d ep en d en t-o x y g en a ses  [33 ]. 
Su ch  e n z y m e s  h a v e  an a b so lu te  requirem ent for d io x y ­
gen  as co-sub stra te  and w e a k ly  b ind iron11 for  u se  as a  
co-factor . A cco r d in g ly , w h en  o n e  su ch  e n z y m e  w a s pre­
vented  from  b in d ing  iron , its  a ctiv ity  w a s co m p lete ly  
inh ib ited . T h e  activ ity  w a s a ls o  inh ib ited  by co b a ltou s  
io n s and th is p o ssib ly  reflects su bstitu tion  for  iron w ithin
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the protein [33 ]. B e fo re  this find in g , m ech a n istic  stud ies 
concentrated  on a R O S sen so r  or  o x y g e n  sen s in g  h em e  
protein as m odulators o f  c h a n g es  in  H IF -1 activ ity  [34 , 
35],
O ur data (F ig . 2 C ) sh o w s that the iron ch ela tor  H B Ser  
increases IR P/IR E  b inding in a d o se -d ep en d en t m anner, 
thereby ind icating a d ep letion  o f  in tracellu lar  iron. T he  
fun ction  o f  H B Ser as an intracellu lar iron chelator is 
further ind icated  by our ob servation  (data  not sh o w n ) 
that H B Ser, as w e ll as D F O  and SIH , s ig n ifica n tly  d e ­
crease  the lev e l o f  intracellu lar ferritin in  F E K -4  sk in  
fibroblast c e lls . T aken together, our data  dem onstrate  
that it is p o ssib le  to  u se  an e x o g e n o u s  iron ch elator to  
m odulate  g en es asso c ia ted  w ith  iron h o m eo sta s is  and  
d isso c ia te  this from  e ffe c ts  a sso c ia ted  w ith  hyp ox ia . A l­
though m ost iron chela tors have  m u ltip le  b io lo g ica l  
properties in addition to  their ab ility  to  c h e la te  iron [36 ], 
w e  b e liev e  that the m o st lik e ly  exp la n a tio n  as to  w h y  
H B S er d o es  not activate  H IF-1 D N A  b in d in g  and pro­
m oter activ ity  in the sa m e w a y  as D F O  and SIH , is  due  
to  its lo w er  affinity for iron. H B S er  is  therefore sim ilar  to  
en d o g en o u s iron-bind ing proteins in that it can  acquire  
iron w ithout activating  H IF -1 , an e ssen tia l property o f  
proteins w ith  a central ro le  in  cellu la r  iron  h om eo sta sis .
W e propose that chela tors o f  th is ty p e  m ay be partic­
ularly va luab le  for a ssess in g  ch a n g es in g e n e  ex p ressio n  
or other b io lo g ica l e ffe c ts  that arise so le ly  from  iron  
chelation . T h ey  have the potentia l to  d ep le te  the im m e­
diate and transient re lea se  o f  L M rF e and protect c e lls  
from  iron-m ediated o x id a tiv e  stress w ith o u t the ind uc­
tion  o f  severa l g en es  a sso c ia ted  w ith  the h y p o x ic  re­
sp on se.
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ABBREVIATIONS
D F O — d esferr ioxam in e m esy la te
G A P D H — g ly cera ld eh y d e  3-ph osp hate  d eh y d ro g en a se
H B S er— h yd ro x y b en zy l serine
H IF -1— h y p o x ia  in d u cib le  fa c to r -1
H O -1— h a e m o x y g e n a se -1
L M rFe— lo w  m olecu lar  m ass iron
R O S— rea ctiv e  o x y g e n  sp ec ie s
SIH — sa licy la ld eh y d e  iso n ic o tin o y l hyd razone
U V A — ultrav io let A
